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Abstract 
Introduction    
Magnesium is required by the human body in modest amounts for the maintenance of health 
and optimal functioning. 
Objectives 
This portfolio of work sets out to investigate whether magnesium supplementation has 
hypotensive effects and to determine if habitual dietary magnesium intake or loading 
strategies modulate the effects of magnesium supplementation.  The habitual dietary 
magnesium intake of hypertensive patients was also examined to ascertain adequacy of 
dietary magnesium in this cohort.  A meta-analysis was performed on the effect of 
magnesium supplementation on blood pressure. Other variables such as dosage, duration 
and study design were considered and findings from the meta-analysis used to influence 
future work. 
A further objective was to examine the effect of supplementation on aerobic and resistance 
exercise and subsequent recovery.  Finally, the efficacy of an alternative means of 
magnesium delivery in the form of a transdermal magnesium cream was investigated. 
Methods 
A 300 mg.day-1 elemental magnesium aspartate or magnesium citrate was used as a 
supplementation in studies 1,2,4 and 5. 
Participants were instructed to continue with their normal diet and for study 6 participants 
were required to eat the same foods for the 24 hours prior to both laboratory blood taking 
sessions.  With the exception of the meta-analysis, food diaries were kept for various lengths 
of time, detailed in the publications.  Aerobic and resistance exercise protocols were carried 
out in studies 1,2 and 4, with both performance and cardiovascular parameters investigated 
for any effect from supplementation.  
Where supplementation was in the form of a transdermal cream, this was applied to the 
torso and absorption of the cream was determined by investigating changes in serum and 
urinary magnesium levels. 
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Summary of results 
Blood pressure decreased with magnesium supplementation of 300 mg.day-1 for 7 days with 
greater reductions in systolic versus diastolic blood pressure consistently evident. 
Magnesium supplementation of 300 mg.day-1 for 7 and 14 days increased power during 
resistance exercise but no changes in aerobic exercise performance were observed. 
A high habitual dietary magnesium intake attenuated the hypotensive effect derived from 
magnesium supplementation when compared to those on a low habitual dietary intake.  The 
meta-analysis supported these results. 
A habitually low dietary magnesium intake was observed in a cohort of clinically diagnosed 
primary hypertensives. 
Conclusion 
These studies show that there is a link between low habitual dietary magnesium intake and 
elevated blood pressure and that magnesium supplementation appears to be associated 
with blood pressure.  An improvement in resistance exercise performance with magnesium 
supplementation was also observed.  Finally, a transdermal magnesium cream was shown 
to increase serum magnesium levels and may provide an alternative to oral 
supplementation. 
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Definitions and abbreviations 
 
Hypermagnesemia   High levels of magnesium in the blood 
Hypomagnesemia  Low levels of magnesium in the blood 
NAOEL    No observable adverse effect level hypomagnesia.   
RDA  Recommended Dietary Allowance 
RNI     Reference nutrient intake 
Transdermal   Route of administration whereby active ingredients are delivered 
across the skin 
TRPM6 and TRPM7          Transient receptor potential melastatin 6 and 7 
WAnT Wingate anaerobic test to measure mean and peak power 
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Section 1 Introduction 
Literature Review 
 
1.1 Background to magnesium 
Minerals, such as magnesium (in the form Mg2+), are required by the human body in modest 
amounts for the maintenance of health and the development of optimal functioning (Lukaski, 
1995). Mg2+ is an important mineral and it is the fourth most abundant cation in the human 
body after calcium, potassium and sodium and the second most abundant in cellular 
systems after potassium.  Magnesium  is a cofactor to over 325 enzymatic reactions in the 
body (Newhouse and Finstad, 2000). 
 
 Around 99% of total body Mg2+ is located in the bone, muscles and non-muscular soft tissue 
with extracellular magnesium accounting for 1% of the body’s total stores and which is 
identifiable in serum and red blood cells (Elin, 2010). The mean serum  Mg2+ concentration 
in humans is roughly 0.85 mmol.l-1 , with a referenced interval of 0.7-1.0 mmol.l-1  (Wacker, 
1980). In serum, approximately one third of Mg2+ is bound to protein, 25% is bound to 
albumin and 8% to globulins (Maguire, 2006). For the two thirds of the plasma Mg2+ that is 
ultrafiltrable, approximately 80% is in the form of free ion and approximately 20% is 
complexed to phosphate, citrate and other compounds (Elin, 1987). 
 
The stores of Mg2+ in the body equate to approximately 24 g (1 mole). Total Mg2+ in an 
average adult (70 kg with 20% body fat) equates to ~20 mmol/kg of fat free mass (~1000-
1200 mmol) (Fox, Ramsoomair and Carter, 2001). 
 
Magnesium has a  variety of biological functions, including structural roles by complexing 
negatively charged groups such as phosphates in nucleic acid, a controlling role in the 
inhibition or activation of enzymes and regulatory roles by modulating cell proliferation, cell 
cycle progress and differentiation (Fox, Ramsoomair and Carter, 2001) 
 
1.2 Magnesium absorption, excretion and markers of flux and homeostasis  
Mg2+ homeostasis is maintained by the intestine, kidneys and bones (Jahnen-Dechent and 
Ketteler, 2012). Mg2+ is absorbed in the intestine, stored in the bone and any excess Mg2+ 
that has been consumed will be filtered by the kidneys, then excreted from the body in urine. 
Absorption of Mg2+ mainly takes place in the small intestine (Fox, Ramsoomair and Carter, 
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2001; Yogi et al., 2011) although some Mg2+ is also absorbed in the large intestine. Both the 
duodenum and jejunum have a high fractional absorption of Mg2+. These segments of 
intestine are relatively short however, and the transit time is rapid. Therefore, their relative 
contribution to total Mg2+ absorption is less than that of the ileum. Two Mg2+ absorbing 
pathways have been identified in the mammalian intestine. Para-cellular transport is a 
passive mechanism which involves absorbing Mg2+ through small spaces between the 
epithelial cells. The second system involves the active transport of Mg2+ to the blood via the 
interior of the epithelial cell. During transport, Mg2+ must pass through two cell membranes 
(de Baaij, Hoenderop and Bindels, 2012) using transport proteins.  Para-cellular Mg2+ 
absorption is responsible for roughly 80-90% of intestinal Mg2+ uptake.  
It has been suggested that the ileum and distal parts of the jejunum are the most permeable 
for ions because of the relatively low expression of tightening claudins 1, 3, 4, 5 and 8 (de 
Baaij, Hoenderop and Bindels, 2012). As such para-cellular Mg2+ transport seems mainly 
restricted to these areas. Claudins 16 and 19, linked with Mg2+ permeability (Schweigel and 
Martens, 2000), are not expressed in the small intestine. Therefore, the exact mechanism 
involved in the facilitation of Mg2+ absorption remains unknown.  
 
The non-saturable paracellular pathway accounts for the majority of Mg2+ absorption (90%) 
which occurs passively between the enterocytes consisting of tight junctions and intracellular 
space; this is mediated by the transepithelial electrochemical gradient, transepithelial 
concentration gradient and solvent drag, allowing the movement of ions across cell 
membranes by bulk transport following the movement of water (Touyz, 2003).   
 
The saturable pathway mechanism may act via a carrier-mediated process or by diffusion 
across the intestinal mucosa, each of which is functionally associated with low and high Mg2+ 
intakes, respectively (Bohl & Volpe 2002), therefore consumption of adequate magnesium 
intake may affect the absorption of Mg2+ via the TRPM 6 and 7 pathways. Mg2+ transcellular 
absorption is via the brush border epithelium across the luminal membrane and extrusion 
out of the cell across basolateral membranes, both of which exhibit passive and active 
transport (Schweigel and Martens, 2000).  Whether this saturable transcellular active 
transport system is key to the regulation of Mg2+ absorption is unknown.  It would be of 
interest to determine the effect of high and low dietary intake on the transporters to 
determine a saturation point of the transporters with a high Mg2+ diet and further to determine 
whether there is a downregulation of the transporters with a high Mg2+ intake.  
 
In Addition to the carrier mediated transport mechanisms discussed above, other 
mechanisms have also been suggested to facilitate the influx of Mg2+ for example solute 
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transport carriers (SLC41A1/A2) and other protein carriers (ACDP1, MagT1, MMgT1 and 
MMgT2) (Romani and Scarpa, 1992; Quamme, 2010).  Recent publications have shown 
active transcellular transportation of Mg2+ in relation to specific Mg2+ transport proteins 
TRPM6 and TRPM7 (transient receptor potential melastatin 6 and 7), which are situated 
within the length of the intestine (TRPM6) and among various tissues (TRPM7). TRPM6 is 
associated principally with Mg2+ transport within the epithelium in both the intestine and distal 
convoluted tubule (DCT) of the kidney (Quamme, 2010). TRPM6 has been shown to 
fundamentally influence Mg2+ homeostasis via (re)absorption and excretion within the DCT.  
This Mg2+ absorption function of TRPM6, which is expressed in the kidney may be related 
to additional cellular mechanisms of Mg2+ absorption evident via paracellin-1 (Rondón et al., 
2008). Paracellin-1(PCLN-1) is a newly identified protein also known as claudin 16. This 
protein is expressed in humans in the thick ascending Loop of Henle in the tight junctions 
and is thought to play a critical role in the control of paracellular permeability for magnesium 
and calcium (Blanchard et al., 2001). 
However, the exact mechanistic action by which paracellin-1 effects the paracellular fluxes 
of Mg2+ remains inconclusive (Wolf, 2004). Schlingmann et al (2007) suggest that when 
intraluminal Mg2+ concentrations are low, Mg2+ absorption occurs primarily via the active 
transcellular pathway, with any further intraluminal Mg2+ concentration increases re-
establishing Mg2+ absorption via paracellular pathways.   
Previous research indicates that a diet deficient Mg2+  induces an increased TRPM6 
expression thus enhancing Mg2+ absorption and reabsorption (Rondón et al., 2008).  A 
review by Schlingmann and Gudermann (2007)  concluded that the novel identification of 
TRPM6+7 provides insight into the  cellular mechanism and multifunctional role of TRPM7 
and specific role of TRPM6 in relation to  epithelial Mg2+ uptake. These mechanisms, in 
particular TRPM7, are modulated by coupling of TRPM7’s channel-kinase domain and 
phosphotransferase activity (Schlingmann et al., 2007) and it could therefore be suggested 
that TRPM7 may be the biological modulator of Mg2+ homeostasis (Wolf, 2004).  Again, no 
research examined this to determine whether diet affects TRPM7.   
Finally it has been shown that  Mg2+ nucleotide complexes i.e. MgATP, G-proteins and 
phosphoinositide turnover suppress/inhibit the active ion channel and function expressed by 
TRPM7 (Wolf, 2004; Schlingmann et al., 2007). It has been suggested that this inhibitory 
action and the potential association with suboptimal plasma Mg2+  may affect cellular 
processes requiring Mg2+ as a co-factor for enzymatic activity such as ATP production and 
therefore may affect critical cellular metabolic processes (Wolf, 2004) 
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The average dietary intake of Mg2+ is approximately 300 mg.day-1, all derived primarily from 
green vegetables, cereal grains and meat. An individual consuming this diet absorbs around 
40% of the Mg2+ consumed, which is absorbed primarily in the small intestine (Elin, 2010). 
The absorption process commences around 1 hour after consumption and continues at a 
uniform rate for 2-8 hours.  Twelve hours after ingestion the material will normally be in the 
large bowel, which absorbs very little Mg2+. The absorption of Mg2+ in the small intestine is 
inversely related to consumption levels (Nicar and Pak, 1982). When a diet low in Mg2+ is 
consumed up to 75% of  ingested Mg2+ may be absorbed, whilst when consuming a diet rich 
in Mg2+ as little as 25% may be absorbed (Elin, 2010). 
The major excretory pathway for absorbed Mg2+ is via the kidneys. The capacity for renal 
excretion of Mg2+ is thought  to be between 120 to 140 mg/24 h, for a person consuming a 
diet adequate in Mg2+ (Wacker, 1980). Therefore, the amount of Mg2+ that is absorbed in the 
small intestine is similar to the amounts excreted by the kidneys.  This process allows one 
to maintain Mg2+ balance, and as such the kidney is the major organ responsible for serum 
magnesium homeostasis. The excretion rate of Mg2+ from the kidney can range from 10 to 
500 mg/24 hour, depending on the Mg2+ levels in the plasma (Wacker, 1980).  
It has been estimated that 70% to 80% of the plasma Mg2+ is filtered through the glomerular 
membrane; in a person consuming an adequate diet, the Mg2+ which is bound to the protein 
does not pass through the glomerular membrane (Elin, 2010). Roughly 20% to 30% of the 
filtered Mg2+ is absorbed along the proximal tubule (Quamme, 2010). The primary site for 
the absorption of Mg2+ is the thick ascending limb of the loop of Henle, where more than 
50% of the filtered Mg2+ is reabsorbed. The distal tubules and collecting ducts therefore 
absorb very little  Mg2+ (Quamme, 2010).   
The excretion of Mg2+ follows a circadian rhythm, with most Mg2+ being excreted in the 
evening/night (Fox, Ramsoomair and Carter, 2001). Under normal physiological conditions 
approximately 2400 mg of Mg2+ located in blood plasma is filtered by the glomeruli in 24 
hours. Of this filtered Mg2+, 95% is re-absorbed instantaneously, leaving 3-5% which is 
excreted in urine (Fox, Ramsoomair and Carter, 2001).  However, the kidneys can 
manipulate the Mg2+ excretion by increasing or lowering the amount removed from the 
serum. It is believed that the excretion and reabsorption rates can fluctuate immensely from 
0.5% to 70% respectively. This means that the kidneys are able to conserve Mg2+ when the 
body is falling into a state of hypomagnesemia; by reducing the excretion amount in urine.  
Conversely, the kidneys can also increase excretion when the body is in a state of 
hypermagnesemia (Jahnen-Dechent and Ketteler, 2012). 
A growing list of hormones and other factors have also been reported to influence TRPM6 
and TRPM7 protein expression and, in some cases, TRPM6- and TRPM7-mediated Mg2+ 
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transport. Angiotensin II, aldosterone, bradykinin, epidermal growth factor, thrombin, 
oestrogen, metabolic acidosis/alkalosis, thiazide diuretics, certain immune-suppressants 
and mechano- or osmo-induced stretch have been implicated in affecting TRPM7 and/or 
TRPM6 in a variety of cells. These changes may be mediated by covalent modification, or 
through controls at the level of gene and protein expression (Quamme, 2010) 
 
1.3 Methods of Assessment of Magnesium absorption and concentration  
In order to clarify human requirements and assess  Mg2+ status, it is essential to identify 
specific biomarkers of Mg2+ status (Witkowski, Hubert and Mazur, 2011). A variety of 
methods have been used to measure magnesium in the body including serum magnesium, 
plasma magnesium, red blood cell (RBC) magnesium, and 24h urinary magnesium 
excretion  
1.3.1 Serum Magnesium 
It has been postulated that serum Mg2+ correlates poorly with total body stores. When serum 
magnesium level is low, intra- cellular magnesium may also be low. However, when serum 
magnesium levels are normal, intra-cellular magnesium may be depleted. Therefore, if the 
serum magnesium level is low, a person is deficient; however, if it is normal, the person may 
still be magnesium deficient at the cellular level (Fox, Ramsoomair and Carter, 2001)  
However, it is still amongst the most widely used method of Mg2+ assessment (Shils and 
Rude, 1996). There is preferential use of serum over plasma as the anticoagulant used for 
plasma separation tubes is often magnesium salts and or may be contaminated with Mg2+ 
(Swaminathan, 2003). As intracellular methods of Mg2+ assessment, including RBC and 
muscle biopsies, are often expensive as their assays include nuclear magnetic resonance 
(NMR) spectroscopy and ion-specific electrode measures, therefore, due to the cost 
implications, serum magnesium is often deemed acceptable in assessing changes in Mg2+ 
status (Fox, Ramsoomair and Carter, 2001). It was thought that the analysis of serum Mg2+, 
despite being the "entry level” test, was a good determinant of assessing possible disorders 
or deficiency as a low Mg serum concentration is concomitant with low intracellular Mg2+ 
levels (Elin, 1991). However, more recent research has found that serum Mg2+ does not 
reflect total body Mg2+, neither does it correlate with tissue stores, excluding interstitial fluid 
and bone (de Baaij, Hoenderop and Bindels, 2012). The point being that it is possible to 
have serum levels ≥0.7 mmol.l-1  but be intracellularly depleted. It is thought that severely 
depleted serum Mg2+ (<0.4 mmol.l-1 ) is  a marker of intracellular depletion (McLean, 1994). 
Fawcett, Haxby & Male (1999) reported that only 1% of Mg2+ in the body is located in 
extracellular fluids, furthermore only 0.3% was found in the serum, where it is present in 
three altered states, ionised (62%), protein bound (33%) and phosphate (5%) with most 
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Mg2+ being stored in bone (53%), intracellular compartments of muscle (27%) and soft 
tissues (19%). It was concluded therefore, that serum Mg2+ is a poor indicator of Mg2+ status 
and can only be used as a predictor or an indicator of Mg2+, not total body Mg2+ content. 
1.3.2   24-hour Urinary Mg2+ Excretion  
Although time consuming and cumbersome, 24h urinary excretion of Mg2+ has been used 
to measure magnesium intake. Mg2+ excretion has been shown to increase in response to 
an elevated level of Mg2+ ingestion whether this be through dietary manipulation or 
supplementation (Fatemi et al., 1991; Feillet-Coudray et al., 2002; Lukaski and Nielsen, 
2002). The circadian rhythm plays a role in the renal excretion of Mg2+, with the maximum 
excretion occurring at night. Therefore it is important for a full 24h sample to be collected for 
accurate assessment of Mg2+ excretion and absorption (Jahnen-Dechent and Ketteler, 
2012). The results of a 24h urinary test after ingestion or an intravenous load of Mg2+ can 
provide information on intake and absorption with high urinary excretion indicating a renal 
elimination  of Mg2+ due to sufficient Mg2+ and greater Mg2+ retention suggesting insufficient 
intake or high absorption rates (Elin, 1988). Trauninger (2002) suggested an estimation of 
normal 24 hour  urinary Mg2+  loss to be  3.6 mmol  (range 2.7-4.4 mmol) for females and 
4.8 mmol (range 3.2-5.2 mmol) for males.  
 
1.4 Magnesium and blood pressure 
Mg2+ supplementation has been shown to significantly improve blood pressure (Cunha et al. 
2012;  Bain et al. 2015) and modify vascular tone (Cunha et al., 2012) and is considered an 
important regulatory factor for the pathophysiology of hypertension.  This may be attributed 
both to the intra and extracellular concentrations of Mg2+ present in cardiac and vascular 
cells; influencing cardiac excitability, vascular reactivity, contractility and tone (Laurant and 
Touyz, 2000), all of which support the underlying aetiology of hypertension as an increase 
in peripheral resistance (Touyz, 2003).  Mg2+ has been shown to be a mediatory cation for 
an induced vasodilatory action in addition to acting as a Ca2+ antagonist (Laires, 2004). The 
exact cellular basis for the molecular contractile action of Mg2+ is unknown, but it has been 
suggested that Mg2+ influences Ca2+ handling, which has been shown to increase 
contractility of vascular smooth muscle cells (Jahnen-Dechent and Ketteler, 2012). Inside 
the vascular smooth muscle cells, Mg2+ acts by inhibiting transmembrane calcium transport 
and calcium entry into the cell thus decreasing contractile actions of vasoactive agents 
relying on calcium signalling. By acting as a calcium antagonist Mg2+ modulates the 
vasoconstrictor actions of increased Ca2+ in smooth muscle cells. Elevated levels of Mg2+ 
compete with the influx of Ca2+ and stimulate a mediated calcium efflux resulting in 
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decreased intracellular free calcium which in turn may reduce vascular contractility reducing 
blood pressure by vasodilatation (Touyz, 2003). 
 
Conversely, low intra/extracellular Mg2+ concentration results in an ionic imbalance causing 
an influx of Ca2+ and an increased Ca2+:Mg2+ ratio (Kesteloot et al., 2011), causing arterial 
stiffness (Resnick et al., 1997). Low Mg2+ concentration may also potentially prevent the 
dephosphorylation processes associated with inositol-1,4,5-triphosphate (PI3) that may 
stimulate PI3 mediated Ca2+ mobilisation, resulting in an increased intracellular Ca2+  and 
increased vascular tone (Laurant and Touyz, 2000). These effects will subsequently result 
in a yet to be determined increase in blood pressure.  
 
1.5 Magnesium and energy metabolism 
With regards to energy metabolism, Maguire (2006) states that the binding of Mg to ATP 
(MgATP complex) influences fundamental cellular phosphorylation processes, which are 
crucial for physical performance. The role of Mg2+ in the formation of the MgATP complex, 
is it facilitates the resynthesising of ATP via  a conformational change which results in 
improved adenosine diphosphate (ADP) and inorganic phosphate (Pi) alignment, in addition 
to  aiding the removal of a water molecule while bound to Pi so as to complete the formation 
of ATP (Schlingmann et al., 2007). This conformational change lowers the activation energy 
required for the formation of the MgATP complex and subsequently improves the 
bioenergetics involved   (Gout et al., 2014).  Mitochondrial Mg2+  also enhances energy 
metabolism by improving  enzyme activation e.g. enzymes such as  dehydrogenases and 
cytochrome c oxidase   impact directly on the mitochondrial respiratory rate by increasing 
the release of adenine nucleotides and also affecting  mitochondrial membrane potential, 
and hence the mitochondrial volume, (Wolf and Trapani, 2008). In light of the potential of 
magnesium to enhance ATP generation,  Mg2+  also has an impact on muscle contraction, 
a process that requires crossbridge cycling between actin and myosin,  which is ATP 
dependant (Schlingmann et al., 2007). Mg2+ alters myosin motor activity by altering the steps 
associated with actin attachment and detachment. The mechanism of altering detachment 
may be due to Mg2+ exchange at the active site, this has still to be fully elucidated.  Further  
free Mg2+concentrations increase in skeletal muscle during exercise and initial recovery, 
which suggests that Mg2+could also play a role in muscle fatigue (Swenson et al., 2014). 
 
1.6 Magnesium and exercise  
As well as blood pressure, magnesium has also been investigated with regards to its 
potential to enhance exercise performance, in particular ATP re-phosphorylation and muscle 
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contraction. There is limited research on this and to date there are no systematic reviews or 
meta-analyses to provide an overview of this area.   
Performance improvements have been limited when supplementing with Mg2+  and the 
mechanisms  responsible for the limited performance increases, are likely multifactorial 
(Pokan et al., 2006).  
Lukaski (2004) suggests the relevance of magnesium supplementation in relation to 
physically active individuals based on two principles determined from their previous review 
on micronutrient intake and athletes (Lukaski, 1995); 1) active individuals consume a dietary 
intake consisting of less vitamins and minerals in relation to their inactive counterparts, and 
2) physical activity increases the rate of turnover of micronutrients resulting from excessive 
micronutrient loss via increased catabolism and excretion (sweat and urine). Consequently, 
the distortion of neuromuscular function due to Mg2+ deficiency may occur and causes the 
decline of overall physical performance and impair exercise capacity (Finstad and 
Newhouse, 2001; Bohl C and Volpe, 2002; Nielsen and Lukaski, 2006) and impair 
cardiovascular parameters in the general population (Chakraborti et al., 2002; Khan et al., 
2010). Laires et al ( 2014) have highlighted the importance of evaluating magnesium status 
in athletes not only because the practice of exercise with a magnesium deficit may 
compromise performance, but also because the practice of exercise with a magnesium 
deficit may render the athlete more susceptible to cellular damage (Laires et al., 2014). 
Therefore, the consumption of dietary Mg2+ along with supplementation is a consideration 
for the athlete. 
Higher intracellular Mg2+ levels may improve intracellular adenosine triphosphate production 
as Mg2+ is a cofactor for several ATP synthases (Laurant and Touyz, 2000). Mg2+ has also 
been reported as an ubiquitous  physiological calcium blocker (Shechter, 2010; Lutsey et 
al., 2014) reducing the release of calcium from and the re-uptake into the sarcoplasmic 
reticulum whilst protecting the cells from calcium overload under conditions of ischaemia. 
As mentioned above, Mg2+ reduces systemic and pulmonary vascular resistance with a 
concomitant decrease in blood pressure resulting in a slight increase in the cardiac index 
(Wilborn et al., 2004; Cunha et al., 2012).  Cardiac index is defined as cardiac output/body 
surface area (Jefferson et al., 2015) and therefore relates heart performance to the size of 
the individual. Investigations into magnesium’s effect on muscular contraction and strength 
are limited (Bohl C and Volpe, 2002; Carvil and Cronin, 2010; Matias et al., 2010).  The 
rationale for investigating this is that muscle contraction and relaxation are dependently 
regulated by intra/extracellular Ca2+ and Mg2+ concentrations. During a state of Mg2+ 
depletion it has been suggested that there is insufficient relaxation time for crossbridge 
formation due to the  antagonistic role of Mg2+ as a Ca2+ channel-blocker (Lukaski and 
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Nielsen, 2002). An elevated extracellular Mg2+ concentration influenced by supplementation 
has been seen to induce an increased intracellular Mg2+ concentration, changing the Mg2+ 
to Ca2+ ratio and therefore optimising vascular smooth and skeletal muscle cell bioenergetics 
and contraction (Zhang, Altura and Altura, 1997).  
 
The research in regard to strength is considerably weaker and restricted to just 4 published 
articles, three of which were conducted in athletic populations (Brilla and Haley, 1992; Matias 
et al., 2010; Santos et al., 2011) and the other in an elderly male and female population 
(Dominguez et al., 2006b). In regard to the only study that looked at strength and Mg2+ 
supplementation, Brilla and Haley (1992) illustrated significantly greater absolute and 
relative peak torque quadriceps strength for the Mg2+ supplemented group versus control 
group. Mechanisms implicated in the augmented strength due to Mg2+ intake and 
supplementation include: 1) MgATP complex formation optimising energy metabolism and 
muscular contraction, 2) increased protein synthesis rate, and 3) protection against cellular 
damage. Further findings have shown that high intracellular Mg2+ concentrations and 
subsequent formation of the MgATP complex, influence protein synthesis and cell 
proliferation by stimulating the activation of mammalian target of rapamyacin (mTOR), 
therefore accelerating translation towards DNA synthesis (Rubin, 2005); Mg2+ regulatory 
action on insulin and the activation of specific enzymes (i.e. phosphotidylinositol-3 kinase 
(PI3K)) within the mTOR cascade further account for cellular functions augmenting protein 
synthesis (Zhang, Altura and Altura, 1997; Rubin, 2005).   
 
1.6.1 Magnesium, exercise and inflammation 
It has been postulated that low serum and dietary Mg2+ levels are correlated with low grade 
systemic inflammation. Magnesium plays an essential role in a wide range of fundamental 
cellular reactions with a focus being on the association with markers of inflammation being 
associated with Mg2+ deficiency (Mazur et al., 2007)   
 
Kruse & Orent (1932) were the first to observe clinical symptoms of inflammation in 
magnesium deficient rats. Characteristics commonly seen in reaction to allergies including 
erythema (redness of the skin or mucous membranes), hyperemia, and oedema, occur 
spontaneously in the hypomagnesemic hypercalcemic rats (Classen et al., 1993). The 
most prominent change identified in blood is an increase in leukocytes, predominantly 
neutrophils and eosinophils (Belin and He, 2007). The increase in leukocytes is also 
accompanied by an increase in pro-inflammatory cytokines such as Interleukin 6 (IL6) 
which also has transcriptional control of C-reactive protein (CRP) (Pepys and Hirschfield, 
2003). In most cases the circulating value of CRP reflects ongoing inflammation whether in 
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response to tissue damage or to a systemic inflammatory state  (Pepys and Hirschfield, 
2003).  Acute or unaccustomed exercise can induce inflammation due to damage to the 
contracting muscle which activates signalling via the NFKB pathway, resulting in release of 
TNF-alpha and IL6, stimulators of the release of CRP from hepatocytes (Beavers, Brinkley 
and Nicklas, 2013). However, chronic exercise training has been shown to have an anti-
inflammatory effect.  The exact mechanisms by which physical activity may reduce 
inflammation are not entirely understood, however there are some data pointing to factors 
that may contribute to an effect of repeated bouts of muscle contraction leading to 
improvements in inflammatory status over time. These factors include, shifts in monocyte 
phenotype, specifically reductions in immune cell production of inflammatory mediators, 
with exercise training.  Immune function adaptations that occur locally in exercised skeletal 
muscle and exercise-induced adaptations in intracellular generation of reactive oxygen 
species (ROS) (Beavers, Brinkley and Nicklas, 2013) 
 
With regards to dietary supplementation, a study by Phillips et al  (2003) investigating the 
effect of a dietary supplement containing tocopherols, flavonoids and docosahexaenoate 
concluded that exercise induced inflammation, evaluated by changes in IL6 and CRP were 
significantly reduced by this supplement (Phillips et al., 2003) 
A more recent study by Welch et al (2016) investigated association between circulating CRP, 
muscle mass and leg explosive power to determine whether dietary magnesium may impact 
on this association.  This study specifically looked at females and age related skeletal 
muscle loss in order to identify indirect and direct impact of dietary magnesium on chronic 
low-grade inflammation which is a risk factor for loss of skeletal muscle mass and strength. 
They concluded that higher CRP was negatively associated with skeletal muscle mass and 
that a higher dietary Mg2+ intake attenuated this negative relationship by 6.5% with greatest 
effects in women older than 50y (Welch et al., 2016).  This association between magnesium 
intake and inflammation may impact magnesium studies investigating performance and 
recovery from performance as well as muscle power and sarcopenia. 
  
1.7 Magnesium consumption 
To maintain an adequate physiological levels of Mg2+, humans must consume Mg2+ at 
regular intervals (Jahnen-Dechent and Ketteler, 2012). The daily recommendation for Mg2+ 
is controversial, as the literature is conflicting and varies between countries, although values 
of ≥ 300 mg.day-1  are usually reported for healthy adults with adjustment for age, sex and 
nutritional status (Jahnen-Dechent and Ketteler, 2012). The Committee On Medical Aspects 
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(COMA) calculated a reference nutrient intake (RNI) of 300 mg.day-1 for adult males and 
270 mg.day-1 for adult females (Public Health England, 2014b).  
 
The richest dietary sources of Mg2+ include whole seeds such as un-milled grains, 
vegetables, legumes and nuts. Green leafy vegetables are also a key source of Mg2+ as  the 
mineral plays a key role in plants as well as biological systems as it is the central ion of 
chlorophyll (Black, Yin and Casey, 2006). It is difficult to absorb Mg2+ from refined foods as 
the refining process almost completely leaches the Mg+ content from the unprocessed form 
of the food.  Dietary Mg2+ in the western diet is declining due to the ever increasing 
consumption of processed foods (Ford and Mokdad, 2003). The nutritional guidelines in the 
UK for Mg2+ consumption may be inappropriate as research now suggests, that the 
Committee on Medical Aspects (COMA) calculation of an RNI of 300 mg.day-1 for adult 
males and 270 mg.day-1 for adult females (Ashwell, 1991) is below the recommended values 
in the literature and less than the US recommendation.  After adjustment for age, sex and 
nutritional status values of ≥300mg are usually reported within the literature (Jahnen-
Dechent and Ketteler, 2012) and The institute of Medicine recommends 320 mg.day-1 and 
420 mg.day-1 for adult females and males respectively (Institute of Medicine (US), 2005). 
This is the minimum consumption as it is based on daily recommended intakes, the lowest 
continuing intake level of a nutrient that, for a specified indicator of adequacy, will maintain 
a defined level of  adequate nutrition in an individual (Institute of Medicine (US), 2005).  
Additional Mg2+ may be consumed via drinking water with ~10% of total intake coming 
naturally from this source (Marx and Neutra, 1997). The total amount of Mg2+ received from 
water will differ depending on geographical location as water in different parts of the country 
will contain varying concentrations of Mg2+. 
The main dietary constituent that interacts with Mg+ absorption is dietary fibre. A high fibre 
diet can reduce Mg2+ absorption through the binding of magnesium to phytate (Bohn et al., 
2004). As well as phytate, intestinal absorption can be attenuated by alcohol or an excess 
of phosphate and Ca2+ by lowering the concentrations in the lumen (Fine et al., 1991). 
Although there are interactions between magnesium and calcium, at the cellular level, Fine 
et al. (1991) detected no significant effect of Ca2+ supplementation on magnesium 
absorption. 
 
1.8 Magnesium supplementation – dosage and type 
Magnesium supplementation regimes applied to elicit improvements in exercise 
performance have differed considerably across the research literature in terms of duration, 
dose and the type of Mg2+ salt administered. For instance duration of Mg2+ administration 
has ranged between 1-3 months, with a dose between 116-500 mg/d provided as an organic, 
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inorganic or amino acid chelate form (Newhouse and Finstad, 2000; Walker et al., 2003).  In 
regard to the latter, the characteristics highlighted by each Mg2+ supplement are influenced 
by the specific anion attachment with Mg2+, thus influencing supplement solubility, elemental 
Mg2+ bioavailability and supplement effectiveness (Ranade and Somberg, 2001). Research 
has shown that organic forms of Mg2+ supplementation i.e. attached to aspartate, citrate, 
lactate, pidolate, fumurate, acetate, ascorbate and gluconate to demonstrate  greater 
solubility and bioavailability in comparison to inorganic forms i.e. oxide, sulphate, chloride 
and carbonate (Newhouse and Finstad, 2000). Despite such factors influencing the efficacy 
of Mg2+ supplementation, the inorganic form of Mg2+ oxide due to its low cost has been 
extensively used in research. However, although Mg2+ oxide has been reported to sustain 
high elemental Mg2+ quantities (61%) (Guerrero-Romero and Rodríguez-Morán, 2002) the 
administration of this supplement may be questioned due to findings showing that Mg2+ 
oxide has a consistently poor bioavailability of only approximately 43% (Lindberg et al., 
1990), in comparison to organic forms of Mg2+  (55-70%) (Mühlbauer et al., 1991; Ranade 
and Somberg, 2001; Walker et al., 2003; Coudray et al., 2005). Previous findings suggests 
that the poor bioavailability of Mg2+ oxide induces an osmotic effect in the bowel, resulting 
in an increase in stool frequency and intestinal motility (Walker et al., 2003), therefore 
potentially hindering the complete absorption of elemental Mg2+.  
 
Nevertheless, analysis of Mg2+ bioavailability literature from differing supplement forms does 
little to clarify the most effective type of Mg2+ supplementation in humans (Coudray et al., 
2005).  Mühlbauer et al. (1991) compared the bioavailability of Mg-L-aspartate hydrochloride 
(HCL) and Mg2+ oxide in healthy males and females for a duration of 28 days 
supplementation. Results showed that Mg-L-aspartate HCL at both 60 and 90 mEq daily 
doses for 7 days gave a greater total absorption compared to the same dose of Mg2+ oxide. 
Additional research supports findings from both an acute (24h) and chronic (60 days) 
supplementation design, whereby a comparable 300 mg/d dosage of elemental Mg2+ from 
Mg2+ citrate facilitated a greater absorption when compared to amino acid chelate and oxide 
forms (Walker et al., 2003). A more recent publication evaluated the comparative 
bioavailability of ten organic and inorganic Mg2+ salts (oxide, chloride, sulphate, carbonate, 
acetate, pidolate, citrate, gluconate, lactate and aspartate) using a methodological approach 
inducing an initial dietary  Mg2+ depletion, followed by 2 weeks of Mg2+ repletion via 550 
mg/d supplementation (Coudray et al., 2005). Findings corroborated previous research 
indicating that organic Mg2+ forms had a greater bioavailability than inorganic forms. 
However, solely basing supplementation on bioavailability may be flawed as the amount of 
substance needed to consume the 300 mg elemental dosage varies greatly between the 
different magnesium intake requirements (table 1). 
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Table 1. Supplemental Mg2+ quantity relative to the production of elemental Mg2+ 
corresponding to the male RNI of 300 mg.d-1. 
Type of supplemental Mg2+ Quantity mg 
Mg L-Aspartate HCL 3750 
Mg Citrate 2670 
Mg Lactate 2530 
Mg Gluconate 6000 
 
 
This thesis will consider the effect of magnesium supplementation on blood pressure, 
exercise performance and recovery.  It will also consider the habitual dietary habits of a 
cohort of hypertensives and the absorption of a magnesium cream.  Dietary magnesium 
intake and magnesium loading strategies will also be presented. 
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Section 2.  Aims, objectives, methodology and overview of findings 
 
2.1 List of contribution, by publication, from Lindsy Kass:- 
Study 1 Kass contributed 40% of the work, to included data analysis, interpretation of results 
and writing of abstract. 
Study 2 As Principal Investigator and first author, Kass contributed 70% of the work, to include 
initial idea, project design, research methodology, data analysis and interpretation and writing 
of manuscript. 
Study 3 As Principal Investigator and first author, Kass contributed 70% of the work, to include 
initial idea, data collection, data analysis and interpretation and writing of manuscript. 
Study 4 As Principal Investigator and first author, Kass contributed 70% of the work, to include 
initial idea, project design, research methodology, data analysis and interpretation and writing 
of manuscript. 
Study 5 As Principal Investigator and first author, Kass contributed 90% of the work, to include 
initial idea, project design, data collection, research methodology, data analysis and 
interpretation and writing of manuscript 
Study 6 As Principal Investigator and first author, Kass contributed 80% of the work, to include 
initial idea, project design, data collection, research methodology, data analysis and writing of 
manuscript. 
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2.2 Aims and objectives 
 
   2.2.1 General aim 
The overarching aim of this PhD by publication was to investigate effect of dietary and 
supplemental magnesium on blood pressure and exercise. 
 
 
   2.2.2 Specific aims 
 
1. To determine if magnesium supplementation effects blood pressure in healthy males. 
2. To determine if magnesium supplementation effects  aerobic and resistance exercise in 
recreationally active people. 
3. To establish the habitual dietary magnesium intake in a population group of with primary  
hypertension. 
4. To determine the effect of loading strategies of magnesium supplementation on 
recovery from exercise and blood pressure in a recreationally active group of people. 
5. To review previous research on magnesium supplementation and blood pressure, 
evaluating overall results via a meta-analysis 
6. To determine via serum and urinary magnesium analysis the absorption of a transdermal 
magnesium cream on a healthy male and female population group. 
 
 
2.3 General Methods 
2.3.1 Ethical approval, consent forms and health and safety considerations 
Prior to data collection, ethical approval was granted.  With the exception of Study 5 this 
was granted from the University of Hertfordshire School of Life and Medical Science Ethics 
Committee.   For study 5 ethical approval was granted by the North and East Herts Local 
Research Ethics Committee. 
Before any testing started, participants were informed orally and in writing of the aim, risks 
and benefits of taking part and were given the opportunity to ask any questions.  A health 
screen was then completed along with a consent form.  Risk assessments were undertaken 
for all studies and formed part of the ethics procedure. 
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2.3.2 Participants 
For all studies participants were volunteers and did not receive any financial or other 
incentives to complete the study.  However, upon completion of each study each participant 
could receive their results as appropriate to the investigations undertaken.  Common 
inclusion criteria were that the participants were in good health, with the exception of study 
5 where the intervention group were hypertensives. For those studies that included 
resistance or aerobic exercise participants needed to be injury free and “recreationally 
trained”.  This was defined as training 2-3 times a week for the past year in the study specific 
exercise protocols as described and justified in the submitted papers. 
 
2.3.3 Measurements 
Common to all studies was the recording of food diaries.  These varied between 3-8 days.  
Dietplan 6 software (Forestfield software Ltd, West Sussex, UK) was used for all dietary 
analysis. Study 6 required participants to repeat their dietary intake on the days when serum 
magnesium was to be collected in order that an acute high dietary magnesium intake on one 
day would not skew results.  All other studies did not have any specific dietary requirements. 
Participants were instructed on how to complete a food diary and provided with pictures of 
sample food sizes adapted from The Medical Research Council Collaboration Centre for 
Human Nutrition Research, (Public Health England, 2014b). 
 
Both serum and urinary magnesium were analysed by colorimetric assay (RX MONZA, 
Randox Laboratories Ltd, UK).  All samples were frozen at -80oC for between 4-12 weeks 
and then analysed in one batch.  Blood samples were collected by venepuncture from the 
median cubital, basillic or cephalic vein.  Serum separator vacutainers were inverted 10 
times before being left to rest for 30 minutes.  Subsequently samples were centrifuged at 
3000rom for 10 minutes.  Serum was checked to be free from haemolysis and was 
immediately pipetted and frozen.   
 
Urine was collected into 3 litre collection vessels over 24 hours, with the first collection being 
the second evacuation of the day and the final collection being the first evacuation the next 
day.  Urine was then decanted into a measuring vessel and volume of urine was recorded.  
The measuring vessel was then placed on a magnetic stirrer at 100rpm.  To re-suspend the 
magnesium, the pH was lowered to 3-3.25 by adding 5 M hydrochloric acid.  Duplicate 1 mL 
aliquots were then frozen. 
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All cycle protocols were carried out on the Monark Ergomedic 874 E Cycle Ergometer 
(Monark, Sweden) and handle bar height and seat height were recorded at baseline and 
duplicated for each visit to the laboratory. 
 
Blood pressure was taken from the right arm using the Omron MX3 (Omron Healthcare, 
Kyoto, Japan).  Callibration is required every 5 years and equipment was less than 5 years 
old.  However, at random sampling times blood pressure was taken twice, once with the 
habitual cuff and again with another cuff in order that validity could monitored. 
 
Data were presented as mean values and standard deviation for numeric variables or as 
percentages for categorical variables.  All investigated parameters were tested for normality 
using the Kolmogorov-Smirnov test.  SPSS (Version 22, IBM New York, USA) or STATA 
(Version 11, StatCorp LP, College Station, TX, USA)) were used for all data analysis. The 
alpha value was set at 0.05 for all studies.  Power analysis, were undertaken using GPower 
(Faul et al., 2007) for studies 4 and 5.  Where data in magnesium were limited, as was 
expected due to the novelty of this work, calcium results were used from previous research 
to determine sample size for the studies.  Post Hoc power calculations, with a power level 
of 80%, have now been undertaken for pilot and main studies and are discussed in section 
2.3.7 (Limitations to studies). 
 
For study 3, the meta-analysis, the Critical Appraisal Skills Programme (CASP) (copyright 
Public Health England 2006, Appendix 1) was used to judge the quality of the research for 
inclusion into the study.  This is a critical appraisal tool that uses 10 questions to help to 
consider, if the trial is valid, what are the results and will the results help locally.  This 
information was not required for publication and was removed from the methodology.   
 
2.4 Overview, findings and results 
2.4.1 The effect of magnesium on blood pressure, power and peak torque with short 
term high intensity exercise 
The first study undertaken as part of this portfolio investigated the effect of Mg2+ 
supplementation on three main outcomes: (i) peak and mean power during an all-out 
maximal intensity short term exercise protocol, (ii) systolic and diastolic blood pressure post 
maximal exercise and (iii) recovery of isokinetic knee extensor muscle function post 
exercise. 
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The reason for undertaking this study was due to there being limited previous research on 
the effect of Mg2+ on short term high intensity exercise and its subsequent effect on blood 
pressure and muscle recovery post exercise.  
 
The study used a double blind, repeated measures design with participants supplemented 
with either placebo (cornflour) or 300 mg of Mg2+ aspartate for 2 days prior to the test day 
and 300 mg on the test day 60 minute prior to testing. Maximal isokinetic extensions of 5 
repetitions by the right leg were performed by each participant 1 week prior to the testing to 
establish a baseline for peak torque (Nm). The test day consisted of participants performing 
a 30 second Wingate Anaerobic Test (WAnT) and resting for 30 minutes post-WAnT before 
performing 5 maximal isokinetic knee extensions at 60º/second on the right leg. A further 
100mg Mg2+ aspartate or placebo was given to each participant immediately post-WAnT. 
Peak power and mean power (W) were recorded from each WAnT. Peak torque (Nm) was 
measured from the isokinetic knee extensions. Systolic and diastolic blood pressure was 
recorded at rest and every 5 minutes during the 30 minutes recovery after the WAnT 
 
Mean peak power (W) was significantly (p=<0.05) increased during the WAnT between the 
placebo condition (851.1±119.5 W) and the Mg condition (911.9±107.7 W).  Mean total 
power (W) was also significantly increased during the WAnT with the intervention compared 
to the placebo (704.5±97.1 W & 683.1±95.6 W respectively). A significant increase was also 
found in mean peak torque (N/m) between the placebo condition (195.7±47.4 N/m) and the 
Mg condition (222.2±33.2 N/m). Systolic blood pressure (SBP) was 5% lower during the 30 
minutes post-WAnT  in the Mg condition (119.7±6.8 mmHg) compared to the placebo  
(125±7.3 mmHg). However, this effect was not seen in the diastolic blood pressure. 
 
These improvements in knee extension peak torque may be due to increased  ATP  
synthase activity due to the  magnesium  supplementation along with an increase in tyrosine-
kinase activity and auto-phosphorylation at the insulin receptor level (Guerrero-Romero et 
al., 2004).  This improvement may also  be attributed to the role of Mg2+  at the ribosomal 
level in protein synthesis (Brilla and Haley, 1992)  although no further studies have 
investigated this and the exact mechanism has, to date, not been demonstrated. 
 
MgATPase activity and Mg-bound ATP present on the acto-myosin heads results in faster 
and higher rate of filament detachment and reattachment producing faster and more 
powerful muscle contraction. This also occurs due to the increased rate of ATP hydrolysis 
from higher ATPase activity on the myosin heads (Brilla and Haley, 1992).   
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The results from this study concur with previous research such as Brilla & Haley (1992) and 
Finstad & Newhouse (2001) and therefore efficacy of Mg supplementation for endurance 
exercise and recovery was investigated in subsequent papers submitted as part of this 
thesis. 
 
This study is the first to investigate the effect of Mg2+ supplementation on blood pressure 
after exercise.  The observed decrease in systolic blood pressure was in line with previous 
work in the resting state, but the effect on post-exercise blood pressure had not previously 
been investigated.    The results from this small study raised many questions that led to 
further investigation forming part of the body of work. Mechanisms for this reduction in blood 
pressure have been postulated in the introduction above (p15-16) but only observational 
measurements were available in this first investigation. 
 
For this study magnesium aspartate was used, but it was subsequently banned in the UK 
due to the concern that aspartate is a known excitatory neurotransmitter and that an 
overdose may occur.   
 
From the positive results found from this first study, Mg2+-L-Aspartate HCL would have been 
the primary choice of supplemental form for administration for further studies.  However,  
European legislation as published by the European Food Safety Authority (Aguilar et al., 
2008) banned the consumption  of supplemental aspartate  due to the  NAOEL (no 
observable adverse effect level) being low and an intake above this may induce an amino 
acid imbalance which has been shown to cause neural excitability (Aguilar et al., 2008). It 
is, however, still available on prescription. Magnesium citrate or oxide were used for all 
subsequent studies.   
 
The changes in blood pressure were greatest in this investigation compared to other work 
forming part of this thesis.  It cannot necessarily be attributed to the form of magnesium used 
but is a consideration for future work.  
Nevertheless, the literature available of Mg2+ bioavailability from differing supplement forms 
provides minimal indication as to elucidate and specify the most effective type of Mg2+ 
supplementation within humans (Coudray et al., 2005).  
 
Having used Mg2+ aspartate for this first study the results showed a significant increase in 
peak power and mean peak power during the WAnT and a significant increase in peak 
torque on the knee extension.  There was also a significant decrease in SBP during the 30-
minute recovery with the magnesium supplemented group.    The results for this were 
presented at the Nutrition Society Annual Conference (2010) as a poster and interest in the 
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blood pressure results was much greater than had been anticipated.  Previous research had 
already shown that there was an association between magnesium and blood pressure 
although the literature did not demonstrate consensus with respect to dose and length of 
intervention.  There was also very little research examining this in combination with physical 
activity or exercise.  It was also questioned whether the amount of habitual dietary 
magnesium intake impacts on the absorption and effect of magnesium supplementation. 
These therefore formed the research questions for the next investigation. 
 
2.4.2 Dietary stratification of high and low magnesium intake and effect on blood 
pressure and performance 
After demonstrating the benefits of magnesium supplementation on anaerobic power, peak 
power and blood pressure in the first study, the next study was designed to determine 
whether magnesium supplementation influenced aerobic and resistance exercise 
performance and post-exercise blood pressure.  To date no research has analysed habitual 
dietary Mg2+ intake and any interaction with the effects of supplementation.  As Mg2+ 
transporters TRPM6 and TRPM7 have upper saturation levels (Rondón et al., 2008), it was 
postulated that those with adequate dietary intake of magnesium may not benefit from an 
additional intake via the supplement, although no harmful effect would be anticipated  either. 
 
Many studies have asked participants to record food diaries to establish what are habitual 
daily magnesium intake with the goal of determining whether the RNI for magnesium was 
achieved. However, the influence of habitual Mg intake on the efficacy of Mg 
supplementation has not previously been assessed. 
 
The objective for this pilot intervention was to investigate the effect of magnesium 
supplementation on systolic blood pressure whilst resting and during recovery from aerobic 
and resistance exercise and on endurance and resistance exercise performance. The 
stratification of high and low dietary intake was not an a-priori to the study and was 
introduced after dietary magnesium intake had been analysed from the food diaries. 
 
Sixteen male volunteers were randomly assigned to either a 300 mg/d magnesium oxide 
supplementation or a control group for 14 days with a parallel design.  This was further 
stratified into high and low dietary Mg2+ intake with the cut off being at the RNI of 300mg/d.  
Resting blood pressure and heart rate was measured before a 3 minute warm-up after which 
participants performed a maximal 30 minute cycle time trial immediately followed by three 
isometric contractions held for five seconds each whilst performing a bench press, blood 
pressure measurement was repeated post exercise. The laboratory conditions were a 
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constant 210c on all days of testing and data was collected between November and January.  
A 3-minute warm-up had been considered standard up to this study but 5 minute warm-ups 
were undertaken for subsequent research as reference to other studies showed this to be 
the standardised time for a warm-up and to decrease risk of injury for a maximal protocol, 
although no injuries were experienced in the present study.  A 3-day food diary was recorded 
for all participants. In the experimental group for all participants (n=8), mean resting systolic 
BP was reduced by 8.9 mmHg, p=0.01) and post exercise by 13 mmHg (p=0.01). Recovery 
BP was 11.9 mmHg lower in the experimental group compared to control (P=0.006). HR 
was 7 beats per minute lower in the experimental group (69.0 ± 11.6 bpm, P=0.02). 
Performance indicators were not different between the groups.  
 
When blood pressure results were stratified by dietary Mg2+ intake there was no significant 
difference found for resting systolic BP in the control group for those above or below the RNI 
pre to post intervention.  However, a significant change was seen in resting systolic BP in 
the experimental group from pre to post intervention in the low dietary magnesium intake 
cohort  (n=3) (from 126.3±8.2 to 114.6 ± 11.6 mmHg, P=0.02) but with no change observed 
in  those with a high dietary Mg intake after supplementation (n=5). Whilst the sample size 
of this pilot study were low, the results suggest that supplementation has a greater effect on 
those with a habitual low dietary intake than on those with a high dietary intake.  No other 
studies have set out to determine this and further research is warranted in this area. Baseline 
SBP was also different between the high (121±6.1 mmHg) and low (127±8.3 mmHg) habitual 
dietary intake groups although a post hoc t-test showed that there was no significant 
difference between the groups (p=0.115). The differences in SBP found between a low and 
high magnesium dietary intake both at baseline and after supplementation also raises the 
question as to whether habitual dietary intake is low in those with clinically diagnosed 
hypertension and was investigated for Study 5 below.  
 
The Honolulu heart study undertaken by Joffres, Reed and Yano (1987) determined that 
Mg2+ intake from diet and supplementation had a strong inverse relationship with both 
systolic (SBP) and diastolic blood pressure (DBP). Results from both habitual diet and 
supplementation showed that greater Mg2+ intake reduced SBP by 4.6 mmHg and DBP by 
2.8 mmHg. Supporting these findings, Zhao (2004) also observed an inverse relationship 
between magnesium and hypertension when studying dietary differences and blood 
pressure between north and south China. It was identified that the population in the south 
of the country consumed significantly more Mg2+ than the north, and both SBP and DBP 
were lower in the south by 7.9mmHg and 6.9 mmHg respectively (Zhao et al., 2004). 
Although there was a relationship between the two variables, the lower blood pressures 
could not be completely attributed to the intake of magnesium as other nutrients may have 
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also affected blood pressure and were not adjusted for, although these were not analysed 
as part of this study. Joffres et al ( 1987) observed 61 dietary variables in a group of 615 
men who were free of cardiovascular disease. Their results were similar to those of Zhao et 
al., (2004) who, in finding an association between total Mg2+ intake and blood pressure, 
could not attribute the findings solely to Mg2+ as the trend was also associated with dietary 
potassium, phosphorous and fibre. Their results suggested that the high Mg2+ content of 
vegetables, whole grains and fruits may contribute to the low blood pressure seen in 
vegetarians.  On the contrary a cross-sectional study using data from the National Health 
and Nutrition Examination Survey (Public Health England, 2014b) reported no significant 
correlation between magnesium intake and blood pressure. 
 
Magnesium intake, in addition to other food sources, affects the bioavailability of Mg2+, 
highlighting the significance of dietary analysis. The current recommendation for dietary 
Mg2+ intake in the UK is the reference nutrient intake (RNI) values of 300 mg.day-1 and       
270 mg.day-1 for males and females, respectively, implemented by the Committee on 
Medical Aspects of Food and Nutrition policy (Department of Health, 1998). The National 
Diet and Nutrition Survey (Public Health England, 2014b) stated that the average 
consumption of the RNI in the UK is at 90% for males and  82% for females, representing a 
population consuming less than recommended.  Such statistics corroborate the increased 
prevalence of hypertension in the UK.  For example the UK prevalence of hypertension is at 
42% , establishing UK as the fourth highest European country in terms of hypertension 
prevalence,  which is also greater than for the United States (14.2%) and Canada (16.6%) 
(Wolf-Maier et al., 2003).  Reasons suggested for this prevalence include both dietary and 
lifestyle factors and better health checks where hypertension can be diagnosed and 
medication prescribed  (Geleijnse, Grobbee and Kok, 2005). In a comparative study between 
5 European countries Geleijnse et al (2005) found that mineral intake inadequacies i.e. 
suboptimal Mg2+ (<350mg/d) and K+ (<3.5g/d) or surplus Na+ (>2.4g/d) increased   the 
prevalence of hypertension.  In this study 80% of the UK participants were below the RNI, 
which was greater than in other countries; additionally, the study associated the low Mg2+ 
intake as a risk factor for hypertension with a population attributable risk percentage (PAR) 
of 7%. This realisation of the insufficient Mg2+ intake in the UK from these previous studies 
shaped future work and study 5 from this PhD investigates whether those with hypertension 
habitually ate a diet that was low in Mg2+. 
 
In addition to the established RNI for Mg2+ which applies to the general population, it has 
been shown that the amount required for an athletic population may be higher in order to 
avoid hypomagnesia.  For example, for general population dietary Mg2+ intakes of <200-250 
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mg/d would be needed to cause hypomagnesia (<0.65 mmol.l-1 )  but in an athletic 
population this would only need to be less than 300mg/d (Geiger and Wanner, 2012).  
 
This study has been the first to investigate whether dietary intake influenced the effects of 
Mg supplementation. To date there are no studies that determine if higher habitual dietary 
intake affects absorption of Mg supplements or if supplementation affects absorption of 
dietary intake.  There is no direct evidence to suggest a threshold effect but this has been 
proposed with the suggested mechanism of saturation of the TRMP transporters.  This 
natural divide of the high and low dietary magnesium intake, although not an a-priori 
hypothesis in this study allowed a new area to be piloted for further work. Other questions 
that arose due to this study were that of length of supplementation.  If intestinal Mg 
transporters were to become saturated, would continued supplementation add further 
benefit or would absorption efficiency be impaired as transporters became saturated?  There 
were no definite guidelines on how long Mg2+ supplementation should be taken, how much 
should be ingested and little information on what type was best.  There was also conflicting 
information with regards to the benefit of Mg2+ supplementation on hypertension.  Many 
studies showed a reduction in blood pressure in particular systolic pressure, yet the NICE 
guidelines specifically stated that Mg2+ supplements should not be considered for 
hypertension.  Therefore, for study 3 a meta-analysis was performed to pool data across all 
available studies to investigate effects of Mg2+ on BP.  
 
2.4.3 Effect of magnesium supplementation on blood pressure – a meta-analysis 
This study was a systematic review of existing literature to determine the overall effect of 
magnesium supplementation on blood pressure.  This was a defining piece of work that was 
to shape future investigations on magnesium by synthesising the evidence and identifying 
gaps in the literature and following publication received much attention. 
 
Previous research on magnesium supplementation and blood pressure was equivocal and 
this meta-analysis was undertaken to synthesise all available evidence as to the effect of 
Mg2+ on blood pressure and to establish the characteristics of trials showing the largest effect 
size.  Primary outcome measures were systolic blood pressure and diastolic blood pressure 
at the end of a follow up period. 
 
One hundred and forty-one papers were identified of which 22 trials with 23 sets of data 
(n=1173), with 3 to 24 weeks follow up, met the inclusion criteria with a supplemented 
elemental magnesium range 120mg to 720mg (mean dose 398mg). 95% confidence 
intervals were calculated using DerSimonian and Laird's (DerSimonian and Laird, 1986) 
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random effect model with effect size calculated using a Hedges G (Hedges and Olkin, 1985). 
The inclusion criteria were: 1) magnesium supplements as the only active Intervention 2) 
presence of a placebo or control group. 3) participants over the age of 18. 4) random 
allocation of participants to treatment conditions. 5) parallel or crossover trial design. All 
criteria had to be met for inclusion in the meta-analysis. 
 
Combining all data, an overall effect size of 0.36 and 0.32 for DBP and SBP respectively 
was observed (95% CI 0.27 to 0.44 for DBP and 0.23 to 0.41 for SBP), with a greater effect 
for the intervention observed in crossover trials (DBP 0.47, SBP 0.51). Effect size increased 
in line with increased dosage. Although not all individual trials showed significance in BP 
reduction, combining all trials did show a decrease in systolic BP of 3-4mmHg and diastolic 
BP of 2-3 mmHg, this further increased with crossover designed trials and intake above 370 
mg/d.  
 
It was concluded that magnesium supplementation elicits a small but clinically significant 
reduction in BP, an effect worthy of future prospective large scale randomised trials using 
robust methodology.  
 
Several studies have demonstrated that Mg2+ supplementation has a positive effect in 
reducing blood pressure in both hypertensive and normotensive individuals (Motoyama, 
Sano and Fukuzaki, 1989; Itoh, Kawasaka and Nakamura, 1997; Kawano et al., 1998; 
Doyle, Flynn and Cashman, 1999).  Ranges of between 120-1000 mg/d of Mg2+ have been 
used to  reduce blood pressure as can be seen in meta-analyses carried out prior to and 
subsequent to the present meta-analysis (Jee et al., 2002; Dickinson et al., 2006; Zhang et 
al., 2016). However several studies contradict this finding suggesting that Mg2+ 
supplementation will not aid in the reduction of blood pressure (Cappuccio, 1985; Yamamoto 
et al., 1995; Sacks et al., 1998). For these studies there was variation between the 
population groups and the dosage and duration of supplementation, but no single factor can 
be identified to have caused this variation in results. This contradictory literature adds to the 
doubt concerning the potential relationship between Mg2+ and blood pressure.  
However, a previous meta-analysis by Dickinson et al. (2006) did not find an association 
between Mg2+ and blood pressure and despite the fact that this is the  only meta-analysis 
not to have found an association, it was accepted by the Cochrane Library and therefore 
that single review influences healthcare decision makers in the UK and policy makers such 
as the National Institute of Clinical Excellence (NICE) and guides the decision that 
magnesium should not be used as an aid to lower high blood pressure.  Moreover, even the 
authors of the Dickinson study (2006) have made the following conclusion ‘In view of the 
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poor quality of included trials and the heterogeneity between trials, the evidence in favour of 
a causal association between magnesium supplementation and blood pressure reduction is 
weak and is probably due to bias. This is because poor quality studies generally tend to 
over-estimate the effects of treatment. Larger, longer duration and better quality double-
blind placebo controlled trials are needed to assess the effect of magnesium 
supplementation on blood pressure and cardiovascular outcomes’.  
 
 This meta-analysis by Dickinson et al., (2006) found that there was a small but significant 
reduction in DBP but no effect on SBP, a finding that contradicts every other study 
investigating this area.  The report only reviewed 12 trials with a total of 545 people.  
However, the authors concluded that most of the trials were of poor quality, with the 
intervention not long enough or large enough to detect the possible consequences of 
magnesium supplementation on high blood pressure. 
 
The inclusion criteria for Dickinson et al., (2006) were: 1) RCTs of a parallel or crossover 
design comparing oral magnesium supplementation with placebo, no treatment, or usual 
care; 2) treatment and follow-up ≥8 weeks; 3) participants over 18 years old, with raised 
systolic blood pressure (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥85 mmHg; 4) 
SBP and DBP reported at end of follow-up.  The current meta-analysis’ inclusion criteria 
were: 1) magnesium supplements as the only active intervention; 2) presence of a placebo 
or control group; 3) participants over the age of 18; 4) random allocation of participants to 
treatment conditions and 5) parallel or crossover trial design.  All criteria had to be met for 
inclusion into the study.  The inclusion criteria were very similar between the studies.  Of the 
12 studies included in the Dickinson et al (2002) study, 3 were not included in the current 
study, one because of participants being on a low sodium diet (Nowson and Morgan, 1989) 
, a second because the participants were on thiazide, a diuretic used to reduce blood 
pressure (Paolisso et al., 1992) and the third due to hawthorn extract being used as an 
intervention alongside magnesium (Walker et al., 2002).  The inclusion of these studies 
appears to go against the inclusion criteria of ‘no treatment and usual care’ and also adds a 
second intervention into the studies.  However, the current meta-analysis, which is the more 
recent, included 13 studies which were not in the Dickinson et al (2002) study of which only 
3 were published since publication of that earlier study. The reason for the non-inclusion of 
the other 10 studies cannot be determined and reference to the Dickinson et al (2002) paper 
for more detail on this for the interested reader would be suggested. 
  
The current meta-analysis concluded that Mg2+ supplementation lowers BP.  Further it 
showed that a cross-over design affects response more than a parallel design. For crossover 
trials the effect size increased substantially for both DBP and SBP when compared to the 
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non-crossover trials, reinforcing the idea that paired data would have more robust results 
from the intervention than non-crossover and that the effect from the intervention would be 
augmented. 
 
 
Dosage was found to have had a linear effect on response magnitude.  A sub-analysis was 
carried out with results divided into those with supplementation <370 mg.day-1 and those ≥ 
370 mg Mg per day.  Results for both SBP and DBP showed greater efficacy of magnesium 
supplementation at the higher dose.  When the higher magnesium dosage was further 
analysed a much higher effect size (DBP = 0.66 and SBP = 0.70; 95% CI: 0.51 to 0.82 and 
0.56 to 0.89 for DBP and SBP respectively) was found, and those using <370mg 
demonstrated high levels of variation.    
There was substantial heterogeneity between the findings of the trials for both DSP and SBP 
(I2 =82 and 88 respectively) which could be explained by random variation, the various 
population groups, the interventions or the methods used in the trials and length of 
intervention.  A more homogenous sample of studies may increase effect size; although a 
random effects model was used, the difference between the studies was high.   
 
Only one systematic review has previously looked at dietary magnesium and blood pressure 
(Mizushima et al., 1998) and one since the publication of this meta-analysis (Han et al., 
2017).  Mizushima (1998) concluded that there was a negative association between the two 
variables, although the authors indicated that inconsistencies between design and analysis 
of the studies complicated data interpretation.  Han et al (2017) included 10 studies, of which 
only one was published after this meta-analysis by Huitron-Bravo (2015).  This study had 
data collected in 2006 with a 7 year follow-up period and found only modest inverse 
relationship between dietary intake and BP in a Mexican population. In agreement with our 
work, Hans et al (2017) concluded that the current evidence supports the inverse dose-
response relationship between dietary magnesium intake and the risk of hypertension.   
 
In summary major limitations evident in most of the studies included in the meta-analysis 
were: - 
• lack of data on background dietary intake, which may have had major implications for 
all studies (see study 2).  
• lack of pre- and post-supplementation serum magnesium concentration, which would 
have enhanced understanding of absorption over a range of magnesium intakes.   
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Magnesium supplementation produced a greater effect size in studies employing a cross-
over rather than non-crossover design. This may be because the non-crossover design will 
be confounded by inter-individual variation in habitual magnesium intake whereby those who 
habitually consume more magnesium may show less of a response to the supplement than 
those who habitually consume less magnesium.  This meta-analysis highlighted gaps in the 
literature with regards to dietary magnesium intake and blood pressure and the influence of 
dietary magnesium intake on magnesium supplementation effects, both of which form part 
of this body of work.  Another unanswered question was the duration of supplementation 
required for effects to be observed.   
The next study investigated the duration of supplementation.  As mentioned above, 
magnesium transporters may become saturated once optimum magnesium is ingested.  The 
research looks at whether continuing to supplement with magnesium after the initial dosage 
has been given will further enhance the effect of magnesium. This investigation therefore 
sets out to determine whether the response to the first acute dose is the same as that of the 
Nth dose i.e. is chronic dosing necessary?  
 
2.4.4   Further effects of magnesium on blood pressure with acute and chronic dosing 
strategies 
The meta-analysis showed that there are many aspects in relation to the effects of Mg2+ 
supplementation and the most efficacious dosing regime that were still unknown.  One of 
these being the on-going question as to whether there is a cumulative effect of Mg2+ 
supplementation or whether favourable effects are due to repeated acute responses to each 
individual dose. From a mechanistic perspective this would be very difficult to determine at 
the cellular level. We therefore investigated whether the effects of acute (A) (1 week) and 
chronic (Chr) (4 weeks) loading on exercise and blood pressure were comparable as well 
as augmentation index (Aix). This index is a parameter measured by pulse wave analysis 
(PWA) and is used as a surrogate measure of arterial stiffness.  This allowed direct 
comparison of the response to one and four weeks of supplementation to isolate whether 
cumulative effects were evident. We hypothesised that the absence of a cumulative effect 
would indicate transporter saturation was achieved after one week.  No previous studies had 
investigated loading strategies to determine differences in outcomes on exercise 
performance and blood pressure from acute and chronic supplementation.   
 
This study set out to determine whether either acute or chronic magnesium supplementation 
would have an effect on performance (strength and cardiovascular) and blood pressure with 
exercise and/or on a second bout of exercise after a 24 hr recovery period.  It was 
hypothesised that as acute Mg2+ supplementation has been demonstrated to have beneficial 
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effects on BP, CV parameters and augmentation index (Aix) a longer loading strategy (4 
weeks) would amplify these results, giving a more beneficial and greater response.   
 
A total of 13 participants (female = 6) were recruited from recreational running, cycling and 
triathlete clubs. Six participants were allocated randomly to the acute (1 week) intervention 
group (m = 3, f = 3) and 7 to the chronic (4 week) intervention group (m = 4, f = 3), receiving 
the same daily dose with post-supplementation measures taken at the same interval after 
the last supplement dose.  
 
The study was a randomised, double-blind, crossover, placebo controlled, 2 day repeated 
measures protocol and was run across 2 consecutive days pre at baseline and again after 
either 1 or 4 weeks of intervention.   
 
A 40 km cycling time trial was followed by as many bench press as possible at 80% 1RM to 
exhaustion for two consecutive days with distance, blood pressure and augmentation index 
(Aix) being measured for both an acute and chronic loading strategy. 
 
Primary findings showed variance across treatment groups on exercise (strength and 
recovery) and cardiovascular responses. The chronic Mg2+ intervention showed no 
significant performance gains for bench press and strength. The acute Mg2+ intervention 
showed variation in results across all variables analysed with a trend shown for improvement 
in the bench press.  However, the magnitude of the effects of acute and chronic loading of 
Mg2+ were similar. 
 
2.4.4.1   Strength performance: 
For the acute group improvements were seen in 1-RM bench press.  In the published article 
this is presented as 17.7±1.3% (p=0.031) after 1 week of supplementation and no decline in 
recovery (day 2) performance, whereas the correct figure should be 7.7±1.3% (p=0.031). An 
erratum has been submitted to the journal. The chronic group showed no improvement in 1-
RM bench press (p=0.281) and there was a performance decrement of 32.1±8.2% on the 
recovery day (day 2). Previous research has shown that high dietary Mg2+ intake and high 
serum Mg2+ concentration significantly enhanced bench press (Matias et al., 2010) and 
strength performance  (Dominguez et al., 2006a; Santos et al., 2011).  In the present study 
acute but not chronic Mg2+ loading showed a significant strength increase, and where a 
decrease in force would be typically be expected on day 2 (recovery) a small improvement 
was seen.  
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These performance enhancements for the strength associated tests are suggestive of 
physiological-regulatory functions  of Mg2+ in muscle contraction and relaxation; i.e. 
regulating troponin expression via Ca2+ concentration gradients, MgATP complex formation 
optimising energy metabolism/muscular contraction, increasing protein synthesis rate, 
protection against cellular damage and, greater amount of actin-myosin crossbridges (Brilla 
and Haley, 1992; Lukaski, 2004; Barbagallo, Dominquez and Resnick, 2007; Carvil and 
Cronin, 2010) all of which contribute to increased strength and force production. 
Consideration must be given as to why such a contrasting difference between Chr and A 
groups occur specifically when regarding strength performance measures. The Mg2+ 
supplementation dose in the current research was 300mg/d, therefore equating the Chr and 
A group mean daily intake for Mg2+ to 675 mg/d and 668 mg/d, respectively, when combined 
with dietary Mg2+ intake as analysed from food diaries. This adds a sense of greater 
ambiguity when considering the Mg2+ - strength performance relationship, and comparing to 
research highlighting observations that intakes of 500 mg/d or greater result in further 
increases in strength (Brilla and Haley, 1992; Lukaski, 2004).    
 
Although the RNI was exceeded, the expected effect was not seen.  It could be suggested 
that the acute effect observed after 1 week was attenuated after 4 weeks daily 
supplementation due to saturation of Mg2+ transporters. It could be suggested that 
participants within the Chr loading group might be more susceptible to Mg transporter 
downregulation or cell tolerance for Mg2+ absorption based upon the understanding that high 
Mg2+ intakes result in a lower Mg2+ absorption (Jahnen-Dechent and Ketteler, 2012).  This 
is a repeated theme in this body of work and is something that will continue to form future 
research questions.  There is no evidence to support this as, to date, there is no published 
work investigating upper thresholds or tolerance levels. Additionally, Mg2+ homeostasis may 
be postulated to exhibit no greater benefit from the chronic perspective due to the kidney 
function for Mg2+ excretion as to maintain a balanced concentration of Mg2+ (de Baaij, 
Hoenderop and Bindels, 2012; Jahnen-Dechent and Ketteler, 2012); for example, could the 
principle of a higher Mg2+ dose, longer supplemental duration and associated proportional 
increase of Mg2+ excretion highlight the body’s efficiency in maintaining a state of 
homeostasis? Alternatively, chronic loading through providing a regular high Mg2+ intake 
may influence extracellular Mg2+ concentrations which coincide with manipulation of Mg2+ 
transporter TRPM6 function, resulting in a potential decrease in TRPM6 expression in 
conjunction to increasing the urinary excretion of Mg2+ (Alexander, Hoenderop and Bindels, 
2008). Thus, an acute ingestion protocol may prove more effective for enhancing exercise 
performance than a chronic supplementation approach.  
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2.4.2.  Blood pressure 
Significant reductions in SBP and DBP were seen in post-exercise measurements in the 
chronic group and rest and post-exercise in the acute group across day 1 and 2 compared 
to both baseline and placebo groups. Resting SBP declined to a greater extent after A Mg2+ 
( 2±0.6 mmHg), in comparison to 0.7±0.4 mmHg with the Chr Mg2+ treatment. In addition, 
both resting and post-exercise DBP showed reductions with a greater day-to-day DBP 
reduction in the A Mg2+ in comparison to Chr Mg2+ as shown by a 69.2% and 50% (9 mmHg 
and 3 mmHg difference) at rest and post exercise for A and Chr groups respectively. These 
findings are in agreement with previous research (Motoyama, Sano and Fukuzaki, 1989; 
Itoh, Kawasaka and Nakamura, 1997) showing the importance of Mg2+ and its influence on 
blood pressure regulation. This supports the findings discussed previously in the meta-
analysis which forms part of this body of work (study 3).  
 
Such reductions in blood pressure could be speculated as being an outcome influenced by 
increases in the extracellular concentration of Mg2+, an effect that has been associated with 
reductions in arterial tension and tone. These reductions in arterial tension and tone 
correspond to typical Mg2+ induced vasodilatory actions, which potentiate effects of 
endogenous vasodilators such as adenosine, K+, nitric oxide and cyclo-oxygenase-
dependent mechanisms via production of PGI2 (Pokan et al., 2006). In combination, Mg2+ 
acts as an antagonist to blocking Ca2+ channels (O’Rourke, Backx and Marban, 1992; 
Laires, 2004; Santos et al., 2011) and further enzymatic mobilisation of Ca2+ (Laurant and 
Touyz, 2000). Thus, data in the current study concur with previous research on the efficacy 
of Mg2+ supplementation in reducing blood pressure (Itoh, Kawasaka and Nakamura, 1997; 
Guerrero-Romero and Rodríguez-Morán, 2002) and its capacity to suppress  agonist 
vasoconstriction (Touyz, 2003). Many of these models have been shown in rats, with very 
few in vitro studies in humans.  This is another area for future research. 
 
For the augmentation index no changes were seen at rest for both cohorts.  However, there 
was a significant lowering post exercise on day 1 for the acute treatment group and day 2 
for the chronic treatment group which does not correspond to the SBP changes but does 
correspond to changes in DBP for the acute post exercise measurements. 
 
Average dietary Mg2+ intakes within the A and Chr groups corresponded to 368 mg/d and 
375 mg/d, respectively which are above the RNI.  Greater effects may have been seen in a 
population with sub-optimal Mg2+ intake.  Therefore, it could be considered that the blood 
pressure reduction in Chr and A loading strategies, may be attributed to the Mg2+ 
supplementation and that a higher daily intake may be beneficial in reducing blood pressure. 
Research by Geleijnse et al.(2005) in a comparative study between 5 European countries 
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which included the UK, corroborates with this study, recommending a potential increase  in 
Mg2+ intake due to the hypotensive and further suggesting that <350mg/d of Mg2+  may be 
suboptimal,  increasing  the prevalence of hypertension.  
 
 
 
The initial focus of this body of work was on the application of Mg supplementation to 
exercise performance and physiology.   However, despite the absence of ergogenic effects 
of chronic Mg2+ for performance, there appeared to be the potential for health benefits 
associated with the potential for reduced BP. Further, when investigating the effects of 
dietary intake and its effect upon magnesium supplementation and blood pressure it was 
observed that there was a gap in the literature regarding the habitual dietary intake of 
magnesium in those who had been diagnosed with hypertension 
 
 
 
2.4.5    Habitual dietary magnesium intake in the hypertensive population; observations on 
general population dietary intake 
This investigation set out to determine whether those with hypertension habitually ate a diet 
that was low in Mg2+; a question that had not previously been addressed by research in the 
UK.  Many studies have found a positive correlation between magnesium supplementation 
and reductions in hypertension (Kawano et al., 1998; Townsend et al., 2005; Rylander, 2012, 
Itoh, Kawasaka and Nakamura, 1997) Zhang et al., 2016) but to date there have been  no 
studies that have looked at those already diagnosed with primary  hypertension and 
investigated their dietary magnesium intake.  A recent study by Bain (2013) investigated 
magnesium intake and BP in relation to risk of stroke, with BP being  causal  for up to 70% 
of all stroke cases.  This study was specific to the British population with participants 
completing a 7-D food diary. Multivariate adjustment was made for age, BMI, total energy 
intake, education level, smoking status, physical activity, baseline history of stroke, heart 
attack or diabetes mellitus, family history of stroke or heart attack, use of aspirin medication 
(>3 month), antihypertensive medication, dietary sodium, potassium, alcohol and total fat 
intake.  Results showed that there was an inverse relationship between dietary magnesium 
and blood pressure, significant in men, but not in women. In men differences between top 
and bottom quintiles of - 7mmHg and - 4.3mmHg, for SBP and DBP respectively were 
observed. This decrease in BP could be associated with a reduction of stroke risk by up to 
40%, a highly meaningful clinically significant effect that has been explored further in paper 
5 (p.58).  
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A study on a Mediterranean population (Schroder, Schmelz and Marrugat, 2002), observed 
the relationship between diet and blood pressure.  The study specifically looked at sodium, 
calcium and potassium in populations with different blood pressure status and found to be 
directly related to blood pressure.  This relationship was also observed further seen with the 
sodium to potassium ratio, independently of hypertensive drug treatment.  An inverse 
association was also observed between blood pressure and dietary calcium intake.  
Furthermore, moderate sodium in combination with a calcium intake reduced the risk of 
inadequate blood pressure control.  Finally they observed that those with controlled 
hypertension have a significantly higher calcium intake than non-controlled participants 
(Schroder, Schmelz and Marrugat, 2002).  This study found that nutrient intake was similar 
among groups of different blood pressure status after adjusting for sex, age and energy 
consumption.  These adjustments were not made in the study carried out for this portfolio of 
work.  This study set out to determine the habitual dietary magnesium intake in those with 
hypertension and for normotensives in the local area and then to cross reference this with 
the National Health and Nutrition Survey data (Public Health England, 2014b) to ensure that 
the population sample was representative .  This project will form the preliminary work for a 
grant application to conduct a larger study in which the methodology from Schroder et al 
(2002) will be adopted to ensure a statistically robust approach to data analysis and 
interpretation.  This will include adding age as a confounding factor along with energy intake.  
The mean age in the Schroder et al (2002) study were normotensive 45.1±12.5 y, non-
medicated hypertensive 58.6±11.1 y and medicated hypertensive 62.0±9.6 y which are 
similar to the ages of the participants in this study and appear to be a normal representation 
of those with and without hypertension.  This further supports the need for a larger study 
and to include adjustments for age. 
 
The current RNI in the UK is 300mg and 270mg daily for males and females respectively 
from 18-75+ years (Public Health England, 2014b).  For the USA the Recommended Dietary 
Allowance (RDA) is 400mg and 310 mg for males and females respectively from ages 19 – 
30 years and 420-320 mg daily for those aged > 31 years old  (Institute of Medicine. Food 
and Nutrition Board., 1997)  The National Diet and Nutrition Survey (Public Health England, 
2014b) states that the average consumption of the RNI in the UK is at 90% for males and  
82% for females, representing a population consuming less than recommended.  The study 
therefore was to determine whether those with primary hypertension habitually eat a diet 
that is both lower than the RNI and lower than the UK national average for age and sex. 
Further consideration was given to how this compares to the USA RDA with a substantially 
higher recommended intake. As the UK national average intake is already lower than the 
RNI these were compared to the higher RDA used in the USA to observe the greater 
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difference between intake in the UK and recommendation in the USA. Participants were 
recruited from the Lister Hospital.  All participants were clinically diagnosed with primary 
hypertension by Prof Diana Gorog, who was kind enough to allow access to patients in the 
waiting rooms during clinics and would identify those patients who were suitable for the 
study. 
 
Twenty-five participants (female n=11, male n=14, mean age 63.4±10.2y) were recruited 
from the East and North Herts NHS Trust.   
 
A further 21 normotensive participants (female n=11, male n=10, mean age 46.7±10.6y) 
were recruited from the same geographical area to act as normotensive internal controls 
(NT).  Participants were excluded if they suffered from hypertension (BP ≥ 140/90) or were 
being medicated for the condition, a pre-study blood pressure recording was undertaken to 
confirm this.  All participants completed a 4-day food diary in week 1 including 3 mid-week 
days and 1 weekend day, this was repeated in week 4.  The food diary was adapted from 
The Medical Research Council Collaborative Centre for Human Nutrition Research,  
(Medical Research Council.).   Although classified as an estimated food diary, food could be 
weighed and food labels submitted, in addition to photos being provided to establish portion 
size.  An external control of the general UK population  (GP) aged 19y and over  was 
established from data provided by the National Diet and Nutrition Survey (NDNS)(Public 
Health England, 2014b).  
  
Average daily magnesium intake established from the 8-day food diaries were compared 
between the HT, NT and GP groups and these were compared to both the UK RNI and the 
USA RDA to establish differences amongst the hypertensives and the recommendations. 
 
The observation from this study was that 80% of the UK participants analysed, habitually 
consumed below the RNI for Mg2+, which was a greater proportion than in other countries. 
This concurred with the National Diet and Nutrition Survey (Public Health England, 2014b) 
that found 86% of the population were not meeting the RNI.   
 
Public Health England (Public Health England, 2014a) stated that food source contributions 
from diet for Mg2+  intake were as follows:-  cereals and cereal products 31%; dairy products 
16%; meat and fish 13%; vegetables 11% and fruits 8%.  Previous data indicate a 
considerable intake of Mg2+ from foods rich in dietary fibre i.e. cereals that are  high in 
phytate (Food And Nutrition Board and Institue Of Medicine, 1997); the UK phytate daily 
intake has been recently published as 809 mg/d for adults (Amirabdollahian and Ash, 2010).  
It has been shown that phytates may induce  inhibitory effects on Mg2+ absorption 
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decreasing the fractional absorption (Coudray et al., 2005).  Previous research, although 
limited in relation to Mg2+, evaluated the effect of meals based on 200g of added phytic acid 
into acid-free white-wheat bread which equated it to a similar content to phytate products 
i.e. bran and whole-meal bread. The study revealed that the fractional Mg2+ absorption was 
significantly inhibited (60% lower) from white-wheat bread consumption when the phytic acid 
was added (Bohn et al., 2004).   
 
A further negative interaction is that of Ca2+  which has been shown to negate Mg2+ 
absorption when consumed in excess of 2000mg/d (Whiting and Wood, 1997)(Whiting and 
Wood, 1997) , or when combined with high Na+ which has been suggested to lead to a 
negative Mg2+ status due to enforced Mg2+ excretion (Burgess et al., 1999). Kesteloot et al 
(Kesteloot et al., 2011) suggested that an imbalance between the  serum Ca2+:Mg2+ ratio 
can be associated with elevated blood pressure levels.  This reinforces the association 
between Mg2+ and blood pressure and will be considered for future research. 
 
This current study further observed hypertensive cohorts for both male and females had a 
dietary Mg intake significantly lower than the RNI.  Hypertensive males also had an intake 
that was significantly lower than the general population (which is already below the RNI) and 
that hypertensive female intake was significantly lower than the normotensive internal 
control. As age increased there was a general trend towards a decrease in daily Mg intake. 
The hypertensive group was also compared to the US RDA and found to be significantly 
lower for both sexes.  Lastly, the UK general population were compared to the US RDA for 
both males and females and were found to represent 64% and 69% of the RDA respectively.  
It was concluded that daily Mg intake in hypertensives is lower than the general population, 
the UK RNI and the US RDA and that daily magnesium intake reduces with age. 
 
With any dietary intake study in a clinical group of participants there is the concern of reverse 
causality.  However, one of the drivers for investigation into magnesium and hypertension is 
that the general population tend not to know about the effect of magnesium on blood 
pressure and clinicians  will follow the NICE guidelines which state not to recommend 
magnesium (Dickinson et al., 2006).  It is recommended by the Cochrane Library that salt is 
reduced in the diet to aid in the reduction of hypertension (Jürgens and Na, 2008) and this 
tends to be the main adjustment made by those with hypertension.  However, some changes 
may be made by the individual to eat a diet that is perceived as healthier and this could 
affect the amount of green vegetables eaten and therefore increase the amount of dietary 
magnesium intake.  However, the results of this current study do not point to this as the 
amount of magnesium in the hypertensives tended to be lower than the normotensives. 
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Water consumption will also affect the daily amount of magnesium ingested, however, in the 
UK magnesium is not a regulatory parameter and there is no requirement for the water 
authorities to check levels of magnesium (Drinking water inspectorate, 2017), therefore 
these  data are  not available.  A review by Rosanoff et al (2013), stated that drinking water 
in the United States should contain a minimum of 25-50 ppm magnesium and at this 
concentration two litres a day would provide 15-25% of adult RDA.   Yang and Chiu ( 2000) 
demonstrated a negative association between blood pressure and calcium and magnesium 
levels in drinking water in Taiwanese residents.  Further when adjustment was made for 
magnesium levels in drinking water there was no difference between the groups with 
different levels of calcium showing that there is a significant protective effect of magnesium 
intake from drinking water on the risk of hypertension, independent of calcium.  This 
important finding could be investigated in the UK if independent water analysis was taken 
on the local drinking water of participants and would make an interesting future investigation. 
 
 
According to Long Term Health Conditions (Public Health England, 2014a) 1 in 4 adults is 
affected by high blood pressure in the UK.  Figures show that by reducing the blood pressure 
of the nation as a whole, £850 million of NHS and social care costs could be avoided over 
10 years. Further, if 15% more people currently being treated for high blood pressure could 
control it better, a further £120 million could be saved. (Public Health England, 2014a).  This 
study was the first to show the association between low dietary Mg2+ intake in those with 
previously diagnosed hypertension, the first study in the UK to look at this and the first study 
on humans.  It could prove significant in future work with dietary supplementation and it is 
proposed to use these results to apply for funding to carry out a larger study investigating 
dietary intake and hypertension.  At present fortification of foods in the UK is voluntary for 
most foods, with some compulsory addition in certain foods.  For example, white and brown 
bread must be fortified with thiamin, iron and niacin to replace those nutrients lost in 
processing.  Magnesium is not compulsory in any foods (The British Nutrition Foundation, 
2017).   With the prevalence of hypertension in the UK, it is felt that additional research into 
dietary magnesium and hypertension. 
  
All previous studies for this PhD have investigated either dietary or oral supplementation.  
However, transdermal creams and oils are now commercially available and offer an 
alternative way for people to supplement their micronutrient intake.  The literature on this is 
varied and there have been no previous studies that have investigated the absorption of 
transdermal magnesium application on humans. The Institute of Magnesium Research has 
recently formulated such a cream and the author of this thesis was approached to investigate 
whether the cream absorbed systemically.  This study forms the final publication for this PhD 
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and is novel in the area of transdermal creams.  Further, this study observes an alternative 
source of magnesium supplementation which can be used in future methodology.  
 
2.4.6   Transdermal magnesium absorption 
The Institute of Magnesium Research undertakes many studies examining magnesium and 
in particular its effect on general wellbeing and on muscle cramps.  After some 
correspondence with the institute’s director a project was set up to determine whether 
magnesium is absorbed transdermally when suspended in a cream. There are various 
creams and oils sold commercially and a number of these contain magnesium.  Current 
formulations include magnesium oils and trans-dermal creams, from which the magnesium 
may be absorbed by the skin and into the systemic circulation. However, in contrast to 
gastrointestinal epithelium, a primary function of the skin is to act as a barrier, which restricts 
the absorption of exogenous chemicals into the body.  
 
Although less studied than organic molecules, metal ions are known to be able to cross the 
skin barrier, with the literature having focussed on metals that are known to cause 
irritant/toxic effects (Hostynek, 2003). The lower resistance to permeation of the skin 
appendages (skin associated structures such as hairs and sweat glands) and the ionised 
nature of metals means that their permeation across skin appendages is considered to be 
the most likely route of absorption (Hostynek, 2003; Staff et al., 2011). However, the low 
surface area available for this in human skin means that metal ion absorption across skin is 
expected to be relatively low. Therefore, it has been questioned whether a transdermal route 
of administration could provide sufficient Mg2+ absorption to meet the systemic requirements 
and whether, in fact, any absorption is evidenced by an increase in plasma magnesium or 
urinary magnesium excretion. 
 
Commercially available topical applications range from 75mg to 400mg of Mg2+ depending 
on the dosage recommended by manufacturers. This ranges from 5-30 sprays of 
magnesium oil and 2-4 teaspoons of magnesium cream, which can be applied in one 
application or throughout the day on any area of skin.  Many commercial topical creams and 
oils do not state the concentration of magnesium in the product and to date no study has 
investigated the absorption of transdermal magnesium cream by measurement of either 
serum concentration or urinary excretion in humans. Since less than 1% of total body 
magnesium is contained in the blood, assessment by serum status may be problematic (Elin, 
2010). It was therefore elected to measure both markers of magnesium status. 
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This study was designed as a pilot study to ascertain whether such a topical Mg2+ 
preparation might affect urinary excretion or serum Mg2+.  The purpose of this pilot study 
was to investigate whether a 56 mg.day-1 dose of magnesium in a cream, applied 
transdermally to humans, would affect either serum magnesium levels or urinary excretion 
over a two-week period. Twenty-five healthy adults (female=13 male=12) aged 34.3 ±14.8y, 
height 171.5±11cm, weight 75.9 ±14 kg, were recruited and randomly assigned into either a 
magnesium cream or placebo cream group by random allocation.  
 
Four participants were considered “athletes” as they engaged in at least 2hrs of physical 
exercise at least 5 days per week, three who were assigned to the Mg2+ intervention group 
and one assigned to receive placebo. All other 20 participants who completed the study 
were considered “non-athletes”. High levels of physical exercise have been shown to deplete 
human Mg2+ status (Nielsen and Lukaski, 2006). No previous studies have used physical 
activity level as an exclusion criterion when investigating the effect of magnesium 
supplementation and so the main study comprised of both athletic and non-athletic 
participants.  However, due to the fact that sweat affects magnesium status the data were 
also analysed without the “athletic” sub-group.  Results were statistically analysed in two 
ways:  1. “all participants”, including both athletes and non-athletes (n=24 who completed 
the study) and 2  “non-athletes” (n=20) which excluded the 4 athletes.  Dietary magnesium 
intake was below the RNI in one of the placebo participants and three of the magnesium 
participants.  This was not considered a bar to inclusion into the study as any change in 
serum or urinary Mg2+ from the cream could still be shown, and indeed may be more likely 
in those with suboptimal intakes.  Baseline serum and urine Mg2+ concentrations as well as 
dietary Mg2+ recorded in the randomised intervention and placebo groups did not differ 
significantly from each other in all groups. Baseline data consisted of a 24-hour urinary 
collection to assess baseline magnesium excretion and venous bloods to assess serum 
magnesium levels.   
  
 A 4-day food diary (3 midweek days and 1 weekend day), was recorded prior to the 
intervention with a second 4-day food diary recorded at the end of the 12-14 day period 
giving a total of 8 days dietary analysis over the period of the intervention.  This was analysed 
for Mg2+ intake using Diet Plan 6 software (Forestfield Software Ltd., West Sussex, UK). 
 
After baseline measurements were taken, participants were randomly assigned to either the 
Mg2+ Cream or a placebo control cream and were instructed to apply 2 x 5ml spoon of cream 
per day for two weeks.  The resulting daily Mg2+ dose received by participants in the Mg2+ 
group consisted of 56mg of Mg2+.  
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The placebo was a commercially available aqueous cream containing no magnesium (by 
analysis).  After 12-14 days, final urine and blood samples were collected.  The cream was 
applied up to and including the day of the final urine and blood collection.   
 
After the Mg2+ cream intervention there was a clinically relevant increase of 0.07 mmol.l-1 in 
serum magnesium from 0.82 to 0.89 mmol.l-1, (p=0.29) that was not seen in the placebo 
group (0.77 to 0.79 mmol.l-1 l), but was only statistically significant (p<0.05) in the subgroup 
of non-athletes (0.75 to 0.92 mmol.l-1). A clinically relevant increase can be defined as an 
increase that has an impact in clinical magnesium deficiency.  Gruber et al (2015) stated 
that in individuals with serum magnesium levels of 0.75 mmol.l-1, 50% of the individuals had 
a clinical magnesium deficiency, but at a cut off of 0.80 mmol.l-1  (a 0.05 mmol.l-1 increase) 
only 10% of individuals had a clinical magnesium deficiency (Gröber, Schmidt and Kisters, 
2015).    Urinary excretion of magnesium increased slightly in the Mg2+ group but with no 
statistical significance (p=0.48). The Mg2+ group showed an 8.5 ± 0.72% increase in serum 
Mg2+ and a 9.1±1.3% increase in urinary Mg2+  while these figures for the placebo group 
were smaller, i.e. 2.6±0.36% for serum Mg2+ and -32±8.2% for urinary Mg2+. In the placebo 
group, both serum and urine concentrations showed no statistically significant change after 
the application of the placebo cream.  A recent meta-analysis by Zhang et al (Zhang et al., 
2016) found that an average supplementation of 368 mg Mg.day-1 over a median of 3 months 
showed a mean increase of serum Mg of 0.05 mmol.l-1 , this is the same mean rise that was 
seen after the 2 weeks of transdermal Mg2+ cream application in this investigation reinforcing 
the positive results found from the transdermal cream as determined by the increase in 
serum magnesium. 
 
 
No previous studies have looked at transdermal absorbency of Mg2+ in human participants. 
In this pilot study, transdermal delivery of 56 mg Mg.day-1 (a low dose compared with 
commercial transdermal Mg2+ products available) showed a larger percentage rise in both 
serum and urinary markers from pre to post intervention compared with participants using 
the placebo cream, but statistical significance was achieved only for serum Mg2+ in a 
subgroup of non-athletes.  This was believed to be due to the loss of magnesium through 
sweat in the exercising participants. 
 
Upon analysis for all participants, as well as for only non-athletes, use of the transdermal 
Mg2+ cream showed no significant rise in urinary Mg2+, a measurement that reflects short 
term intestinal absorption of Mg2+ when supplemented orally.  However, participants in the 
Mg2+ group showed slight rises in urinary Mg2+ (+9 to 11%) while those in placebo group 
showed a substantial decrease in urinary Mg2+ (-32%).   Possibly the decreased urinary Mg2+ 
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excretion in the placebo cream group represents more active physiological Mg2+ retention 
processes that are not apparent in the Mg2+ cream group (Trauninger et al., 2002; Larsson, 
2013).  Food diaries did not show a decrease in dietary magnesium intake which was also 
considered.   It has been suggested that 24-hour urine excretion of Mg2+ may be a better 
indicator of tissue status than the serum Mg2+ concentration, but it is highly variable and it is 
questionable whether it can be used to reliably assess a given individual’s Mg2+ status. The 
transdermal cream contained 56 mg of Mg2+ administered daily.  This is at the lower end of 
creams sold commercially.  The recommended dose of the few commercially available 
creams range between 70 mg/d to 400 mg/d per day, therefore results of this study may 
represent an “underdose” of transdermal Mg2+.  A higher concentration may produce greater 
results and is something to be considered for the future. 
 
 
 
2.4.7 Limitations to studies 
The specific limitations surrounding each study have been discussed throughout the thesis 
and therefore will not be repeated here.  However further methodological considerations and 
potential limitations of the overall thesis are discussed below. 
 
A key consideration throughout is sample size and the associated statistical power.  As 
would be expected, the pilot studies had small sample sizes (studies 2 and 6), but the data 
were used to generate hypotheses for subsequent studies.  Study 1 was undertaken as a 
student project with low participant recruitment but was included in the portfolio of work as 
this was the initial project which formed the underlying area of interest for the further studies 
which formed this PhD. For studies 4 and 5, power calculations were performed to ensure 
sample size was adequate (Faul et al, 2007). Study 5 was based on calcium 
supplementation research since no data were available for magnesium supplementation due 
to the novelty of this area.  A subsequent post hoc power calculation based on the actual 
effect size (0.64) demonstrated that 22 participants would need to be recruited in order to 
generate 80% power against the 300 mg RNI.  This compares favourably with the 25 
participants used in the current study.  
 
For study 4, in which the effects of acute and chronic magnesium loading strategies were 
investigated, the main effect was seen in the acute SBP group.  However, with the 
observation effect size of 0.877, 22 people are needed per group to generate 80% power.  
The current study used only 6 participants in one group and 7 in the other.  This is a limitation 
to this study and may have resulted in a type 1 error occurring in the acute group.  Future 
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work should ensure that a large enough cohort is recruited for the investigation to have 
sufficient statistical power. 
 
Both studies 2 and 6 were pilot studies and power analysis were not undertaken in advance.  
When carrying out post hoc analysis on study 2, with an effect size of 1.037, there would 
need to be 22 participants in each group of the high and low dietary magnesium intake.  In 
the current study only 16 people were recruited and these were split into high and low dietary 
magnesium groups. For study 6, based on the serum magnesium results (as nothing was 
found with the urinary magnesium results), 92 people would be need in each group for the 
study to have enough power to make firm conclusions.  The pilot study had 14 participants 
in the intervention group and 10 in the placebo control group.  This small number formed the 
pilot study and a larger study would give a more definitive answer and is something that is 
being prepared for. 
 
A further limitation was that in study 2, stratification of dietary magnesium intake was not an 
a priori hypothesis to the study. This component was added after analysis of food diaries. 
The basis for this was opportunistic as the high and low intake was observed during analysis 
and created an interest that could form a further line of investigation to this pilot study.  The 
intention was to determine whether a diet low in magnesium would affect results. To date, 
no studies have investigated supplementing those with an adequate dietary magnesium 
intake and comparing it to those with a low dietary intake, this would have consequences for 
those who take supplements whilst eating a nutritionally substantial diet as the supplement 
would most likely be excreted without being utilised. 
 
Study 6 was the first human study to investigate the absorption of a magnesium cream.  
Limitations to this study were again the low statistical power, due to this being a pilot study, 
as well as the relatively low dose, since the cream provided only 56 mg per application, 
approximately 1/6th of the RNI. Since completion of this study and on the basis of this work, 
a cream that contains double the concentration has been produced, research will be carried 
out on this shortly. 
 
Limitations to study 5 were the confounding variables that were not taken into account.  For 
example, but not limited to, total energy intake, other  micronutrients known to regulate blood 
pressure, C-reactive protein and glomerular filtration rate (Sabanayagam and Shankar, 
2011; Lutsey et al., 2014).  Most research looks at singular to two variables and their effect 
on blood pressure as it would be too difficult to look at many micronutrients at the same time 
and may increase the chance of a type 2 error (Jones, B., Jaris, P., Lewis, J.A., Ebbutt, A.F., 
1996).  Compounded to this was the low participant numbers and a relatively short food 
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diary (8 days within a one-month period). The average age of the hypertensives was 
63.4±10.2y whereas the control group had a mean age of 46.7±10.6y this results in 
unbalanced groups with a mean difference of 16.7y.  It is particularly difficult to recruit 
hypertensives in the younger age bracket as they do not tend to have primary hypertension.  
Conversely it can be difficult to recruit normotensives in the higher age group as the 
prevalence of hypertension increases with age (Lloyd-Jones et al., 2010). 
 
For robustness, a larger study needs to be carried out with a greater number of participants 
and with a longer examination of dietary intake.  An intervention study would allow for a 
conclusion to be drawn categorically between low Mg2+ intake and hypertension.   
 
Further analysis of the data for the inclusion of confounding variables in the models could 
not be carried out for the data not included in the original publications as it was a requirement 
of the University of Hertfordshire School of Life Sciences Ethics Committee that raw data be 
destroyed on completion of each project. 
2.4.8   Summary of findings, future work and contribution made by the papers in the context 
of the approved field of study. 
The above body of work forms the basis of my PhD by Publication.  The work has focussed 
on magnesium status and effects of supplementation on blood pressure, and exercise 
performance and how these effects might be modulated by habitual dietary intake and the 
mode and form of magnesium delivery.   
 
Reflecting on these studies allows for critical analysis as well as direction for future work. 
 
Two of the studies were pilot studies (studies 2 and 6), where novel hypotheses were tested 
on small cohorts to determine whether further research was warranted. The novel areas 
were that of transdermal magnesium absorption and low and high habitual dietary 
magnesium intake’s effect on magnesium absorption.  Both of these studies were concerned 
with absorption as there is little literature showing how habitual diet may affect the uptake of 
Mg2+ supplementation, either by ingestion or transdermally. Study 2 looked at low and high 
habitual dietary Mg2+ intake and showed differences between results on rest and recovery 
from aerobic and resistance exercise and systolic blood pressure with the different dietary 
intakes suggesting that magnesium transporters can reach a saturation point above which 
further increases in Mg2+ supplement dose are not effective.  A limitation to this study was 
that the stratification of dietary magnesium intake as this was not an a priori hypothesis to 
the study having been added after analysis of food diaries. The basis for this was 
opportunistic as the high and low intake was observed during analysis and created an 
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interest that could form a further line of investigation to this pilot study. Future work could 
make this an a priori hypothesis along with increasing the participant numbers.  This would 
lead to some complexities to the research design.  To make this a priori participants would 
need to be given a strict dietary protocol to follow either a high or low Mg2+ diet for 1-2 weeks.  
This may be difficult for the participants to adhere to.  Normally a 2-week period is the 
shortest time adopted in studies investigating the effects of magnesium supplementation, 
however this study has shown that an acute 1-week dose may be sufficient.  Consideration 
would need to be given to this before a study could be carried out.  Supplementation would 
then be given at a standardised dose to investigate whether habitual Mg2+ affects serum 
Mg2+ and BP, which are the two main variables analysed with Mg2+.  However, results from 
this would add to the literature and to the understanding of magnesium absorption and 
indirectly to the understanding of transporters. To improve scientific robustness, all future 
investigations should standardise the population background for Mg2+ - intake, or at least 
quantify habitual intake and include this variable as a covariate in data analysis. 
 
Study 6 was the first human study to investigate the absorption of a magnesium cream.  
Limitations to this study were again the low statistical power, due to this being a pilot study, 
as well as the relatively low dose, since the cream provided only 56 mg per application, 
approximately 1/6th of the RNI. Since completion of this study and on the basis of this work, 
a cream that contains double the concentration has been produced.  The 56mg application 
did show clinically relevant increases in serum magnesium, but this was only shown on one 
small group of applicants. Urinary excretion showed no significant changes with the 
application of the cream.  Further, those participants who exercised heavily showed a 
reduction in serum Mg levels from pre to post intervention, even when on the magnesium 
cream. This is suggestive of a greater need for Mg2+ supplementation for athletes or those 
who exercise intensely and regularly supporting the work of Matias et al. (2010).  Previous 
research has examined the effect of magnesium supplementation on cramp in elite tennis 
players (Liu, Borowski and Rose, 1983) and has also suggested a higher requirement for 
those undertaking vigorous exercise.   
 
This therefore gives two aspects for future research which to date have not been 
appropriately addressed in the current literature.  One is the need to investigate the demands 
of athletes for magnesium and the changes in serum level pre and post exercise.  Further 
to analyse the normal serum magnesium levels of athletes to determine whether they are all 
below the clinical cut off point for disease of 0.07 mmol.l-1 . Below this level athletes should 
consider supplementation as part of their lifestyle when exercising, or increase consumption 
of magnesium rich foods. 
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The second focus for future work is in relation to the currently poorly understood magnesium 
transporters (TRPM) that facilitate intestinal magnesium absorption. The body of work 
presented in this thesis showed that chronic supplementation does not have a greater affect 
than an acute dosage.  This leaves the question as to whether magnesium supplementation 
effects are saturable. A possible explanation for may be that there is an upper limit of 
absorption and transportation of magnesium via intestinal transporters and/or 
downregulation of capacity with chronic supplementation. Such work would not be possible 
with in vivo research in human participants, but I have been approached to conduct some in 
vitro studies with rat tissue.  Other consideration may be gut microbes and the effect on 
magnesium absorption which presently has equivocal results. The conclusions from these 
studies are harder to apply as a dosage when trying to determine an exact difference in 
nutrient absorption in order that a dose specific amount of magnesium may be ingested. 
Whisner et al (2013) investigated gut bacteria and calcium absorption and found that the 
increase in absorption was greatest in the urine collected after 24h, which is consistent with 
lower gut absorption. Jumpertz et al (2011), investigated energy-balance studies and 
nutrient absorption and concluded that it remains uncertain as to what extent gut microbiota 
are an important regulator of nutrient absorption in humans (Jumpertz et al., 2011).  Dr 
Gautam Bhave of the Vanderbilt University Medical Center, cares for patients with 
magnesium wasting disorders. In personal communication he has expressed the need for a 
cream as the gut absorption of Mg is very low (as discussed above) and gastrointestinal side 
effects can limit compliance with oral consumption.  For this reason, a topical application 
may give a greater net result regardless of the benefit of gut microbes. 
 
Adding to the theme of absorption was study 4 which investigated the effects of acute and 
chronic supplementation on resistance exercise performance and blood pressure.  The 
performance results improved on day 1 of the acute loading strategy but not on day two or 
on either day on the chronic intervention.  The blood pressure results were also different 
between the acute and chronic dosage, leading to the conclusion that different mechanisms 
may affect blood pressure with respect to length of magnesium intake and different 
mechanisms that may or may not become saturated after a longer ingestion period.  As  
mentioned previously, participants within the Chr loading group might be more susceptible 
to a possible Mg-2+ transporter down-regulation or cell tolerance for Mg2+ absorption based 
upon the understanding that high Mg2+ intakes result in a lower Mg2+ absorption (Jahnen-
Dechent and Ketteler, 2012).  Alternatively, chronic loading through providing a regular high 
Mg2+ intake may influence extracellular Mg2+ concentrations which coincide with 
manipulation of Mg2+ transporter TRPM6 function, resulting in a potential decrease in 
TRPM6 expression in conjunction to increasing the urinary excretion of Mg2+ (Alexander, 
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Hoenderop and Bindels, 2008). Thus, an acute ingestion rate as opposed to chronic may 
result in a more efficient use for Mg2+.  
 
 Although this study adds to the literature and to the theme of absorption, a more direct 
approach to assessing transport saturation needs to be considered.  This has previously 
been carried out on rats but further research in vivo on humans would add to the literature.   
 
A further addition to the literature was the finding that those with primary hypertension 
habitually eat a diet that is low in magnesium (study 5).  This finding has implications for the 
cost of hypertension to the NHS.  Although previous literature has examined the dietary 
intake of the UK with respect to Mg2+ and it has been shown that Mg2+ supplementation may 
help to reduce blood pressure, no studies have looked at the habitual diet of hypertensives.   
This finding of the deficiency in Mg2+ intake is exciting and provides much promise for future 
research. Limitations to study 5 include confounding variables that were not examined for 
example, but not limited to, total energy intake, other  micronutrients known to regulate blood 
pressure for example calcium and phosphorus, C-reactive protein and glomerular filtration 
rate (Sabanayagam and Shankar, 2011; Lutsey et al., 2014).  For robustness, a larger study 
needs to be carried out with a greater number of participants and with a longer examination 
of dietary intake.  Further an intervention study would allow for a conclusion to be drawn 
categorically between low Mg2+ intake and hypertension.  It is intended that a funding 
application be submitted in order to continue with this novel approach to dietary intake of 
magnesium. If Mg supplementation proves to be a successful strategy for lowering blood 
pressure in hypertensives, it has the potential to generate considerable NHS cost savings.   
 
Other studies comprising this PhD investigated blood pressure.  With so much inconclusive 
literature on the relationship between magnesium intake and blood pressure, the meta-
analysis carried out as part of this portfolio of work, had the greatest impact, already cited 
over 100 times only 5 years after publication.  In the pooled cross-study population, blood 
pressure was lower in those with a higher magnesium intake, yet this was not a consistent 
finding of previous research.  Across all of the studies for this body of work systolic blood 
pressure was shown to reduce with an average of 300 mg magnesium supplementation by 
between 3-8mmHg and this reduction was seen at rest and after exercise. 
 
The body of work submitted for this PhD by publication suggests an important link between 
low magnesium intake and elevated blood pressure and would support continued research 
in this area through larger scale observational and interventional studies applying both oral 
and trans-dermal supplementation approaches.  
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 A final line of investigation would be to determine whether athletes require a higher daily 
intake of dietary or supplementary magnesium as a recurrent finding amongst the athletic 
participants across these investigations was that serum magnesium levels appear to be low 
in that cohort.  
 
Future work may choose to investigate the athletes further to determine whether magnesium 
has an effect on the inflammatory response to exercise, in particular CRP and IL-6. 
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3.1   Pulford, R & Kass, L,. The effects of acute magnesium 
supplementation on maximal intensity short term exercise and 
subsequent effect on blood pressure and isokinetic knee extension 
during recovery.  Proceedings of the Nutrition Society  (2010), (Abstract)  
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Proceedings of the Nutrition Society (2010), 69 (OCE1), E60 doi:10.1017/S0029665109992485 
Over- and undernutrition: challenges and approaches. 29 June–2 July 2009 
The effects of acute magnesium supplementation on maximal intensity 
short-term exercise and subsequent effect on blood pressure and isokinetic 
knee extension during recovery 
R. Pulford and L. Kass 
University of Hertfordshire, Hatfield, Hertfordshire AL10 9AB, UK 
Mg is an important mineral for >300 processes in the human body such as energy production, muscle anabolism and blood pressure 
regulation. However, there is limited research into Mg2+ performance-related effect on short-term high-intensity exercise and subsequent 
effect on blood pressure and muscle recovery post exercise. The aim of the present study was to investigate the effect of Mg 
supplementation on peak and mean power during all-out maximal-intensity short-term exercise in order to examine its effect on systolic 
(SBP) and diastolic blood pressure (DBP) post maximal exercise and to investigate whether muscular recovery, using post-exercise 
isokinetic knee extensions, could be improved. 
Six healthy male subjects (mean age 20.8 years old, mean height 1.80m and mean mass 79kg) were required to fill out a 3 d diet sheet 
before testing for analysis of Mg intake. The study was a double-blind repeated-measures cross-over design with subjects supplemented 
with either placebo (cornflour) or 300mg magnesium aspartate for 2d before the test day and 300mg on the test day before testing. 
Maximal isokinetic extensions of five repetitions by the right leg were performed by each subject 1 week before the testing to produce 
a baseline result for peak torque (N/m). The test day consisted of subjects performing a 30s Wingate anaerobic test (WAnT)(1) and 
resting for 30min post WAnT before performing five maximal isokinetic knee extensions at 60/s on the right leg. A further 100mg 
magnesium aspartate or placebo was given to each subject immediately post WAnT. Peak power and mean power (W) were recorded 
from each WAnT. Peak torque (N/m) was measured from the isokinetic knee extensions. SBP and DBP were recorded at rest and every 
5min during the 30min recovery after the WAnT. 
Mean peak power (W) was significantly increased (P<0.05) during the WAnT between the placebo condition (851) and the Mg 
condition (912). Mean power (W) during the WAnT was also significantly increased (placebo 683, Mg 705; P<0.05). A significant 
increase (P<0.05) was also found in mean peak torque (N/m) between the placebo condition (196) and the Mg condition (222). There 
was also a significant decrease (P<0.05) in SBP during the 30min post WAnT in the Mg condition (120mmHg) compared with the 
placebo condition (125mmHg), which represents a 5% lower mean SBP over the 30min. However, there was no significant difference 
(P>0.05) in DBP between the placebo and the Mg condition during the 30min recovery post WAnT. 
These improvements in WAnT and peak torque may be a result of Mg acting as a ‘second messenger’ for insulin, thus increasing the 
insulin sensitivity of cell membranes(2), allowing for a greater uptake of energy substrates such as creatine into the muscles(3), a 
consequence of which would be an improved intramuscular recovery of phosphocreatine and ATP. It has been known for some time 
that intramuscular Mg elicits ATPase activity(4) and that Mg-bound ATP present on the acto-myosin cross-bridges has been proved to 
speed up filament detachment(5). This increased rate of ATP hydrolysis (from higher ATPase activity) on the myosin heads results in 
faster and stronger filament detachment and reattachment producing a faster and more powerful muscle contraction, as shown by the 
results of the present study. It is further suggested that the reduction in blood pressure can be attributed to increased vasodilation 
attributed to decreased Ca channel activity in the presence of Mg, resulting in decreased vascular resistance(6). 
The present study demonstrates that Mg supplementation increases peak and mean power during a WAnT and can enhance recovery 
by reducing SBP and improving peak torque in an isokinetic knee extension after maximal short-term exercise. Further research on 
hypertensive recreational athletes is needed to build on these initial findings. 
1. McArdle WD, Katch FI & Katch VL (2006) Energy, Nutrition and Human Performance, 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins. 
2. Paolisso G, Scheen A, D’Onofrio F et al. (1990) Diabetologia 33, 511–514. 
3. Burke L & Deakin V (2006) Clinical Sports Nutrition, 3rd ed. Sydney, Australia: McGraw-Hill Pty Ltd. 
4. Ba´ra´ny M (1967) J Gen Phys 50, 197–218. 
5. Gordon AM, Homsher E & Ragnier M (2000) Phys Revs 80, 853–924. 
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Habitual Dietary Magnesium Intake on Resting and Recovery from Aerobic and 
Resistance Exercise and Systolic Blood Pressure 
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Abstract  
The effects of magnesium supplementation on blood pressure 
(BP) have been studied for over 25 years and results have been 
inconsistent. Blood pressure reductions in randomized studies 
have varied from 12 mmHg reductions to no reduction. The 
objective of this pilot intervention was to investigate the effect of 
magnesium supplementation on systolic blood pressure whilst 
resting and during recovery from aerobic and resistance exercise 
and on performance. A further objective was to see whether the 
effect of a high vs low habitual dietary magnesium intake affected 
these results. Sixteen male volunteers were randomly assigned to 
either a 300 mg·d
-1
 magnesium oxide supplementation (MO) or 
a control group (CG) for 14 days. Resting blood pressure (BP) 
and heart rate (HR) were measured before subjects performed a 
maximal 30 minute cycle, immediately followed by three x 5 
second isometric bench press, both at baseline and after the 
intervention. Blood pressure and heart rate were recorded 
immediately post exercise and after five minutes recovery. A 3 
day food diary was recorded for all subjects to measure dietary 
magnesium intake. At the end of the intervention, the 
supplemented group, had a reduction in mean resting systolic BP 
by 8.9 mmHg (115.125 ± 9.46 mmHg, p = 0.01) and post exercise 
by 13 mmHg (122.625 ± 9.88 mmHg, p  
= 0.01). Recovery BP was 11.9 mmHg lower in the intervention 
group compared to control (p = 0.006) and HR decreased by 7 
beats per minute in the experimental group (69.0 ± 11.6 bpm, p  
= 0.02). Performance indicators did not change within and 
between the groups. Habitual dietary magnesium intake affected 
both resting and post exercise systolic BP and the subsequent 
effect of the magnesium supplementation. These results have an 
implication in a health setting and for health and exercise but not 
performance. 
 
Key words: Blood pressure, magnesium supplementation, 
aerobic performance, isometric contraction, recovery, dietary 
magnesium.  
 
 
Introduction 
 
Magnesium, one of the most abundant minerals in the 
body, is essential for over 300 biochemical processes and 
plays important roles in activating cellular enzymatic 
activity, such as those needed to synthesize DNA and 
RNA, and also in metabolism (Musso, 2009). For athletes 
it is important because of its involvement in glycolysis, the 
citric acid cycle and creatine phosphate production. It has 
also been suggested that free magnesium levels can affect 
excitation contraction coupling of the myocardium 
(Michailova et al., 2004). Magnesium has been 
consistently linked with a reduction in blood pressure 
 
within both a clinically hypertensive population and a 
normotensive population (Itoh et al., 1997). Meta-analyses 
of randomized studies by Jee et al., (2002) and Kass et al. 
(2012) on the effects of magnesium on BP shows dose 
dependent reductions. A study by Itoh et al., (1997) on 33 
normotensive patients showed that magnesium lowered BP 
after 4 weeks. The authors attributed the reduction to the 
excretion of sodium in urine which acts as a relaxant to the 
blood vessels. However, Doyle et al. (1999) performed a 
study on healthy females and found no reduction in BP 
with increased magnesium intake after 4 weeks.  
Exercise causes magnesium levels in the body to be 
depleted through losses in sweat, urine and alterations in 
the blood magnesium levels (Rayssiguier et al., 1990). An 
athlete will therefore have a higher requirement for daily 
magnesium intake than the sedentary population. Athletes 
on calorie restricted diets may also be at risk of deficiency.  
Evidence shows that exercise causes a redistribution 
of magnesium to the active sites in the body (Nielsen and 
Lukaski, 2006), and that deficiency of the mineral 
negatively affects performance (Newhouse and Finstad, 
2000). However, there has been little evidence to show that 
magnesium supplementation in adults with adequate 
magnesium intake will increase performance (Laires and 
Monteiro, 2007).  
There are two suggested mechanisms for the effect 
of magnesium on systolic BP at rest. One mechanism is that 
magnesium acts as a driving force of the sodium potassium 
pump in the cell membrane and mobilizes more sodium to 
be excreted (Bara et al., 1993) . Reduction of intracellular 
sodium may cause the smooth muscle cells in the vascular 
walls to relax and BP to reduce. Another suggested 
mechanism is that magnesium acts as a calcium channel 
blocker (Touyz, 2004), working as a relaxant of the smooth 
muscle in blood vessels, increasing arterial compliance and 
reducing BP.  
There have been suggestions of an inverse 
relationship between daily dietary magnesium intake and 
BP (Kawano et al, 1998; Ma et al. 1995), however, dietary 
magnesium is rarely assessed in the studies reviewed and 
no large studies have looked at the impact of dietary 
magnesium on BP in hypertensive patients. Common foods 
which contain magnesium are grains such as buckwheat 
flour and oat bran, vegetables such as artichoke, spinach 
and black and white beans and nuts for example almonds 
and brazils. It should be considered however that the daily 
dietary intake of magnesium in 
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Western society has been declining from about 500 mg· 
day
-1
 in the 1900’s to a value closer to 175 mg·day-1 
(Altura, 1994), increasing the likelihood of an individual 
being deficient in magnesium. This figure falls someway 
short of the current UK RNI outlined by the UK Food 
Standards Agency, (2003) of 300 mg·day
-1
 for men and 
270 mg· day
-1
 for women (12.35 mmol and 11.10 mmol).  
To the best of the authors’ knowledge, no studies 
have addressed how magnesium impacts maximal aerobic 
exercise and performance in healthy individuals. Further 
there are no studies which look at the effect of magnesium 
supplementation in those with a high vs low habitual 
dietary magnesium intake. 
Although reviews have shown a reduction in blood 
pressure with magnesium supplementation, (Jee et al., 
2002; Kass et al., 2012) there is limited research on the 
effect of supplementation on BP during exercise or on 
performance. It is important for magnesium levels to stay 
high during recovery to affect cellular metabolism and 
protein synthesis (Groff and Gropper, 2000). Therefore 
low magnesium levels may impair muscle recovery and BP 
during and post exercise. Normal BP response post 
exercise is rapid hypotension (Orri et al., 2004). However, 
this may differ in response to magnesium supplementation 
and in the extent of hypotension.  
The aims of this pilot investigation were to 
determine 1) the relationship between magnesium 
supplementation and systolic BP at rest and post exercise 
and its effect on performance, 2) to determine whether a 
high or low dietary magnesium intake impacts on these 
results. Further objectives were to investigate any changes 
in heart rate throughout. 
 
Methods 
 
Subjects  
Sixteen male subjects were recruited. They were all 
undertaking aerobic exercise (>4 hours per week), 
apparently healthy and with no physical impairments. 
Exercise was defined as any physical activity perceived to 
be at 13 or above on The Borg Scaling of Perceived 
Exertion. Fifteen subjects were white Caucasian and 1 was 
Asian. Subjects volunteered to take part in the project and 
completed a consent form and health screen. Ethical 
approval was received from The University of 
Hertfordshire, Life Science Ethics Committee. Full 
inclusion and exclusion criteria can be seen in Table 1. 
 
Design  
Subjects were randomized to either the supplement or the 
 
 
 
control group. Subjects in both groups were asked to come 
in for familiarization and then twice for testing over a 4 
week period, with only the experimental group taking the 
magnesium supplementation and the control group 
undertaking the same tests but with no supplementation. A 
total of 3 visits to the laboratory were required from each 
of the subjects. 
 
Protocol  
Familiarization and Test 1 
Diet: Subjects were asked to complete a 3 day dietary recall 
to assess habitual magnesium dietary intake using 
dedicated software (Dietplan 6.50 Forestfield Software 
Ltd., West Sussex, UK). Dietary intake was categorized 
into high and low categories based on the Committee on 
Medical Aspects of Food and Nutrition Policy (COMA, 
1991) calculated a Reference Nutrient Intake (RNI) of 
300 mg/day for adult males (<300 mg·d
-1
 and ≥300 mg·d- 
1
). 
Supplementation: Supplements consisted of a 
vegetarian capsules filled with 150mg of medical grade 
Magnesium Oxide Light 13138 (Sigma-Aldrich, Missouri, 
USA). Each capsule was individually weighed (Ohaus 
adventurer balance AR1530 New Jersey, USA), Subjects 
were instructed to take two tablets per day resulting in a 
total of 300mg per day per subject, one in the morning on 
waking, and at the end of the day for a total of 14 days. 
Exercise familiarization: On the first visit to the 
laboratory subjects were shown the equipment and the full 
protocol was carried out as described below in order that 
the subjects were able to familiarize themselves with the 
process. They were then invited back to the laboratory in a 
time frame of 3-7 days after familiarization had taken place 
for the protocol to be repeated and baseline measurements 
recorded. Supplementation was distributed after baseline 
measurements were recorded. The protocol was repeated 
14 days after baseline measurements had been taken.  
Exercise protocol: Following 10 minutes of silent 
rest, a 3 minute warm up at self-selected pace was 
undertaken on the cycle ergometer (Monark Ergomedic 
874 E Cycle Ergometer, Monark Sports and Medical, 
Sweden), with 1kg load, with heart rate kept below 
140bpm. A Polar T31 transmitter (Polar Electro Oy, 
Kempele, Finland), measured heart rate throughout all 
exercise. Subjects then cycled on the cycle ergometer with 
a 1kg load for 30 minutes at their maximal capacity in order 
to achieve the greatest distance in the allocated time. After 
completion of the 30 minute maximal cycle a 
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Table 1. Inclusion and exclusion criteria for subjects.  
Inclusion criteria Exclusion criteria 
Male  
Between 19-24 years old 
Normotensive blood pressure (110/70 mmHg - 135/85 mmHg) Exercising for minimum of 4 hours per week Female  
Under 19 and over 24 years of age Hypertensive (>135/85) Hypotensive (<110/70 mmHg) Exercising less 
than 4 hours per week On any medication  
Ingested any supplement 72 hours before baseline test Suffering from any ailment or injury that affects performance Failed 
Health Screen  
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Table 2. Subject characteristics (n=16). Values are means (± Standard Deviation).  
  Control (n = 8) Experimental (n = 8) All (n = 16)  
 Age (years) 21.38 (1.60) 20.38 (2.00) 20.88 (1.82)  
 Height (m) 1.83 (.04) 1.78 (.08) 1.80 (.07)  
 Weight (kg) 74.44 (10.30) 73.39 (15.01) 73.91 (12.49)  
 RHR (bpm) 74 (12) 76 (12) 75 (12)  
 RSBP (mmHg) 125.25 (5.06) 122.75 (7.09) 124.63 (6.05)  
 RDBP (mmHg) 70.75 (7.09) 71.13 (10.06) 71.00 (8.42)  
RHR = Resting heart rate, RSBP = Resting systolic blood pressure, RDBP = Resting diastolic blood pressure. 
 
two minutes rest was given with subjects being advised to 
continue to pedal for at least 60 seconds of the two minute 
interval at self-selected intensity that was lower than that 
undertaken during the 30 minute trial. After the two minute 
interval, 3 x 5 second maximal isometric bench press 
contractions were completed, each separated by a 30 
seconds rest. The isometric contraction was undertaken 
with the subject supine on a bench and pushing maximally 
against a static metal bar on the Marcy Smith Machine 
Plus, (Marcy Fitness Products, Ontario, Canada) and 
measured by a Digital Analyser Isometric Transducer 
(MIE Medical Research Ltd., Yorkshire, UK). The 3 
isometric bench press weights were averaged and 
percentage change calculated between baseline and week  
2. As subjects differed in size, bench press output results 
could be skewed due to the different size of the levers. 
Therefore, the joint angle of the upper arm and shoulder 
was standardized to 40°. 
Measurements pre and post-exercise from rest to 
recovery: After 10 minutes of silent rest, BP was measured 
from the right arm (Omron MX3, Omron Healthcare, 
Kyoto, Japan). At timepoint 15 minutes, during the 30 
minute maximal cycle, gas was analyzed for O2 and CO2 
using Cortex Biophysik Metalyser 3B (Leipzig, Germany) 
with Metasoft 3.9.2 software. Gas was collected again at 
the 30 minute time mark and respiratory exchange ratio 
(RER) calculated. After completing all three of the 
isometric contractions, BP was measured again. A 5 minute 
seated recovery period then took place with subjects having 
a final BP and heart rate measurement taken at this time.  
Heart rate (HR) was measured pre and post-exercise 
and recorded 4 times throughout the protocol. Total HR 
recordings were at Pre-exercise at rest (RHR), after 15 
minutes cycling (HR15), at the end of Exercise (HR30), 
and post-exercise, after 5 minutes recovery (RecHR). 
 
Test 2  
After 14 days both groups repeated the exercise protocol, 
with the same measurements being taken. Subjects came in 
on the same time of day, and the same tester was present 
during both tests for all subjects. 
 
Data analysis  
Food diaries were input into Dietplan 6 (Dietplan 6.50 
Forestfield Software Ltd., West Sussex, UK) and subjects 
were stratified into high and low habitual dietary 
magnesium intake based on these results. Data were then 
analyzed for the cohort as a whole and again stratified for 
low and high habitual dietary intake. All data were 
analyzed using Excel and SPSS7 (PASW Statistics v17.0.2 
IBM, New York, USA) and tested for normality using a 
Shapiro-Wilk test. As the data were normally distributed, 
independent t-tests were performed between groups, and 
dependent paired t-tests between tests to assess 
significance. The alpha value was set at 0.5. 
 
Results 
 
Sixteen male subjects were recruited (age 20.88 ± 1.82 yrs, 
height 1.80 ± 0.07 m, weight 73.91 ± 12.49 kg, resting 
systolic blood pressure 124.63 ± 6.05mmHg). Baseline 
characteristics were further broken down into the control 
and experimental group (Table 2). No statistical 
significance difference was found between the groups.  
In the supplemental group three subjects were above 
the RDA (300 mg·d
-1
) and 5 were below. The control 
group had an even amount of subjects above and below the 
RDA. 
 
Blood pressure  
At baseline there were no significant differences between 
the groups in blood pressure at any of the time points 
(Table 3). Post intervention there was as a significant 
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Table 3. Summary of mean blood pressure values, at baseline and week 2 for both subject groups.  
Values are means (± Standard Deviation). 
  Baseline  Follow-up  
Measurements  Control Supplement Control Supplement  
RSBP (mmHg) 125.3 (5.1) 124.0 (7.2) 124.5 (3.9) 115.1 (9.5) *†  
Post SBP (mmHg)  136.3 (4.3) 135.6 (15.3) 139.1 (4.5) 122.6 (9.9) *† 
Rec SBP (mmHg) 117.5 (8.5) 118.1 (16.2) 121.6 (6.1) 110.4 (9.2) † 
RHR (bpm)  74 (12) 76 (15) 68 (12) 69 (12)  
HR15 (bpm) 155 (20) 152 (24) 163 (16) 171 (11)  
HR30 (bpm)  180 (12) 187 (13) 186 (13) 187 (12)  
RecHR (bpm) 102 (15) 101 (16) 100 (16) 106 (11)   
* indicates significance at week 2 compared to baseline (p < 0.05). † indicates signifincance between 
control and experimental groups at week 2 (p < 0.05). RSBP – Resting systolic blood pressure. PostSBP 
– Post exercise systolic blood pressure. RecSBP – Systolic blood pressure after 5 minutes recovery. RHR 
– Resting heart rate. HR15 – Heart rate at 15 minutes cycling. HR30 – Heart rate at 30 minutes cycling. 
HR30 – Heart rate at 30 minutes cycling. RecHR – Heart rate after 5 minutes recovery 
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Figure 1. Mean resting systolic blood pressure change in the experimental and control groups split 
into high (≥300mg) and low (<300mg) magnesium intake subgroups between baseline and week 2. 
 
difference between the control and the supplemented group 
for resting pre-exercise, post and recovery blood pressure. 
A significant difference from baseline was also seen in the 
supplemented group for resting pre-exercise and post 
exercise blood pressure after 2 weeks supplementation.  
RSBP decreased by 7.7% post intervention in the 
experimental group compared to baseline (p = 0.017) and 
inter-group between experimental and control post 
intervention (p = 0.014). Post SBP decreased by 10.6% at 
follow-up in the experimental group compared to baseline 
(p = 0.017) and between experimental and control groups 
at follow up (p = 0.000) (Table 3).  
Rec SBP decreased by 7.0% at follow-up in the 
experimental group compared to baseline (p = 0.006) 
although no significance was found for Rec SBP at follow-
up between the baseline and experimental group (Table 3). 
 
Habitual dietary magnesium intake  
There was no significant difference found for habitual 
magnesium intake between control and experimental  
 
subjects (p = 0.18). When stratified by dietary magnesium 
intake, the supplemented group showed significance in 
resting systolic BP at week 2 compared to baseline for the 
low habitual dietary magensium intake (114.0 ± 11.6 
mmHg, p = 0.02) (Figure 1) and in the high magnesium 
intake group post exercise (120.7 ± 1.5 mmHg, p = 0.01) 
(Figure 2). The control group showed no significant change 
in either resting or post exercise SBP at week 2 compared 
to baseline (Figures 1 and 2).  
However, significance was found in resting systolic 
BP at week 2 compared to baseline in the low magensium 
intake group (114.00 ± 11.60 mmHg, p = 0.02) within the 
intervention group. 
 
Performance  
Cycling time trial distance increased from baseline to week 
2 significantly in both groups, however this increased 
distance was lower at week 2 in the supplemented group 
compared to the control group. In the experimental group 
baseline distance was 20.5 ± 2.5 Km and after the 
intervention increased to 22.7 ± 2.4Km an increase of 
10.6%. However, in the control group baseline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Mean post exercise systolic blood pressure change in the experimental and control groups 
split into high (≥300mg) and low (<300mg) magnesium intake subgroups between baseline and week 2. 
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distance was 19.4 ± 1.8 Km and at the end of the trial was 
22.1± 2.3 Km, an increase of 14.1%.  
The 3 isometric bench press weights were averaged 
and percentage change calculated between baseline and 
week 2. Average strength increased by 11.4% in the control 
group, from 24.2 ± 8.67 kg to 26.9 ± 8.08 kg and decreased 
by 18.0% in the experimental group from 35.50  
± 16.72 kg to 29.0 ± 10.88 kg. No significant changes 
were shown. 
 
Heart rate and RER  
No significant difference was found between the control 
group and the experimental group at any time point. For the 
RER at the 30 minute time point the intervention group 
changed from 1.14 ± 0.13 to 1.10 ± 0.07 from baseline to 
week 2 and the control group from 1.06 ± 0.03 to 1.11 ± 
0.02 from baseline to week 2. No significance change was 
shown. For heart rate, as expected, significance was found 
timewise in the change from resting to recovery heart rate 
and throughout the 30 minute cycle in both the control and 
supplemented group (Table 3). 
 
Discussion 
 
In this pilot study resting, post exercise and recovery 
systolic BP significantly decreased from baseline to week 
2 for the magnesium supplemented group when compared 
to the control group. This is consistent with other studies 
that have reported significant reductions of 4.1 mmHg and 
5 mmHg respectively for systolic BP (Itoh et al.,1997; 
Kawano et al.,1998).  
Different to most supplementation studies, this pilot 
investigation looked at whether habitual magnesium intake 
influenced the BP results at both resting and post exercise 
conditions. The data were used to stratify results for both 
the supplemented and control group into high and low 
magnesium intake. Although not the main focus for the 
study and the study is not powered to examine this, there is 
an indication that allowed consideration to be given as to 
whether supplementation showed the same changes in 
those who have a naturally high dietary intake of 
magnesium as to those who have a low dietary intake. In 
the control group for both the high and low habitual 
magnesium intake, resting systolic BP did not change at 
week 2 compared to baseline. However, a significant 
lowering was found in resting systolic BP at week 2 
compared to baseline in the low magnesium intake group 
within the intervention group. This suggests that 
magnesium supplementation may have a greater effect on 
resting BP in subjects that have a low habitual dietary 
magnesium intake than those who have a naturally higher 
intake above the RNI. 
Sanjuliani et al. (1996) found over 10 mmHg 
reduction in mean BP with 600 mg·d
-1
 oral magnesium 
oxide supplement in hypertensive patients. They attributed 
this significant reduction to decreased intracellular sodium 
levels and increased magnesium levels in the blood.  
Conversely, two studies found no evidence for the 
 
 
 
role of increased dietary magnesium intake in the reduction 
of high BP. One study was in women only (Doyle et al. 
1999) and magnesium was increased through diet alone but 
was still below the US RDA.  
Mean post exercise BP showed the opposite. The 
results showed mean post exercise systolic BP significantly 
decreased by 24.3 mmHg at week 2 when compared to 
baseline, in the high magnesium intake subgroup of the 
experimental group (20.2%, p = 0.017). This shows that 
magnesium supplementation has a bigger effect on post 
exercise BP in subjects that have a high magnesium intake. 
The mechanism for this is not explained in the literature. It 
may be due to the increased demands of magnesium for a 
physically active person during exercise as it is bound to 
ATP or that a higher plasma concentration may result in 
more magnesium being used as a relaxant of the smooth 
muscle cells in the vascular walls. This has implications in 
health. Patients suffering from hypertension could gain 
larger BP reductions from a combined dietary change and 
oral supplementation program.  
Secondary to the main aim, this investigation set out 
to determine whether supplementation had an effect on 
aerobic and resistance performance. For the 30 minute 
cycling time trial the results showed a significant increase 
of 2.74 kilometers and 2.19 kilometers for mean cycling 
time trial distance in both control and experimental groups. 
However, there was no significance found between groups. 
A review by Newhouse and Finstad (2000) supports this. 
They reviewed 33 years of research and concluded that 
most evidence shows no enhancement of performance. 
However, a study by Cinar et al. (2007) found that 
magnesium supplementation did improve performance of 
subjects who were exercising for 90-120 minutes per day 
for 5 days a week, rather than 2 separate bouts of exercise 
14 days apart. The suggested mechanism for the increase is 
that magnesium increases the red blood cell count and 
hemoglobin levels, allowing greater oxygen distribution.  
For the isometric bench presses the results showed 
the average strength increased in the control group by 
11.4% and decreased by 18.0% in the experimental group, 
showing a 29.4% difference between the groups at week 2, 
although baseline and week 2 data were higher in the 
experimental group compared to control group throughout. 
None of the data were significant at either baseline or week 
2 although a non-significant difference could be seen partly 
due to the fact that the experimental group had a higher 
baseline value than the control group. Much of the 
literature shows the contrary (Brilla and Haley, 1992; 
Domiguez et al., 2006). Reasons for this may be due to 
higher dosages of supplements (8 mg·kg
-1
) over a longer 
period of supplementation (7 weeks) and untrained 
individuals rather than active subjects being used. For 
resistance exercise and isometric contractions magnesium 
supplementation has shown to produce mixed results on 
performance. A study by Brilla and Haley (1992) found a 
20% strength increase of peak knee extension torque which 
they attributed to magnesium’s role at ribosomal level. 
However, a review of 
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supplemental effects by Clarkson (1991) identified no 
relationship between magnesium supplementation and 
performance at any dosage. Magnesium also activates 
amino acids and aids the attachment of mRNA to the 
ribosomes in protein biosynthesis (Groff and Gropper, 
2000). This is important in increasing strength and protein 
synthesis during resistance exercise and recovery. 
Magnesium has been shown to enhance insulin-like growth 
factor 1 (IGF-1) which may elevate testosterone 
(Dominguez et al., 1998). Both being anabolic hormones, 
supplementation of magnesium may increase strength 
when given alongside an exercise training program.  
Limitations to this pilot study included the short 
supplementation period of only 2 weeks and also small 
sample size. Although the cohort were matched for weekly 
physical activity levels a more robust test of 
fitness, such as VO2max testing was not carried out. Dietary 
intake was recorded for 3 days to assess habitual 
dietary magnesium intake. A cross-over design would also 
enhance the effect of the supplementation and allow for the 
trial to be double blinded. 
 
Conclusion 
 
In this pilot study, oral magnesium supplementation 
significantly reduces resting and post exercise BP. 
Furthermore, in those with a low background dietary 
magnesium intake there was a greater effect of 
supplementation on resting BP than those with a high 
dietary magnesium intake. Conversely, post exercise BP 
was reduced more in those with a high dietary magnesium 
intake. This pilot suggests that the effect of magnesium 
supplementation is relevant mainly in a health context 
rather than performance as no enhancements in athletic 
performance were found. Further research could 
investigate the effects of higher and longer dosages of 
magnesium supplementation on both aerobic and 
resistance exercise performance. An analysis of dietary 
intake looking at habitual magnesium intake in those 
showing resting hypertension would also aid in the 
understanding of magnesium and blood pressure 
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Key points 
 
• Magnesium supplementation will have an effect on resting and recovery systolic blood pressure with aerobic 
exercise. 
• Magnesium supplementation will have an effect on resting and recovery systolic blood pressure with 
resistance exercise.  
• Magnesium supplementation did not have an effect on performance indicators.  
• A low habitual dietary magnesium intake will negatively affect blood pressure. 
• A high habitual dietary magnesium intake will impact on the effect of magnesium supplementation. 
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SYSTEMATIC REVIEW 
Effect of magnesium supplementation on blood pressure: 
a meta-analysis 
L Kass1, J Weekes1 and L Carpenter2 
 
 To date, there has been inconclusive evidence regarding the effect of magnesium supplements on blood pressure (BP). This meta-
analysis was conducted to assess the effect of magnesium supplementation on BP and to establish the characteristics of trials 
showing the largest effect size. Primary outcome measures were systolic blood pressure (SBP) and diastolic blood pressure (DBP) at 
the end of the follow-up period. One hundred and forty-one papers were identified, of which 22 trials with 23 sets of data (n ¼ 1173), 
with 3 to 24 weeks of follow-up met the inclusion criteria, with a supplemented elemental magnesium range of 120--973 mg (mean 
dose 410 mg). 95% confidence intervals (CI) were calculated using DerSimonian and Laird’s randomeffects model, with effect size 
calculated using Hedges G. Combining all data, an overall effect of 0.36 and 0.32 for DBP and SBP, respectively, was observed (95% CI 
0.27--0.44 for DBP and 0.23--0.41 for SBP), with a greater effect being seen for the intervention in crossover trials (DBP 0.47, SBP 
0.51). Effect size increased in line with increased dosage. Although not all individual trials showed significance in BP reduction, 
combining all trials did show a decrease in SBP of 3--4 mm Hg and DBP of 2--3 mm Hg, which further increased with crossover 
designed trials and intake 4370 mg/day. To conclude, magnesium supplementation appears to achieve a small but clinically 
significant reduction in BP, an effect worthy of future prospective large randomised trials using solid methodology. 
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INTRODUCTION 
Elevated blood pressure (BP) or hypertension is a major risk factor for 
mortality from cardiovascular and renal disease. Causes of essential 
hypertension include, but are not limited to, smoking, sedentary 
lifestyle, a diet high in sodium, and an inadequate intake of other 
minerals such as potassium, calcium and magnesium.1 
It has been suggested that magnesium supplementation may 
decrease BP, as it acts as a calcium antagonist on smooth muscle tone, 
thus causing vasorelaxation.2 There have been suggestions of an 
inverse relationship between daily dietary magnesium intake and 
BP.3,4 There is also the possibility that individuals with dietary 
magnesium consumption in the higher quantiles are generally more 
health conscious and may take other steps to control BP. It should be 
considered, however, that the daily dietary intake of magnesium in 
the Western society has been declining from about 500 mg/day in the 
1900s to a value closer to 175 mg/day,5 increasing the likelihood of an 
individual being deficient in magnesium. This figure falls someway 
short of the current UK RNI outlined by the Department of Health6 of 
300 mg/day for men and 270 mg/day for women (12.35 and 11.1 
mmol, respectively). 
As hypertensives are usually advised to increase physical activity to 
improve BP and exercise causes increased excretion of magnesium in 
sweat and urine,7 the authors set out to review the effect of 
magnesium on BP during exercise. There are no publications looking 
at the effect of magnesium intake on BP while undertaking physical 
activity or during the recovery period. Although regular exercise is 
advocated for hypertensive individuals, there can be concern that 
exercise may cause a transient increase in BP, negatively impacting an 
individual’s BP. Both aerobic and resistance exercise can cause 
transient increases in BP, with resistance exercise often being 
perceived as having greater risk.8 The introduction of magnesium 
through a supplement may enable the hypertensive to undertake an 
exercise programme at a greater intensity if BP is reduced through 
magnesium supplementation. Magnesium as a supplement has been 
shown to decrease BP in normotensives, yet is rarely considered as a 
supplement for elevated BP. Further, habitual dietary-magnesium 
intake is rarely assessed and no large randomised crossover studies 
have looked at baseline serum magnesium levels together with the 
impact of dietary or supplementary magnesium on BP. However, 
there is a focus in research among small trials on the effect of BP in 
various non-exercising individuals and this meta-analysis therefore 
sets out to review the general effect of magnesium on BP to enable 
future research into the effect of Mg on BP during exercise. Further, 
observation of the study designs used will help to influence the design 
of future research, allowing for more robust methodologies. 
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Some individual studies have shown significant reduction in both 
systolic (SBP) and diastolic blood pressure (DBP) with a magnesium 
intervention, although previous systematic reviews and meta-
analyses have been less conclusive.9 11 Burgess et al.9 found no 
significant benefit of magnesium supplementation in hypertensive 
patients from a review of 12 treatment studies, and did not 
recommend magnesium as an antihypertensive agent. Dickinson et 
al.10 reviewed 12 treatment studies of hypertensive patients and 
reported a small non-significant decrease in SBP of 1.3 mm Hg and 
a significant reduction of DBP of 2.2 mm Hg. Jee et al.11 reported a 
small, non-significant reduction of 0.6 mm Hg SBP and 0.8 mm Hg 
DBP by analysing 20 treatment studies of hypertensive and 
normotensive individuals. However, a dose-dependent effect was 
also reported, with a reduction of 4.3 mm Hg SBP and 2.3 mm Hg 
DBP for every 240 mg/day 
(10 mmol) increase in supplemental magnesium. The variations in 
the dose-dependent relationships found in the above studies 
helped to rationalise the subgroup analysis of high and low 
magnesium dosage included in this meta-analysis. 
The aim of this meta-analysis was to assess the effect of oral 
magnesium supplementation on the BP of both hypertensive and 
normotensive individuals and to establish the characteristics of 
trials associated with the greatest BP reductions. 
MATERIALS AND METHODS 
Article selection 
Treatment studies published before July 2010 relating to the effects of 
magnesium supplementation on human BP were identified through a 
comprehensive search of MEDLINE and the Cochrane Library, using the 
keywords ‘magnesium’, ‘supplementation’, ‘BP’ and ‘human’. Reference 
lists from the returned articles and previous systematic reviews were also 
searched. Relevant data were extracted by one investigator (JW); any 
articles containing data of an unclear or ambiguous nature were submitted 
to another investigator (LK); consensus was reached over whether to 
include these articles. 
Twenty-two trials were included in the analysis, resulting in 23 sets of 
data, as a result of one trial producing two data sets. The dosage of 
magnesium ranged from 120 to 973 mg/day, with an average of 410 mg/ 
day±179. Elemental magnesium was stratified into dosage o370 mg or X370 
mg/day. The majority of studies specified elemental magnesium dosages. In 
studies where elemental magnesium was not shown, the percentage of 
magnesium salt in the compound was used for the elemental magnesium. 
For magnesium oxide (MgO) 60% was used to calculate the elemental 
magnesium and 8.33% for magnesium chloride (MgCl2). 
The inclusion criteria were: (1) magnesium supplements as the only 
active intervention; (2) presence of a placebo or control group; (3) subjects 
over the age of 18; (4) random allocation of subjects to treatment 
conditions; and (5) parallel or crossover trial design. All criteria had to be 
met for inclusion into the study. 
The primary outcome measures were SBP and DBP at the end of follow-
up. Secondary outcome measures were total withdrawals from treatment 
and any adverse effects of treatment. 
Statistical analysis 
For each trial, effect size was calculated using the Hedges G method12 
(m2m1/s.d.2). For randomised controlled trials, net change in BP was 
calculated as the mean difference (magnesium supplementation minus 
control) of the change in BP. For crossover trials, net change was calculated 
as the mean difference between the end of the magnesium 
supplementation and control or placebo periods. Standard error of the 
effect size was adjusted for crossover trials, as advised by Morris.13 
Repeated-measures designs can lead to errors in the exact variance, which 
underestimate the sampling variance. Where this correction can result in 
reduced accuracy of the meta-analysis, the degree of error is generally small 
and is therefore tolerated. Overall effect size estimates and 95% confidence 
intervals (CIs) were calculated using the DerSimonian and Laird’s14 random-
effects model. The meta-analysis, Forest plots and Biggs funnel plots for 
both SBP and DBP were generated using STATA, version 11 (StataCorp LP, 
College Station, TX, USA). 
RESULTS 
In total 141 potentially relevant articles were identified by the 
search strategy. Of these, 108 articles were excluded and 33 were 
electronically retrieved for further analysis. Exclusion criteria were: 
(1) combination of magnesium with other vitamins or minerals that 
can affect BP; (2) lack of a placebo or control group; 
(3) inadequate data being available to calculate the difference in BP 
change between groups; (4) subjects being o18 years of age; and (5) 
non-randomised allocation of subjects to treatment conditions. 
From these, a further 11 articles were eliminated, leaving a total of 
23 sets of data from 22 intervention trials. These trials included a total 
of 1173 individuals, with a sample size ranging from 13 to 155 
participants. Every trial reported the sex of the subjects, with two only 
including males,15,16 three only including females,17 19 and the 
remaining 17 trials including both males and females. The total gender 
split of the subjects was 47% male and 53% female. The subjects were 
from 12 different countries (Brazil, Denmark, England, Finland, 
Holland, Ireland, Italy, Japan, Korea, Mexico, Sweden and USA). 
Thirteen trials were of parallel design, while 10 sets of data from nine 
trials were of crossover design. The mean age of individuals taking 
magnesium supplements in the trials was 50.1 years, while those on 
placebo treatment in the parallel trials had a mean age of 52 years. 
Subjects in three trials had non-insulin-dependent diabetes mellitus20 
-- 22 and one trial observed individuals with insulin resistance.15 Some 
or all of the subjects in six trials were receiving antihypertensive 
medication such as beta-blockers and diuretics. The other trials 
enrolled normotensive subjects, untreated hypertensive subjects or 
hypertensive subjects abstinent from treatment for a period of at 
least 1 month. 
The duration of treatment with magnesium ranged from 3 to 24 
weeks, with a mean duration of 11.3 weeks. The dose of elemental 
magnesium in the observed studies ranged from 120 mg/day (5 mmol) 
to 973 mg/day (40 mmol), with a mean dose of 410 mg/day (16.9 
mmol). A total of seven different supplemental magnesium 
compounds were used (MgO, Mg aspartate, MgCl2, MgOH2, Mg 
lactate, Mg citrate, Mg pidolate). For 21 out of the 23 sets of data, 
trials were under double-blind conditions; the trial by Hattori et al.23 
was single blind, while no blinding was used by Kawano et al.4 All 
studies used a placebo, aside from Kawano et al.,4 which used baseline 
data and compared this with post-intervention results. Mean SBP on 
entry ranged from 110 to 173 mm Hg. Initial DBP ranged from 73 to 
106.5 mm Hg for the subjects assigned to receive magnesium 
supplements. 
 
1 2 
School of Life Sciences, University of Hertfordshire, Hatfield, UK and Centre for Lifespan and Chronic Illness Research, University of Hertfordshire, Hatfield, UK. Correspondence: L 
Kass, School of Life Sciences, University of Hertfordshire, CP Snow Building, College Lane, Hatfield, Hertfordshire, Herts AL10 9AB, UK. 
E-mail: l.s.kass@herts.ac.uk 
Received 10 August 2011; revised 12 December 2011; accepted 20 December 2011; published online 8 February 2012 
                                                                                                                        114   
Bias in the form of publication is difficult to avoid, but trials with a 
negative as well as a positive outcome were included in the meta-
analysis to avoid this bias, as it is known that publication tends to 
favour positive outcomes. The quality of many of the included trials 
was poor and this may bias the results by way of an overestimation of 
the effect of treatment. Conversely, in this metaanalysis, it was seen 
that poorly designed trials may also bias the results against the 
supplement and its effect, as in the case of parallel designed trials. 
Analysis of the overall effect 
Effect size for the meta-analysis for DBP was 0.36 and for SBP was 
0.32, showing a similar effect for both measures (Figures 1 and 2). CIs 
at 95% were 0.23--0.41 for SBP and 0.27--0.44 for DBP. Heterogeneity 
for both cohorts was high (I2 ¼ 82% for DBP and 88% for SBP). 
Sub analysis---crossover vs non-crossover design 
Stratification by crossover and non-crossover design was carried out. 
When stratified by design of the trial, the effect estimates for SBP 
were 0.51 (CI 0.39--0.64) for crossover trials and 0.13 (CI 0.00--0.26) 
for non-crossover trials (Figure 3), and for DBP 0.47 (CI 0.35--0.59) for 
crossover trials and 0.23 (CI 0.10--0.36) for noncrossover trials (Figure 
4). 
In the DBP funnel plot (Figure 5) it can be seen that overall 
estimates of effect sizes in larger sample studies is quite diverse and 
spread quite widely at the top of the funnel, suggesting that only small 
studies showing negative results are more likely to be 
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Figure 1. Forest plot for DBP. 
% 
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Figure 2. Forest plot for SBP. 
0 3.06 
published. For SBP (Figure 6) there seems to be a similar trend, but 
it can also be seen that there is a tendency for larger trials to fall 
within the left side of the funnel, around the 0 mark, suggesting that 
larger trials that show no effect are more likely to be published. From 
Figures 5 and 6 it can generally be seen that crossover trials show a 
more positive effect from the intervention. 
 Subanalysis---dosage 
The Committee on Medical Aspects of Food and Nutrition Policy6 
calculated a Reference Nutrient Intake (RNI) of 300 mg/day for adult 
males and 270 mg/day for adult females. None of the studies 
included in this meta-analysis had intakes between 300 and 370 mg 
and cohorts were all male; therefore two groups were 
% 
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Figure 3. Forest plot for SBP by design. The top half (1) of the figure showing crossover designed studies; the lower half (2) shows non-
crossover designed studies. 
% 
 
Figure 4. Forest plot for DBP by design. The top half (1) of the figure shows crossover designed studies; the lower half (2) shows non-crossover 
designed studies. 
 
Figure 5. Funnel plot for DBP for all studies, coded for crossover and 
non-crossover design. 
 
Figure 6. Funnel plot for SBP for all studies, coded for crossover and 
non-crossover design. 
formed: one below and one above the RNI, with the division starting 
at the study with the nearest dosage above the RNI (370 mg). A 
subanalysis was then carried out dividing the dosage into o370 mg 
Mg/day and X370 mg Mg/day, with results showing greater efficacy 
of magnesium supplementation at the higher dose (Figures 7 and 8). 
The o370 mg trials for SBP had an effect estimate of 0.14 (CI 0.03 to 
0.25) and for DBP had an effect estimate of 0.21 (CI 0.10 to 0.31). 
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The X370 mg trials for SBP had an effect estimate of 0.72 (CI 0.56--
0.89) and for DBP had an effect estimate of 0.66 (CI 0.51--0.82). 
Subanalysis---stratification by country 
From the data analysed, no association could be found between 
country and effect size. Given the wide variation in publication origin 
and lack of information on the country of origin of subjects, no 
clinically relevant stratification by area could be made. 
DISCUSSION 
This review of interventional epidemiological studies is suggestive of 
a negative association between magnesium supplementation and 
DBP and SBP, with a greater reduction being seen in SBP. The 
average reduction in BP based on an effect size of 0.36 for DBP and 
0.32 for SBP translate to an actual reduction of 2--3 mm Hg for DBP 
and 3--4 mm Hg for SBP. At the lower dosage24 the effect sizes for 
SBP and DBP were 0.87 and 1.03, respectively, whereas at the higher 
dosage25 effect sizes were seen to be 1.53 and 0.57, although Zemel 
et al.’s25 work was anomalous to other higher-dosage studies. The 
overall effect size for DBP was slightly higher than that for SBP. The 
majority of trials showed a reduction in BP, although significance was 
not always shown. 
The Antihypertensive And Lipid-Lowering Treatment To Prevent 
Heart Attack Trial (ALLHAT)26 found, when comparing 
antihypertensive treatments, that a SBP reduction of between 0.8 
and 2 mm Hg, depending on drug intervention, was clinically 
significant in reducing the incidence of coronary heart disease, heart 
failure and stroke. The clinical significance in the reductions found 
from this meta-analysis is potentially very important. The subanalysis 
discussed below allow for future research to realise the full potential 
of magnesium in lowering BP with appropriately designed trials. 
Dosage 
When a subanalysis for dosage was carried out (o370 mg Mg and 
X370 mg Mg/day), results for both SBP and DBP showed greater 
efficacy of magnesium supplementation at the higher dose. When 
the higher magnesium dosage was analysed a much higher effect 
size (DBP ¼ 0.66 and SBP ¼ 0.70; 95% CI 0.51--0.82 and 0.56--0.89 
for DBP and SBP, respectively) was found. Those using o370 mg 
demonstrated high levels of variation. One anomaly for this was the 
study by Zemel et al.,25 which used the highest dosage of 973 mg 
Mg/day but showed wide CI limits (DBP 95% CI 1.69 to 0.55, SBP 2.83 
to 0.23) and a low effect size of 0.57 and 1.53 for DBP and SBP, 
respectively. This may be attributed to the small cohort size (n ¼ 13) 
or to study design. However, dosage was not related to habitual 
dietary magnesium intake, which would affect the effect of 
supplementation, and no baseline measures of habitual magnesium 
intake were recorded in any of the studies. Further, no observations 
were made on the social--economic status of the cohorts, which 
would influence dietary intake and may bias the overall results. Only 
one study recorded serum magnesium levels, which the authors 
suggest would affect magnesium absorption from supplementation. 
There was substantial heterogeneity between the findings of the 
trials for both DSP and SBP (I2 ¼ 82 and 88, respectively), which could 
be explained by random variation, the various population groups, 
the interventions or the methods used in the trials, and length of 
intervention. A more homogenous sample of studies may increase 
the effect size; although a random effects model was used, the 
difference between the studies was high. 
Crossover vs non-crossover design 
Further subgroup analysis was carried out for study design 
(crossover vs non-crossover). For crossover trials the effect size 
increased substantially for both DBP and SBP when compared with 
the non-crossover trials, reinforcing the idea that paired data would 
have more robust results from the intervention than non-crossover, 
and that the effect from the intervention would be augmented. 
Interestingly, the majority of crossover studies fell outside of the 
95% confidence limits for SBP, which may be due to the different 
population groups between the studies or may be attributed to 
publication bias; however, effect size was larger in the crossover 
designed trials (SBP crossover 0.51, non-crossover 0.13; DBP 
crossover 0.47, non-crossover 0.23). 
Trials were chosen to be as homogenous as possible, although 
some of the studies were of a lesser quality, with one failing to 
conceal allocation4 and intra-subject variation for age, weight, 
clinical status and nationality. 
A major limitation in most of the studies was lack of data on 
dietary intake, which would have had major implications for all 
studies. It would also have been beneficial if trials had looked at pre-
trial serum magnesium levels and then looked at this again 
% 
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Figure 7. Forest Plot for DBP by dosage. The top half (0) of the figure shows o370 mg dosage magnesium; the lower half (1) shows X370 mg dosage 
magnesium. 
% 
 
Figure 8. Forest plot for SBP by dosage. The top half (0) of the figure shows o370 mg dosage magnesium; the lower half (1) shows X370 mg dosage 
magnesium. 
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after supplementation; this would also have given a better understanding of absorption over a range of magnesium intakes. 
Differences were seen between cross-over and non-crossover design and this would exaggerate inter-individual dietary habits in both 
design groups. Those who had the higher-magnesium diet may show less of a response to the supplement than those who had a lower 
intake, with a non-crossover design being more greatly affected by diet than a crossover design. To the best of the investigators’ 
knowledge, only one systematic review has looked at dietary magnesium and BP,27 and this concluded that there was a negative 
association between the two variables, although the authors attributed methodological problems of dietary data collection to this. 
Of the 22 studies in this meta-analysis, 13 reported adverse effects from the intervention and placebo treatments,4,15,16,18 22,28 32 six 
reported no adverse effects24,33 38 and three did not report any information relating to adverse effects.17,23,25 Of these studies, the 
adverse effects were largely either diarrhoea, or unspecific mild abdominal or bone pain. Only three studies reported serious adverse 
effects from the treatments that led to withdrawal from the investigations: Lind et al.29 reported one case of visual impairment of a 
subject on magnesium treatment; Wirrel et al.31 reported a myocardial infarction of a subject but did not specify the treatment that 
the subject was receiving; Plum-Wirrell et al.32 reported a blood coagulation defect of one subject but also did not specify the 
treatment arm. Three subjects of Ferrara et al.30 were also unable to complete the study due to an increase in BP. 
All the trials analysed for this meta-analysis used magnesium supplements, and although the data had a high level of heterogeneity 
there was a reduction in BP, being more evident in the higher-dosage trials. Future research could potentially observe the effect of 
increased dietary magnesium intake to see if the results were correlated to similar amounts given as a supplement. Some studies have 
looked at magnesium and exercise in respect to performance and recovery parameters;7,38 future research may investigate BP 
response alongside performance parameters. 
In summary, this meta-analysis showed an overall reduction in SBP and DBP from magnesium supplementation. Studies had high 
heterogeneity, but the effect of treatment could still be seen. The average reduction in BP based on an effect size of 0.36 for DBP and 
0.32 for SBP translates to an actual reduction of 2--3 mm Hg for DBP and 3--4 mm Hg for SBP. This could be strengthened by both 
crossover design and dosage 4370 mg. Subanalysis for dosage showed greater efficacy of magnesium supplementation at the higher 
dose, with a higher effect size being seen. Those using o370 mg also demonstrated high levels of variation. Although these reductions 
are small, if optimised by the above suggestions, they could have a significant effect on BP, particularly on the pre-hypertensive 
population group. Further investigation may look at this effect during exercise and on pre-hypertensives who are encouraged to 
change their lifestyle and increase their physical activity level in order to maintain a normalised BP. 
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Background: Magnesium supplementation has previously shown reductions in blood pressure of up to 12 mmHg. A 
positive relationship between magnesium supplementation and performance gains in resistance exercise has also 
been seen. However, no previous studies have investigated loading strategies to optimise response. The aim of this 
study was to assess the effect of oral magnesium supplementation on resistance exercise and vascular response after 
intense exercise for an acute and chronic loading strategy on a 2-day repeat protocol. 
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pressure and total peripheral resistance (TPR) recorded. 300 mg/d elemental magnesium was supplemented for either 
a 1 (A) or 4 (Chr) week loading strategy. Food diaries were recorded. 
 
Results: Dietary magnesium intake was above the Reference Nutrient Intake (RNI) for all groups. Bench press showed 
a significant increase of 17.7% (p = 0.031) for A on day 1. On day 2 A showed no decrease in performance whilst Chr 
showed a 32.1% decrease. On day 2 post-exercise systolic blood pressure (SBP) was significantly lower in both A (p = 
0.0.47) and Chr (p = 0.016) groups. Diastolic blood pressure (DBP) showed significant decreases on day 2 solely for A 
(p = 0.047) with no changes in the Chr. TPR reduced for A on days 1 and 2 (p = 0.031) with Chr showing an increase 
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increase but not a decrement as expected with Chr showing a decrease. DBP showed reductions in both Chr and A 
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Background 
Magnesium (Mg
2+
) elicits significant enzymatic cellular 
involvement and physical regulation such as energy 
metabolism/production through formation of the Mg-ATP 
complex [1] and physiological regulation and control of 
neuromuscular cardiac activity, muscular contraction, 
vascular tone and blood pressure [2,3]. Its effect on mus-
cular contraction and vascular tone have been shown to 
reduce blood pressure and subsequently vascular resistance 
[4].  
Nutritional supplementation is a well-established method for 
enhancing performance in conjunction to training. 
Micronutrient intake has been highlighted to have gained 
greater prominence with athletes in relation to the importance 
of an adequate nutritional status [5], However, previous 
research highlights nutritional inadequacies and thus an 
impaired nutritional status (i.e. marginal nutrient defi-ciency) 
from both an athletic [5] and general population perspective 
[6]. This identifies physical activity as increasing the rate at 
which micronutrients are utilised, promoting excessive 
micronutrient loss via increased catabolism and excretion 
(sweat and urine). Magnesium is a mineral required at rest and 
during exercise [7]. This increase in Mg
2+
 turnover during 
exercise may lead to a state of in-sufficiency acting as a 
contributory factor towards an in-crease in blood pressure and 
a state of hypertension [8]. This, together with a decline in 
dietary intake below the RNI may have a negative impact on 
both performance and blood pressure. 
 
Magnesium supplementation in relation to exercise has 
differed considerably in research opinion as to the dose and 
type of Mg2+ salt administered. It is influenced by the specific 
anion attachment with Mg2+, thus influencing supplemental 
solubility, elemental Mg2+ bioavailability and supplemental 
effectiveness [9]. Research has illustrated organic forms of 
Mg2+ supplementation i.e. Aspartate, cit-rate, lactate, 
pidolate, fumurate, acetate, ascorbate and glu-conate to 
exemplify a greater solubility and bioavailability in 
comparison to inorganic forms i.e. oxide, sulphate, chloride 
and carbonate [10] When considered relative to the quantity 
needed to be ingested to release 300 mg of elemental Mg2+ 
along with the fact that certain magnesiums are unavailable in 
the UK, magnesium citrate was considered to be the best 
option for this protocol.  
Research to date consists of both positive [11-13] and negative 
[14,15] findings. The research appears to agree that Mg
2+
 
supplementation has no effect on physical performance when 
serum concentrations are within the normal range (serum 
Mg
2+
 0.8-1.2 mmol·L
−1
) [12,16]. However, manipulating 
intakes of Mg
2+
 by diet or supple-mentation has been shown 
to have performance [11,17] and blood pressure 
enhancements [13,18]. Limitations to many of these studies is 
the lack of information regard-ing either serum magnesium or 
dietary intake [19]. The 
 
 
 
 
general consensus appears to be that Mg
2+
 supplementa-
tion has a greater effect when habitual dietary intake or 
serum levels are low.  
Further, to the best of the authors’ knowledge research to date 
lacks analysis of Mg
2+
 from an acute (A) and chronic (Chr) 
viewpoint within the same study. Therefore, the aim of the 
current study was to assess the effect of oral Mg
2+
 
supplementation on strength performance and vascular 
responses from both an A and Chr loading strategy as to 
establish potential differences in supplemental duration and 
influences of dietary status and supplemental dose on 
performance and vascular responses. 
 
Methods  
Subjects  
= total of 13 subjects (males (m) = 7 females (f ) = 6) were 
recruited from recreational running, cycling and triathlete 
clubs. Six subjects were allocated randomly to the acute 
intervention group (m = 3, f = 3) and 7 to the chronic 
intervention group (m = 4, f = 3). Subjects were recruited 
in accordance to meeting the inclusion/exclusion criteria, 
(Table 1). Informed consent and health screen were 
completed and ethical approval was granted by the 
University of Hertfordshire School of Life Sciences Ethics 
Committee. 
 
Experimental design  
The study was a randomised, cross-over, double-blind, 
placebo controlled, 2 day repeated measure protocol. 
Subjects were assigned to either the acute or chronic 
intervention and the two trials ran parallel. Within each trial 
subjects undertook both the magnesium interven-tion and 
a placebo intervention with a one week wash-out period in 
a randomised order. The two interventions were a chronic 
(Chr) (4 weeks) and acute (A) (1 week) loading strategy, 
sub-divided into a supplemental and a placebo control 
group with a 1 week washout period. A maximal graded 
exercise test for determination of VO2max was conducted 
to ensure participant homogeneity with a cut off of 45 
ml/kg
−1
 and 35 ml/kg
−1
 oxygen for males and females 
respectively. The study was tested across 2 consecutive 
days at each treatment time-point i.e. baseline 
 
Table 1 Subject characteristics; including group sample 
size (n), age, height, weight, VO2max, HRmax   
 Chronic Acute 
N 7  6 
    
Age (years) 40.8 ± 4.4 35.8 ± 6.2 
Height (cm) 176.2 ± 11 174.6 ± 12 
Weight (kg) 73.2 ± 13.2 72.1 ± 13 
VO2max (ml/kg) 51.8 ± 9.1 53 ± 4.8 
HRmax (bpm) 176.4 ± 3.8 180.8 ± 7.7   
Values are mean ± SD. 
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and again after either 1 or 4 weeks intervention. A one 
week washout was then given and then a further interven-
tion of the opposite treatment was given (placebo or mag-
nesium) with the same loading phase. 
 
 
Protocol  
After familiarisation, subjects were tested for baseline 
measurements Anthropometric measures (height (cm), 
weight (kg)) and age (y)) were recorded. All subjects 
attended a familiarisation session on all equipment and 
testing protocols prior to testing. On both day 1 and re-
covery day 2 participants completed a 40 km time trial on 
bicycles owned by the subjects and set onto a rig. A set 40 
km flat course with no wind setting was used on a 
Computrainer Pro ergometer (Computrainer, Seattle). All 
on-screen course data information was blinded, verbal 
encouragement was not given during the exercise testing. 
The time trial was carried out to elicit physiological stress 
as normally determined by training and competition. After 
a 30 minute rest participants completed the following tests 
to determine the effect of magnesium on strength and car-
diovascular parameters.  
Blood pressure, and augmentation index (Aix) were re-
corded at rest immediately and before the bench press. 
Subjects then performed a bench press corresponding to a 
5 repetition maximum (5-RM) protocol [20]) for deter-
mination of their 1-RM. Upon completion, a 5-minutes rest 
period was given. Subsequently, a bench press at 80% 1-
RM was performed to exhaustion. A measure of force 
(Newtons) was recorded during the bench press, with 
additional measures of blood pressure and Aix im-
mediately upon completion of the bench press. 
 
 
Supplementation  
Magnesium citrate and placebo (cornflour) were capsu-
lated into large vegetarian capsules. Capsules consisted of 
a total of 75 mg of elemental Mg
2+
 citrate, (Pioneer analyt-
ical balance. OHAUS, UK), 4 capsules per day were taken 
orally, equating supplemental Mg
2+
 to a total daily dose of 
300 mg/d elemental Mg
2+
. Supplements were ingested 
evenly throughout the day on a non-testing day, or ingested 
3 hours before exercise testing. Finally, the sup-
plementation period for both placebo and Mg
2+
 accounted 
for a total ingestion period of 1 week or 4 weeks within the 
A and Chr groups, respectively. 
 
 
Diet  
A 4-day weighed food and beverage diary was recorded in 
relation to 3 weekdays and 1 weekend day, which was used 
for analysis of habitual dietary magnesium intake through 
use of dietary analysis software (Dietplan 6.70 Forestfield 
Software, UK). 
 
 
 
 
Statistical analysis  
Data were analysed using SPSS version 20 (IBM limited, 
UK) and Microsoft excel 2007 for Windows. Box-whisker 
plots measured normality/data distribution and showed that 
the data were not normally distributed. Therefore non-
parametric Wilcoxon 2 related samples tests were carried 
out on all results to look for differences. Alpha value was 
set at 0.05. 
 
Results  
There were no statistically significant difference found 
between anthropometric data, VO2max and HR deter-
mining a homogeneous cohort (Table 1).  
Table 2 shows averaged dietary data for both the Chr and 
A groups. Both the Chr and A control groups showed no 
significant difference between macronutrient and mag-
nesium ingestion. 
 
Performance  
Bench press  
Net strength gains as determined by 1-RM showed sig-
nificant increase of 17.7% with the acute Mg
2+
 loading 
strategy compared to baseline (p = 0.031) (Figure 1). No 
significant strength gains were seen in the Chr interven-
tion group (p = 0.281).  
Furthermore, A Mg
2+
 showed no decline in recovery (day 
2) performance for force (N) resulting in a small day 2 
(recovery day) force increase of 2.7%, showing a trend but 
no significance (Figure 2). On the contrary Chr Mg
2+
 
showed a day-to-day 32.1% performance decrement 
(Figure 3).  
Resting SBP measures from day 1 and 2 show a significant 
decrease within A Mg
2+
 treatment (P = 0.031), conversely 
placebo showed a significant increase in SBP (P = 0.047) 
(Table 3). Further, significant day 2 reductions in SBP 
were noted between A treatments of Mg
2+
-placebo (P = 
0.016). On the contrary, Chr Mg
2+
 shows no significant 
reductions in resting SBP on day 1 or day 2.  
In relation to post SBP responses, both Chr and A Mg
2+
 
treatment resulted in significant SBP reductions; however, 
such reductions can be noted on day 1 (P = 0.016) and day 
2 (P = 0.016) for a Chr Mg
2+
 induced SBP 
 
Table 2 Dietary intake, values are mean ± SD   
 Chronic Acute Chronic Acute 
 intervention intervention placebo placebo 
     control control 
     
Kcal 2513 ± 1201 2686 ± 938 3985 ± 519 3785 ± 734 
CHO (g) 274 ± 170 296 ± 118 397 ± 209 343 ± 79 
Fat (g) 96 ± 58 115 ± 49 114 ± 63 105 ± 48 
Pro (g) 119 ± 38 114 ± 37 136 ± 66 129 ± 16 
Mg2+ (mg) 375 ± 104 368 ± 173 551 ± 347 378 ± 79 
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Figure 1 Acute and chronic bench press 1-RM scores on day 1 ± SD. * denotes significance. 
 
 
 
 
 
 
 
 
 
 
 
 
Acute 
 
Chronic 
 
 
reduction in comparison to placebo, whereas an A Mg
2+
 
reduction can be accounted for on day 2 (P = 0.047) in 
comparison to placebo.  
Resting DBP showed no difference for day 1 to day 2 be-
tween the placebo or Mg
2+.
Post DBP showed no differ-
ences between Day 1 to Day 2 for acute supplementation 
group (Table 4). However, chronic intervention showed a 
decrease in DBP for post bench press on the recovery day 
2.  
Although no significance was seen for Aix at rest for both 
A and Chr loading strategies, a significant lowering post 
bench press was found as highlighted in Table 5 on day 1 
for A treatment and day 2 for the Chr treatment group. Day 
1 Aix reductions correspond to a significant Mg
2+
 lowering 
effect compared to baseline (P = 0.016) and placebo (P = 
0.031), respectively. Whereas, similar Aix reductions for 
the Chr Mg
2+
 group is noted on day 2  
 
 
post bench press resulting in significant values of P = 0.039, 
when compared to baseline and placebo, respectively. 
 
Discussion  
This study set out to determine whether either acute or 
chronic magnesium supplementation would have an effect 
on performance (strength and cardiovascular) and blood 
pressure with exercise and/or on a second bout of exercise 
after a 24 hr recovery period. As has been shown 
previously [13,21] acute magnesium supplementation has 
a positive effect on BP, plyometric parameters and torque, 
however its effect on resistance exercise has not been 
evident to date. Further, chronic loading strategies have not 
been investigated in respect to exercise as well as the effect 
of Mg supplementation on a second bout of exercise. It was 
hypothesised that as acute Mg
2+
 supplementation has been 
seen to have beneficial effects 
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Figure 3 Chronic force (newtons) output on day 1 and 2 (recovery) during repetitions to fatigue ± SD. 
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on BP, CV parameters and peak torque a longer loading showed a significant net strength increase of 5.5 kg between 
strategy (4 weeks) would amplify these results, giving a baseline and supplemental Mg
2+
 trials. Other strength re- 
more  beneficial  and  greater  response.  However,  this lated measurements of force (Newtons) illustrated A Mg
2+ 
study did not find that chronic loading of Mg
2+
 has a cu- induced improvements. Typically, where a decrease in force 
mulative effect on the effect of supplementation, perhaps would be expected on day 2 (recovery) of training as a 
due to saturation of Mg
2+
 within the blood or limitations normal physiological response to training, an A group 
to transporters. improvement of 0.25 Newtons (2.7%) was seen with 
Primary findings showed variance across treatment Mg
2+
 supplementation compared to the Chr where a 2.0 groups on 
exercise (strength and recovery) and cardio- Newtons (32.1%) decrement was seen. 
vascular responses. The Chr Mg
2+
 intervention showed When examining net strength of Chr compared to A 
no significance in performance gains for bench press net groups a notable difference between baseline scores is  
strength and force output (Figures 1, 2 and 3). The A evident implying that subjects within the A group might 
Mg
2+
 intervention showed variance in results across all well be stronger due to a 7.3 kg 1-RM difference at baseline 
variable analysed with some improvements being seen in (Figure 1). Therefore, when considering the 10.5 kg differ-  
resting HR and blood pressure for both Chr and A treat- ence between Chr and A group 1-RM trials after interven- 
ment  groups  regarding  strength  related  performance tion of Mg
2+
, inter-subject lifting capacity/ability could be a 
(Figures 1, 2, 3 and Tables 3, 4, 5). factor of concern for validating such a difference.  
These performance enhancements for the strength asso-  
Strength performance ciated tests are suggestive of physiological-regulatory func- 
Strength related performance within the bench press tions of Mg
2+
 within muscle contraction and relaxation; 
showed statistical significant improvements (P = 0.031) i.e. regulating troponin expression via Ca
2+
 concentration 
within the A group and Chr group. Previous research gradients,  Ca
2+
  transport,  MgATP complex  formation 
has shown that Mg
2+
 significantly enhances bench press optimising energy metabolism/muscular contraction, in- 
[22] and strength performance [11,23]. Acute Mg
2+
 loading creasing protein synthetic rate, protection against cellular 
 
Table 3 Acute and chronic group mean SBP values at rest and post bench press at 80% 1-RM to fatigue on day 1 and 
2 ±SD   
Physiological variable Treatment Group   Physiological variable Treatment  Group   
            
  C Chr A    Chr  A  
           
Resting SBP (mmHg) day 1 Placebo 119 ± 7 120 ± 5*
1 
Post SBP (mmHg) day 1 Placebo 143 ± 7*
3 
136 ± 5 
 Mg2+ 118 ± 6 122 ± 4*2  Mg2+ 136 ± 9*3 137 ± 6 
Resting SBP (mmHg) day 2 Placebo 121 ± 8 125 ± 2*
1, 3 
Post SBP (mmHg) day 2 Placebo 144 ± 9*
4 
144 ± 7*
5 
 Mg2+ 118 ± 7 117 ± 7*2, 3  Mg2+ 137 ± 10*4 134 ± 5*5   
*Denotes significance as paired by numbers. 
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Table 4 Acute and chronic group mean DBP values at rest and post bench press at 80% 1-RM to fatigue on day 1 and 
2 ± SD   
Physiological variable Treatment Group   Physiological variable Treatment Group   
           
  Chr A    Chr A  
            
Resting DBP (mmHg) day 1 Placebo 85 ± 7 75 ± 7 Post DBP (mmHg) day 1 Placebo 92 ± 8 85 ± 12 
 Mg2+ 79 ± 6 75 ± 4  Mg2+ 87 ± 7 82 ± 5 
Resting DBP (mmHg) day 2 Placebo 78 ± 8 79 ± 6 Post DBP (mmHg) day 2 Placebo 91 ± 5*1, 2 86 ± 13 
 Mg2+ 75 ± 7*1 74 ± 5*2  Mg2+ 84 ± 8*2 76 ± 8*3   
*Denotes significance as paired by numbers. 
 
damage and, greater amount of actin-mysoin crossbridges [23-
26] all of which contribute to the result of increased strength 
and force production. Consideration must be given as to why 
such a contrasting difference between Chr and A groups occur 
specifically when regarding strength performance measures. 
The A Mg
2+
 supplemented group showed day-to-day 
performance improvements across 3 trials, as opposed to 3 
day-to-day non-performance im-proved trials exhibited within 
the Chr Mg
2+
 supplemented group which may be attributed to 
the different loading strategies within the current study. The 
Mg
2+
 supplemen-tation within the current research was 300 
mg/d, therefore equating the Chr and A group mean daily 
intake for 
 
increase of Mg
2+
 excretion highlight the body’s effi-ciency 
in maintaining a state of homeostasis? Alterna-tively, 
chronic loading through providing a regular high Mg
2+
 
intake may influence extracellular Mg
2+
 concentra-tions 
which coincide with manipulation of Mg
2+
 trans-porter 
TRPM6 function, resulting in a potential decrease in 
TRPM6 expression in conjunction to increasing the urinary 
excretion of Mg
2+
 [29]. Thus, an acute ingestion  
rate as opposed to chronic could result in a more efficient 
use for Mg
2+
. 
 
Cardiovascular responses at rest and post bench 
press performance 
Mg
2+
  to 675 mg/d and 700 mg/d, respectively, when Significant reductions in SBP and DBP are illustrated 
combined with dietary Mg
2+
 intake as analysed from food from post testing in the chronic group and rest and post 
diaries. This adds a sense of greater ambiguity when con- testing in the acute group data across day 1 and 2 com- 
sidering the Mg
2+
  - strength performance relationship, pared to baseline and placebo (Tables 3 and 4). Resting 
and comparing to research highlighting observations that SBP was accounted for by a greater reduction in the A 
intakes of 500 mg/d or greater result in further increases Mg
2+
 of 2 mmHg, in comparison to 0.7 mmHg with the 
in strength [24,25]. It could be suggested that subjects Chr Mg
2+
 treatment. In addition, both resting and post 
within the Chr loading group might be more susceptible DBP showed reductions with a greater day-to-day DBP 
to a possible reduction threshold or cell tolerance for reduction in the A Mg
2+
 in comparison to Chr Mg
2+
 as 
Mg
2+
  absorption based upon the understanding that shown by a 69.2% and 50% (9 mmHg and 3 mmHg dif- 
high Mg
2+
  intakes result in a lower Mg
2+
  absorption ference) at rest and post exercise for A and Chr groups 
[27]. Additionally, Mg
2+
 homeostasis may be postulated respectively. These findings are in agreement with previ- 
to exhibit no greater benefit from the chronic perspec- ous research [13,30] showing the importance of Mg
2+ 
tive due to the kidney function for Mg
2+
  excretion as and its influence on blood pressure regulation. This is 
to maintain a balanced concentration of Mg
2+
 [27,28]; supported by findings within a recent meta-analysis [19] 
for example, could the principle of a higher Mg
2+
 dose, looking at Mg
2+
  supplementation which showed that 
longer supplemental duration and associated proportional SBP and DBP reductions of 2–3 mmHg and 3–4 mmHg, 
 
Table 5 Acute and chronic group mean Aix values post bench 
press at 80% of 1-RM to fatigue on day 1 and 2 ± SD   
Physiological Treatment Group   
variable 
      
 Chr A     
       
Post Aix day 1 (%) Baseline 7 ± 11 17 ± 5*
3 
 Placebo 9 ± 6 14 ± 6*4 
 Mg2+ 7 ± 5 10 ± 5*3 *4 
Post Aix day 2 (%) Baseline 14 ± 7*
1 
12 ± 6 
 Placebo 14 ± 8*2 16 ± 4 
 Mg2+ 8 ± 12*1, 2 11 ± 6   
*Denotes significance as paired by numbers. 
 
respectively. These observations oppose some previous  
findings which emphasise supplemental ineffectiveness of 
Mg
2+
 [31-33].  
Such reductions in blood pressure could be speculated as 
being an outcome influenced by increases within the 
extracellular concentration of Mg
2+
, an effect that has been 
associated with reductions in the arterial tension and tone. 
These reductions in arterial tension and tone corres-pond to 
typical Mg
2+
 induced vasodilatory actions which 
potentiate effects of endogenous vasodilators such as ad-
enosine, K
+
, nitric oxide and cyclo-oxygenase-dependent 
mechanisms via production of PGI2 [34]. In combination, 
Mg
2+
 acts as an antagonist to blocking Ca
2+
 channels 
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[11,35,36] and further enzymatic mobilisation of Ca
2+ 
3. Thus, data within the current study concur with pre-
vious research on the efficacy of Mg
2+
 supplementation in 
reducing blood pressure [13,38] and its capacity to sup-  
press agonist vasoconstriction [4]. The above mechanisms 
may also be attributed to Mg
2+
 induced specific alter-ations 
within the vasculature, for example, Mg
2+’s medi-atory role 
within the endothelium corresponds to increased  
nitric oxide, PGI2 and decreases platelet aggregation, in 
combination to stringent down-regulation of Ca
2+
 voltage 
operated channel activity and release from the sarcoplas-  
mic reticulum [39]. 
Average dietary Mg
2+
 intakes within the A and Chr groups 
corresponded to 368 mg/d and 375 mg/d, respectively. 
However, it must be considered that the blood pres 
sure reduction in Chr and A loading strategies, may be 
attributed to the Mg
2+
 supplementation. With this in mind, it 
could be suggested that despite average dietary intakes of 
Mg
2+
 meeting the UK RNI a higher requirement for Mg
2+
 
may be beneficial in reducing blood pressure. Further rec-  
ommendations within the U.S are 420 mg/d and 320 mg/d for 
males, and females, respectively, in addition to Mg
2+
 re-
quirements within the UK being determined many years ago 
[40]; Research by Geleijnse et al. [41] in a comparative study 
between 5 European countries which included  
the UK, corroborates with this study suggesting a potential 
increase of Mg
2+
 based on supplemental blood pressure 
enhancements, whereby the researchers highlighted a <350 
mg/d of Mg
2+
 as suboptimal, augmenting the prevalence of 
hypertension. The study further accounted for an 80% 
insufficiency corresponding to Mg
2+
 intake to be evident 
within the UK population analysed [41].  
A principle limitation within the current study concerns 
lack of monitoring of the subjects’ Mg2+ status via serum 
concentrations therefore this research is limited to infer 
indirect associations between Mg
2+
 supplementation and 
performance from dietary intake determined from food 
diaries. The study duration and the nature of a consecutive 
2 day protocol both consisting of a 40 Km time trial can be 
seen as to limit the potential for subject recruitment and 
therefore final number of participants recruited. The use of 
males and females within groups must also be noted to 
account for occasional group data variance, on various 
parameters and a high level of standard deviation. 
 
 
Conclusion 
The current study showed a positive effect with A Mg
2+
 
supplementation in relation to net strength and force gains 
with bench press, findings that support previous research 
[11,22,23,25]. Further, cardiovascular responses to the 
bench press were significantly enhanced by Mg
2+
 
supplementation reducing resting SBP and DBP with the 
greatest effect seen with A Mg
2+
 supplementation for rest 
 
 
 
 
and post exercise. Similarly, SBP, DBP and Aix showed a 
significantly greater and more consistent reduction in re-
sponse to the A Mg
2+
 loading strategy, as opposed to the 
minimalistic effect induced by Chr Mg
2+
 loading strategy.  
In conclusion, it can be stated that improvements seen with 
the A loading strategy cannot to the same extent be 
observed with the Chr loading of Mg
2+
, thus potentially 
suggesting a regulatory effect within the body influenced 
by the duration of Mg
2+
 supplementation intake.  
To conclude, from this study there appears to be no benefit 
in long term magnesium supplementation for those who 
have adequate dietary intake, but there are some benefits 
for taking an acute dose, particularly before intense 
exercise.  
Future work may focus on the above parameters for those 
with low dietary Mg
2+
 intake and also for the optimum 
time that supplementation should be given to induce these 
positive findings. 
 
Competing interests  
The authors declare that they have no competing interests. 
 
Authors’  contributions  
LK conceived of the study, participated in its design and coordination, 
statistical analysis and writing of the manuscript. FP carried out the 
data collection, statistical analysis and writing of the manuscript. Both 
authors read and approved the final manuscript. 
 
Received: 9 September 2014 Accepted: 14 April 2015  
 
 
References  
* Maguire ME. Magnesium transporters: properties, regulation 
and structure. Front Biosci. 2006;11:3149–63.  
* Bohl CH, Volpe SL. Magnesium and exercise. Crit Rev 
Food Sci Nutr. 2002;42(6):533–63.  
* Fawcett WJ, Haxby EJ, Male D a. Magnesium: physiology and 
pharmacology. Br J Anaesth. 1999;83:302–20.  
* Touyz RM. Role of magnesium in the pathogenesis of 
hypertension. Mol Aspects Med. 2003;24:107–36.  
* Lukaski HC. Micronutrients (magnesium, zinc, and copper): are mineral 
supplements need for athletes? Int J Sport Nutr. 1995;5suppl:S74–83. 
* Ford ES, Mokdad AH. Dietary magnesium intake in a national 
sample of U.S. adults. J Nutr. 2003;133:2879–82.  
* Uzun A. The acute effect of maximal strength, power 
endurance and interval run training on levels of some elements 
in elite basketball players. Life Sci J. 2013;10:2697–701.  
* Kass LS, Skinner P, Poeira F. A pilot study on the effects of magnesium 
supplementation with high and low habitual dietary magnesium intake on 
resting and recovery from aerobic and resistance exercise and systolic 
blood pressure. J Sports Sci Med. 2013;12:144–50.  
* Ranadel VV, Somberg JC. Bioavailability and pharmacokinetics 
of magnesium after administration of magnesium salts to 
humans. Am J Ther. 2001;8:345–57.  
* Newhouse IJ, Finstad EW. The effects of magnesium supplementation 
on exercise performance. Clin J Sport Med. 2000;10:195–200. 
* Santos DA, Matias CN, Monteiro CP, Silva AM, Rocha PM, Minderico CS, 
et al. Magnesium intake is associated with strength performance in elite 
basketball, handball and volleyball players. Magnes Res. 2011;24:215–9.  
* Lukaski HC, Nielsen FH. Dietary magnesium depletion affects 
metabolic responses during submaximal exercise in 
postmenopausal women. Hum Nutr Metab. 2002;132:930–5.  
* Itoh K, Kawasaka T, Nakamura M. The effects of high oral magnesium 
supplementation on blood pressure, serum lipids and related variables in 
apparently healthy Japanese subjects. Br J Nutr. 1997;78:737–50. 
                                                                                                                        114   
 
Kass and Poeira Journal of the International Society of Sports Nutrition 
 
 
 
 
± Finstad EW, Newhouse IJ. The effects of magnesium supplementation 
on exercise performance. Clin J Sport Med. 2001;33:493–8. 
± Terblanche S, Noakes TD, Dennis SC, Marais D, Eckert M. Failure of 
magnesium supplementation to influence marathon running performance or 
recovery in magnesium-replete subjects. Int J Sport Nutr. 1992;2:154–64. 
 
± Williams M. Dietary supplements and sports performance: amino 
acids. J Int Soc Sports Nutr. 2005;2:63–7.  
± Golf SW, Bender S, Gruttner J. On the significance of magnesium in 
extreme physical stress. Cardiovasc Drugs Ther. 1998;12(2):197–202.  
± Jee SH, Miller ER, Guallar E, Singh VK, Appel LJ, Klag MJ. The effect 
of magnesium supplementation on blood pressure: a meta-analysis of 
randomized clinical trials. Am J Hypertens. 2002;15:691–6. 
± Kass L, Weekes J, Carpenter L. Effect of magnesium supplementation 
on blood pressure: a meta-analysis. Eur J Clin Nutr. 2012;66:411–8. 
± Baechle T, Earle R. Essentials of Strength Training and 
Conditioning. 3rd ed. Human Kinetics: Illonois; 2008.  
± Setaro L, Santos-Silva P, Nakano E, Sales C, Nune N, Greve J, et al. 
Magnesium status and the physical performance of volleyball players: 
effects of magnesium supplemenatation. J Sport Sci. 2014;32:438–5. 
± Matias CN, Santos DA, Monteiro CP, Silva AM, Raposo MDF, Martins F, 
et al. Magnesium and strength in elite judo athletes according to 
intracellular water changes. Magnes Res. 2010;23:138–41.  
± Dominguez LJ, Barbagallo M, Lauretani F, Bandinelli S, Bos A, 
Corsi AM, et al. Magnesium and muscle performance in older 
persons: the InCHIANTI study. Am J Clin Nutr. 2006;84:419–26.  
± Lukaski HC. Vitamin and mineral status: effects on physical 
performance. Nutrition. 2004;20:632–44.  
± Brilla LR, Haley TF. Effect of magnesium supplementation on 
strength training in humans. J Am Coll Nutr. 1992;11:326–9.  
± Carvil P, Cronin J. Magnesium and implications on 
muscle function. Strength Cond J. 2010;32:48–54.  
± Jahnen-Dechent W, Ketteler M. Magnesium basics. Clin 
Kidney J. 2012;5 Suppl 1:i3–i14.  
± De Baaij JHF, Hoenderop JGJ, Bindels RJM. Regulation of 
magnesium balance: lessons learned from human genetic 
disease. Clin Kidney J. 2012;5 Suppl 1:i15–24.  
± Alexander RT, Hoenderop JG, Bindels RJ. Molecular 
determinants of magnesium homeostasis: insights from human 
disease. J Am Soc Nephrol. 2008;19:1451–8.  
± Motoyama T, Sano H, Fukuzaki H. Oral magnesium supplementation in 
patients with essential hypertension. Hypertension. 1989;13:227–32. 
± Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook JV, 
et al. Lifestyle interventions to reduce raised blood pressure: a systematic 
review of randomized controlled trials. J Hypertens. 2006;24:215–33. 
± Cappuccio FP. Lack of effect of oral magnesium double blind 
study. Br Med J. 1985;291:235–8.  
± Doyle L, Flynn a, Cashman K. The effect of magnesium supplementation 
on biochemical markers of bone metabolism or blood pressure in healthy 
young adult females. Eur J Clin Nutr. 1999;53:255–61.  
± Pokan R, Hofmann P, von Duvillard SP, Smekal G, Wonisch M, 
Lettner K, et al. Oral magnesium therapy, exercise heart rate, 
exercise tolerance, and myocardial function in coronary artery 
disease patients. Br J Sports Med. 2006;40:773–8.  
± Laires MJ. Biochemistry Laboratory, Faculty of Human Kinetics, 
Technical University of Lisbon, Portugal, 2 Genetics Laboratory, Faculty 
of Medicine, University of Lisbon, Portugal. Front Biosci. 2004;9:262–76.  
± O’Rourke B, Backx PH, Marban E. Phosphorylation-independent 
modulation of L-type calcium channels by magnesium-nucleotide 
complexes. Science. 1992;257:245–8.  
± Laurant P, Touyz RM. Physiological and pathophysiological role 
of magnesium in the cardiovascular system: implications in 
hypertension. J Hypertens. 2000;18:1177–91.  
± Guerrero-Romero F, Rodríguez-Morán M. Low serum magnesium 
levels and metabolic syndrome. Acta Diabetol. 2002;39:209–13. 
± Geiger H, Wanner C. Magnesium in disease. Clin Kidney J. 2012;5 Suppl 1:i25–38. 
 
± Nielsen FH, Lukaski HC. Update on the relationship between 
magnesium and exercise. Magnes Res. 2006;19:180–9.  
± Geleijnse JM, Grobbee DE, Kok FJ. Impact of dietary and lifestyle 
factors on the prevalence of hypertension in Western populations. 
J Hum Hypertens. 2005;19 Suppl 3:S1–4. 
(2015) 12:19 Page 8 of 8  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Submit your next manuscript to BioMed Central and 
take full advantage of: 
 
• Convenient online submission 
 
• Thorough peer review 
 
• No space constraints or color figure charges 
 
• Immediate publication on acceptance 
 
• Inclusion in PubMed, CAS, Scopus and Google Scholar 
 
• Research which is freely available for redistribution 
                                                                                                                        114   
 
3.5   Kass, L  & Sullivan, K ., Low dietary magnesium intake and 
hypertension. World Journal of Cardiovascular Disease, (2016). 
  
                                                                                                                        114   
 
 
World Journal of Cardiovascular Diseases, 2016, 6, 447-457  
http://www.scirp.org/journal/wjcd  
ISSN Online: 2164-5337  
ISSN Print: 2164-5329 
 
 
 
Low Dietary Magnesium Intake and Hypertension 
 
 
 
Lindsy Kass, Keith R. Sullivan 
 
School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK  
 
 
 
 
How to cite this paper: Kass, L. and Sulli-
van, K.R. (2016) Low Dietary Magnesium 
Intake and Hypertension. World Journal of 
Cardiovascular Diseases, 6, 447-457. 
http://dx.doi.org/10.4236/wjcd.2016.612048 
 
Received: July 21, 2016  
Accepted: December 4, 2016  
Published: December 7, 2016 
 
Copyright © 2016 by authors and 
Scientific Research Publishing Inc.  
This work is licensed under the Creative  
Commons Attribution International  
License (CC BY 4.0).  
http://creativecommons.org/licenses/by/4.0/   
Open Access 
 
 
 
 
Abstract 
 
Purpose: Magnesium (Mg) is a key factor in blood pressure regulation. However, only 
in recent years, magnesium dietary intake has been studied in relation to hyper-tension, 
with equivocal conclusions. Further no comparisons have previously been made 
between the UK general population and primary hypertensives, the UK RNI and the 
USARDA. Methods: Twenty-five hypertensives (HT) (mean age 63.4 y) and twenty-
one normotensives (mean age 46.7 y) were recruited from the same geo-graphical area. 
Food diaries were completed and analysed to determine average daily Mg intake. Mg 
intake was compared between the observed group (OB), normotensives (NT) and 
general population (GP) and both the UK RNI and the USA RDA. Results: Study 
participants had a significantly lower dietary Mg intake than the UK RNI (p < 0.05) and 
the US RDA (p < 0.05). Intake for HT males was significantly lower (p < 0.0001) than 
the external control (general population) and, for HT females, intake was significantly 
lower than the NT (p = 0.006). The findings also suggest that with ageing there is a 
reduction in daily dietary Mg intake. Finally, when UK external controls were compared 
to the USA RDA for both males and females they were found to be around 35% and 
30% respectively below the recommended values. Conclusions: Daily Mg intake in 
hypertensives is lower than the general population, the UK RNI and the USA RDA. 
Daily magnesium intake reduces with age. These findings suggest that low Mg dietary 
intake increases the risk of hypertension. 
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1. Introduction 
 
Increasing evidence suggests a key role for magnesium in the regulation of blood pressure [1] [2] and a deficiency of it has been 
demonstrated to contribute to a number of disease states such as type 2 diabetes, metabolic syndrome, elevated C reactive protein 
L. Kass, K. R. Sullivan  
 
and hypertension [3]. Observational studies have shown an inverse association between dietary magnesium intake and blood 
pressure (BP) [2] [4] [5]; however, a number of meta analyses examining magnesium supplementation have produced conflicting 
results [1] [6] [7] [8] [9] [10]. Experimental studies have suggested that a deficiency in magnesium may have detrimental effects 
on blood pressure and the cardiovascular system, and previous studies have examined the effect of magnesium supplementation 
on hypertension [11] [12] [13] yet there are limited studies that look at long term dietary intake and association with HT. A study 
by Chidambaram (2014) [14] looked at the Indian population and divided participants into normotensive and hypertensive groups 
and found that a reduction in Mg consumption was associated with increased blood pressure. However, this study looked only 
at urinary biomarkers and not food intake. Choi and Bae (2015) [15] investigated Mg intake in Koreans. The participants were 
grouped into quartiles of magnesium intake and BP assessed. Women were found to have a negative relationship between 
magnesium intake and HBP. However, this study did not include those on HT tablets or those with previously diagnosed HT. 
This cur-rent study aims to look at the association between habitual dietary Mg intake and those with existing HT. 
 
Magnesium is the fourth most abundant cation in the body, involved in more than 300 enzymatic systems [16]. Total body stores 
vary between 21 - 28 g in the average 70 kg adult with most of the magnesium being stored in the bone mass, the remainder is 
found in soft tissue with only 0.3% in extra-cellular stores [16], this makes magnesium measurement difficult and is the reason 
why dietary magnesium intake is often the best measure of hypomagnesia. 
 
Elevated blood of Mg can cause vasodilation and reduce vasoconstriction of the vas-culature in common with other minerals 
such as Ca
2+
, a key contributor to vascular smooth muscle constriction [17] [18]. Magnesium exhibits a pharmacological profile 
comparable to a synthetic calcium channel antagonist; therefore, it has been suggested to be nature’s “physiological calcium 
blocker” [19]. 
 
Few intervention studies have examined the effect of habitual dietary magnesium in-take on blood pressure. Furthermore, there 
have been no assessments of habitual dieta-ry magnesium intake in those clinically diagnosed as hypertensive. Therefore, the 
aim of this investigation is to determine if there is an association between habitual dietary magnesium intake and hypertension. 
A study by Ohira et al., (2009) [20] attempted to determine whether there was a cor-relation between dietary magnesium intake 
and serum magnesium concentrations in relation to CVD risk. They found that individuals with both dietary and serum mag-
nesium greater than the median had an approximately 35% lower risk of ischemic stroke. 
 
The Honolulu heart study undertaken by Joffres, Reed and Yano, (1987) [21] demonstrated an inverse relationship between 
dietary magnesium supplementation and both systolic (SBP) and diastolic blood pressure (DBP). When dietary Mg without addi-
tional supplementation was studied, results were similar although the link with DBP 
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was reduced (r = 0.6). In contrast, a cross-sectional study using data from the National Health and Nutrition Examination 
Survey (NHANES) [22] reported no significant correlation between magnesium and blood pressure but a limitation of 
the study was the fact it did not allow for directional or causal influences. The absence of firm consensus despite a 
demonstrated mechanistic link between the blood pressure reducing action of Mg suggests that dietary Mg intake is 
worthy of further investigation. 
The current RNI in the UK is 300mg and 270mg daily for males and females respectively from 18 - 75+ years [23]. For 
the USA the Recommended Dietary Allowance (RDA) is 400 mg and 310 mg for males and females respectively from 
ages 19 - 30 years and 420 - 320 mg daily for those aged >31 years old [24]. The National Diet and Nutrition Survey [23] 
states that the average consumption of the RNI in the UK is at 90% for males and 82% for females, representing a 
population consuming less than recommended. This study therefore sets out to determine whether those with primary 
hyper-tension habitually eat a diet that is both lower than the RNI and lower than the UK national average for age and 
sex. Further consideration will be given to how this compares to the USA RDA with a substantially higher recommended 
intake. As the UK national average intake is already lower than the RNI these will be compared to the higher RDA used 
in the USA to observe the greater difference between intake in the UK and recommendation in the USA. 
 
According to Long Term Health Conditions [25] 1 in 4 adults is affected by high blood pressure in the UK. Figures show 
that by reducing the blood pressure of the nation as a whole, £850 million of NHS and social care costs could be avoided 
over 10 years. Further, if 15% more people currently being treated for high blood pressure could control it better a further 
£120 million could be saved [25]. To date there have been no studies investigating the dietary intake of those with 
hypertension with regard to magnesium intake from habitual dietary intake. 
 
2. Materials and Methods 
 
Twenty-five participants (female n = 11, male n = 14, mean age 63.4 ± 10.2 y) were re-cruited from the East and North 
Herts NHS Trust. Ethical approval was granted by North and East Herts Local Research Ethics Committee. Individuals 
already diagnosed with primary hypertension (and not hypertension caused by either other medical con-ditions or drug 
intervention) were identified by a Consultant Cardiologist and were re-cruited as subjects. Written informed consent was 
obtained during their appointments with the cardiologist. Thirty-three subjects were recruited with 8 excluded for non-
completion. 
 
A further 21 normotensive participants (female n = 11, male n = 10, mean age 46.7 ± 10.6y) were recruited from the same 
geographical area to act as internal controls (NT). Participants were excluded if they suffered from hypertension (BP ≥ 
140/90) or were being medicated for the condition, a pre-study blood pressure recording was undertaken to confirm this. 
All participants completed a 4-day food diary in week 1 including 3 mid-week days and 1 weekend day, this was repeated 
in week 4. The food diary was 
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adapted from The Medical Research Council Collaborative Centre for Human Nutri-tion Research, National Diet and Nutrition 
Survey [26]. Although classified as an esti-mated food diary, food could be weighed and food labels submitted, in addition to 
photos being provided to establish portion size. All food diaries were recorded between January and March. An external control 
of the general UK population (GP) aged 19y and over was established from data provided by the National Diet and Nutrition 
Survey (NDNS) [23]. The two control groups were measured against each other to ensure ho-mogeneity between groups to 
validate the food diary analysis and no statistically signif-icant difference was found between the external observed and internal 
control groups for both the males (p = 0.6) and females (p = 0.12), except for the fact that the internal control group’s mean 
intake of Mg was more than the RNI (See Table 1). 
 
All diaries were analysed using Dietplan 6 (Forestfield software Ltd. West Sussex UK). Data were analysed for skewness and 
kurtosis and one way ANOVA used for in-terpretation of differences using SPSS (Version 22, IBM New York, USA). 
Average daily magnesium intake established from the 8 day food diaries were com-pared between the HT, NT and GP groups 
and these were compared to both the UK RNI and the USA RDA to establish differences amongst the hypertensives and the re-
commendations. 
The magnitude of the differences between observed and control groups were ex-pressed as the effect size using Cohen’s d, 
calculated as the absolute difference between means divided by the pooled SD [27]. Qualitative descriptors of the effect size 
were as follows: negligible (d < 0.19), small (d = 0.20 - 0.49), moderate (d = 0.50 - 0.79), or large (d > 0.8). 
 
3. Results 
 
Mean Mg intake of the hypertensive males (HT) was compared to that of the normo-tensive male controls (NT) and the general 
UK population (GP) (90% of the RNI) as well as the RNI (Figure 1). A significant difference in dietary magnesium intake was 
seen between the HT group and the GP group (p < 0.0001) and the RNI (p < 0.0001). The observed group did not show a 
significant difference in intake compared to the internal control group, although a trend could be seen (p = 0.14) with a moderate 
effect size of 0.6 shown between the groups. 
Mean Mg intake of the hypertensive females was compared against that of normo-tensive females, the general population and 
the RNI (Figure 2). The HT group had a 
 
Table 1. Mean Mg intakes (mean ± SD) for all participants (HT + NT) stratified by age group (n = number of participants). 
 
 
 Age range All Mg (mg/d) 
   
 19 - 50y 244 ± 65 (n = 17) 
 51 - 64y 259 ± 79 (n = 16) 
 65 + y 200 ± 45 (n = 14) 
 All 236 ± 69 (n = 47) 
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significantly lower mean dietary Mg intake than the RNI (p = 0.006) and the NT group (p = 0.006). However, there was 
no significant difference between the HT group and the GP (p = 0.264). An effect size of 0.4 was found between the HT 
group and the GP control corroborating with the lack of significance between these two groups. 
When total data (hypertensive and normotensive together) for both males and fe-males were analysed, a one way ANOVA 
showed that there was a significant difference between the age groups (p = 0.042) (Table 1). 
In females there is a reduction of over 100 mg/day between all participants (both HT and NT) aged 51 - 64 y and those 
aged 65 y and above giving a 37% reduction in intake. 
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Figure 1. Mean +/− SD male daily magnesium intake comparing the hypertensive, normo-tensive, general UK population and the 
RNI (+denotes significant difference between ob-served and RNI, *denotes significant difference between HT and the GP with p ≤ 
0.05). 
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Figure 2. Mean (± SD) female daily magnesium intake comparing the observed, internal con-trol, external control groups with the 
RNI, (+denotes significant difference between observed and RNI, *denotes significant difference between HT and NT (p ≤ 0.05). 
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For males the greatest difference was 31 mg between the 18 - 50 yr and 65+ yrs population groups (Figure 3). 
Male UK data for both the HT and NT was compared against the USA RDA (Figure 4). A significant difference in mean daily 
magnesium intake was shown when com-pared to the USA RDA (420 mg) for both groups (p ≤ 0.001). 
In females, there was a significant difference between the mean daily Mg intake of the hypertensive group and the USA RDA (p 
≤ 0.001); however, the normotensives did not show a significant difference to the USA recommendations (p = 0.238) (Figure 
5). 
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Figure 3. Mean daily dietary Mg intake for both males and females, (HT + NT) decreases with age. Error bars showing SEM. 
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Figure 4. Male mean daily magnesium intakes (mean ± SD) for HT and NT groups com-pared with the USA RDA (+denotes significant 
difference between HT and USA RDA, *denotes significant difference between HT and NT of p ≤ 0.05. 
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Figure 5. Female mean daily magnesium intake (mean ± SD) for HT and NT against USA RDA (*denotes significance of p ≤ 
0.05. This can be seen between the HT and the USA RDA). 
 
The UK general adult population’s mean daily Mg intakes of 270 mg and 221.4 mg (90% and 82% of the RNI) for males 
and females respectively, represented 64% and 69% of the USA RDA. 
 
4. Discussion 
 
The primary finding from the current study is that hypertensive females appear to have a significantly lower intake of 
dietary magnesium than normotensive females. Both male and female hypertensives appear to have low dietary Mg intake 
when compared to both the RNI and RDA. 
Analysis based on individual sexes elicited different results with observed males de-monstrating a significantly lower 
daily dietary magnesium intake compared to both the GP and the RNI. The daily intake of the HT group was 94 mg/day 
less than the RNI and 54 mg/day less than the general population, considered to be a healthy population group. The 
normotensives demonstrated a trend (as evidenced by a moderate effect size of 0.8) towards a difference in daily intake 
although this was 11 mg/day less than the general population and therefore significance was expected. The large standard 
deviation may have affected the statistical results but in real terms both the NT and GP had a similar intake in males. 
 
Females showed a significant difference between both the NT and the RNI although the GP did not show a significant 
difference compared with the HT group. The GP was only 82% of the RNI, a low value which was also seen in the HT 
group’s daily intake. However, female NT’s mean daily intake of magnesium was above the RNI, the only group to have 
met this recommendation. As the NT groups are considered normotensive, it can be suggested that low magnesium intake 
(82% of the RNI), does not have a negative effect on blood pressure; however, the reduction of a further 24 mg/day as 
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found in the HT group may be important in explaining hypertension. It would be of interest to see if the GP group developed 
hypertension over time due to their low mag-nesium intake and thought must also be given to the previously mentioned fact that 
25% of the general population in the UK is thought to be hypertensive [25]. 
In this study, the difference between Mg intakes of the HT and NT groups was small, however, the GP is already below the RNI 
suggesting that when this further decrease in Mg intake is seen the long term consequence on BP could be even greater. 
When mean male intake of 206 mg for the HT group across all ages is compared to the RNI the hypertensive patients have a 
significantly lower intake than recommended. Furthermore, the NDNS [26] states that generally males are at approximately 90% 
of the RNI, The NT group of healthy individuals were actually at 96%, supporting these findings. Although both the HT and the 
NT group were below the RNI, NDNS [26] da-ta used for the GP group showed that only 5% and 7% of the cohort (male and 
female respectively) had hypertension between the ages 19 - 64 y, increasing to 36% and 33% for the 65 y+ group. This results 
in mean hypertension of 21 and 20% for males and females in total, slightly below the established norm according to Public 
Health Eng-land [25]. This group (the GP) was at 90% of the RNI but below the expected norm for prevalence of hypertension. 
It can be suggested that Mg intake at 90% of the RNI has a small effect on blood pressure reinforcing previously published work 
showing a re-duced magnesium intake is correlated with increased blood pressure [6] [28] However, the HT male group 
consumed just 69% of the RNI implying that a lower intake may have an effect on blood pressure. 
 
For females the HT group’s mean daily Mg intake was at 196.6 mg/day equating to 72% of the RNI, while the NT group was 
above the RNI. Again this may suggest that a daily magnesium intake at 72% of the RNI may negatively affect blood pressure 
in adult women. 
 
The NT group of healthy individuals for the North and East Herts NHS area were at 96% and 131% of the RNI compared to 
90% and 82% for the general population show-ing that internal validity was higher in males than females. The high intake of 
dietary magnesium in the female NT group was unusual but the cohort was quite small and this over consumption only equated 
to 21 mg/day above the RNI. The Mg intake fig-ures are also means and therefore it is expected that about half of the subjects 
will fall above this mean value and half will fall below. However, the small female cohort and the high standard deviation could 
both be considered limitations of this work. 
 
Previous research has shown that magnesium supplementation can have a positive effect on blood pressure [6] [28] [29], however 
the research in the UK is very limited. Bain et al. [29], using a UK population base found a greater association between males 
with low magnesium intake and risk of stroke, for which blood pressure is often a pre-cursor, than in females. However, there is 
very little research which has examined Mg intake in the UK with consequences for blood pressure. Furthermore, until now, 
there have been no studies observing the habitual dietary intake of those with high blood pressure in the UK. Choi and Bae 
(2015) [15] found that there were a higher percentage 
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of hypertensive males across all dietary magnesium intakes compared to females in the Korean population and Itoh (1997) 
[30] found a blood pressure decrease in 33 healthy Japanese who supplemented with magnesium. However Dickinson et 
al. (2009) [9] writing for the Cochrane Review used extensively for recommendations to the medical profession in the 
UK, did not find strong evidence for Mg reducing blood pressure. This study hopes to address this matter and move 
towards showing an association be-tween those with hypertension and habitual dietary intake low in magnesium. 
In the USA the RDA, set at 320 and 420 mg/d for females and males respectively, is higher than the RNI of the UK. As 
a comparison, the data from this UK study was also compared with the USA RDA and the results showed a significantly 
lower intake than recommended by the USA for all population groups. The UK general population’s mean intake of 270 
mg and 221.4 mg (90% and 82% of the RNI) for males and females respectively, represented only 64% and 69% of the 
USA RDA. 
Previous research has shown that 48% of the general population in the USA was be-low the RDA in 2005-2006, with 
rising calcium to magnesium ratios implicated in the rise of diabetes and stroke over the past 20 years [3]. Touyz [31], 
stated that magnesium may reduce arterial thickening and abnormal vascular tone as well as endothelial dys-function 
linked with cardiovascular disease and high blood pressure. Therefore, a magnesium deficiency may play a role in the 
pathophysiological processes underlying blood pressure elevation. 
With the exception of females in the 51 - 65 y age group, all age groups consumed Mg below the RNI. The lowest intake 
could be seen in the >65 y age groups. In this age group, blood pressure increases become more prevalent due to decreases 
in arterial compliance and changes in the endothelial cells. Consideration should be given as to whether supplementation 
of this micronutrient might help reduce blood pressure in-creases normally seen in the older population group. 
Although the USA has set the RDA at a higher level than the UK, the real issue lies with dietary intake and not with the 
recommendations. Initiatives to increase know-ledge and awareness of this micronutrient may help to reduce blood 
pressure in the UK, subsequently saving the NHS money on costly drug intervention. Although no conclusions can be 
drawn on the mechanistic role of magnesium in prevention of hy-pertension, the current study does provide evidence that 
further investigation is war-ranted on the role of dietary magnesium intake in this area. 
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Abstract 
 
 
Background 
 
Oral magnesium supplementation is commonly used to support a low magnesium diet. 
This investigation set out to determine whether magnesium in a cream could be absorbed 
trans-dermally in humans to improve magnesium status. 
 
Methods and findings 
 
In this single blind, parallel designed pilot study, n = 25 participants (aged 34.3+/-14.8y, 
height 171.5+/-11cm, weight 75.9 +/-14 Kg) were randomly assigned to either a 56mg/day 
magnesium cream or placebo cream group for two weeks. Magnesium serum and 24hour 
urinary excretion were measured at baseline and at 14 days intervention. Food diaries were 
recorded for 8 days during this period. Mg test and placebo groups' serum and urinary Mg did 
not differ at baseline. After the Mg2+ cream intervention there was a clinically relevant 
increase in serum magnesium (0.82 to 0.89 mmol/l,p = 0.29) that was not seen in the pla-
cebo group (0.77 to 0.79 mmol/L), but was only statistically significant (p = 0.02)) in a sub-
group of non-athletes. Magnesium urinary excretion increased from baseline slightly in the 
Mg2+ group but with no statistical significance (p = 0.48). The Mg2+ group showed an 8.54% 
increase in serum Mg2+ and a 9.1% increase in urinary Mg2+ while these figures for the pla-
cebo group were smaller, i.e. +2.6% for serum Mg2+ and -32% for urinary Mg2+. In the pla-
cebo group, both serum and urine concentrations showed no statistically significant change 
after the application of the placebo cream. 
 
Conclusion 
 
No previous studies have looked at transdermal absorbency of Mg2+ in human subjects. In 
this pilot study, transdermal delivery of 56 mg Mg/day (a low dose compared with commer-
cial transdermal Mg2+ products available) showed a larger percentage rise in both serum and 
urinary markers from pre to post intervention compared with subjects using the placebo  
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magnesium concentration is more than double 
that used in the pilot study and it is a different 
formulation. The name of the cream is Natural 
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cream, but statistical significance was achieved only for serum Mg
2+
 in a subgroup of 
non-athletes. Future studies should look at higher dosage of magnesium cream for 
longer durations. 
 
Trial registration 
 
ISRCTN registry ID No. ISRTN15136969  
 
 
 
Introduction 
 
Mineral elements, such as magnesium (Mg2+), are required by the human body in modest amounts for the maintenance of health and 
the development of optimal functioning[1]). Mg2+ is an important mineral element and it is the fourth most abundant cation in living 
organisms, with Mg2+ being a cofactor to over 325 enzymatic reactions within the body [2]. Around 99% of total body Mg2+ is located in 
the bone, muscles and non-muscular soft tissue [3]. Mg2+ supplementation has been shown to significantly improve blood pressure 
[4±6] as well as modifying vascular tone by regulating endothelium and smooth muscle cell function [4].  
To maintain an adequate Mg2+ status humans must consume Mg2+ at regular intervals [7]. The daily recommendation 
for Mg2+ is controversial, as the literature is conflicting and varies between countries, although values of 300 mg/day are 
usually reported for healthy adults with adjustment for age, sex and nutritional status [7].   
Oral magnesium supplementation has been shown to affect various parameters, such as blood pressure [5,8], immune function 
[9], cardiovascular system [10] and metabolic syndrome [11]. A recent meta-analysis by Zhang et al (2016) in the Journal of 
Nutrition [12] found that in a healthy population group there was a dose dependent increase in both serum Mg concentration 
and urinary Mg excretion with supplemental oral magnesium intake ranging from 250±500mg/day. Kass, Weekes and 
Carpenter (2012) identified that a supplement of >370 mg/day of Mg
+
 shows greater efficacy than a lower dose in improving 
blood pressure and that magnesium supplementation gives a dose dependent response with regards to blood pressure [5].   
An alternative method of perhaps attaining recommended magnesium intakes might be through topical application. Current 
formulations include magnesium oils and trans-dermal creams, from which the magnesium may be absorbed across the skin 
and into the systemic circulation. However, in contrast to gastrointestinal epithelium, a primary function of the skin is to act as a 
barrier, which restricts the absorption of exogenous chemicals into the body. The barrier function of the skin is thought to lie 
predominately in the outermost layer of the epi-dermis, the stratum corneum. The stratum corneum is thought to largely present 
a hydropho-bic barrier to the absorption of transdermal creams. The dermis, immediately below the epidermis, contains the 
blood vessels that are able to transport substances that have permeated the skin into the systemic circulation. 
 
Although less studied than organic molecules, metal ions are known to be able to cross the skin, with the literature having focussed on metals 
that are known to cause irritant/toxic effects [13]. The lower resistance to permeation of the skin appendages, skin structures that serve a 
particular function including sensation, lubrication and heat loss, and the ionised nature of metals means that their permeation across these 
skin appendages is considered to be the most likely route of absorption [13,14]. However, the low surface area available for this in human skin 
means that metal ion absorption across skin is expected to be relatively low. Therefore, it 
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has been questioned that a transdermal route of administration might provide sufficient Mg2+ absorption to help meet systemic Mg2+ 
requirements. This investigation aims to determine if transdermal absorption of Mg2+ from a topical cream occurs ªin vivoº in humans.  
To date, no study has investigated the absorbency of transdermal magnesium cream in human subjects. Commercially available 
Mg
2+
 topical applications range from 75mg to 400mg depending on the dosage recommended by manufacturers. This ranges 
from 5±30 sprays of magnesium oil or 2±4 teaspoons of magnesium cream, which can be applied in one application or 
throughout the day. Disappointingly, many commercial topical creams and oils do not state the concentration of magnesium in 
the product.  
This study was designed as a first time, pilot study to ascertain whether such a topical Mg2+ preparation might affect urinary or serum Mg2+. 
Since less than 1% of magnesium is contained in the blood, assessment by serum status may be problematic [3]. It is often considered that 24-
hr urine excretion of Mg2+ may be a better indicator of intestinal absorption than serum concentra-tion; however, urinary Mg2+ excretion is also 
highly variable and it is questionable whether it can be used reliably to assess an individual's Mg2+ status [15]. However, serum Mg2+ can 
reflect a lon-ger term dietary Mg2+ status over weeks or months whilst urinary Mg2+ can be a better marker of one's recent dietary intake [16]. 
These studies using serum and urinary Mg2+ markers in dietary Mg2+ research could not be assumed to be helpful in the design of this study. 
Djurhuus et al,[17], however, reported that although it is unlikely that a single determination of serum Mg2+ can be used in assessing whole-
body Mg2+ status in an individual, serial determinations of serum Mg2+ might prove useful as an indicator of changes in whole body Mg2+ 
status. These authors also found that 24-hr urinary Mg2+ excretion is unlikely to be a reliable measure of whole body Mg2+ status and is not a 
good marker to measure changes in whole body Mg2+ status. Nonetheless, we decided to use 24-hr urinary Mg2+ as well as serum Mg2+ in this 
pilot study.  
Therefore, the purpose of this pilot study was to investigate whether a 56 mg/day dose of magnesium in a cream, applied 
transdermally to humans, would affect either serum magne-sium levels or urinary excretion over a two-week period and to 
measure effect, if any, and vari-ance to inform a properly powered future study, if warranted. 
 
Methods 
 
Recruitment 
 
Subject recruitment started April 2014 and data collection and follow-up was completed by February 2015. The study 
was not registered on a CT Database at the time of subject recruitment as trial registration in these kinds of studies is 
not commonly practiced. The trial was subsequently registered in order to comply with publication requirements 
according to the WHO guidelines. The authors confirm that all ongoing and related trials for this intervention are 
registered. 
 
Participants 
 
Twenty-five healthy adults (female = 13 male = 12) aged 34.3+/-14.8y, height 171.5+/-11cm, weight 75.9 +/-14 Kg, were recruited from the staff 
and student population of the University of Hertfordshire and word of mouth to local residents and randomly assigned into either a magnesium 
cream or placebo cream group by random allocation. Randomisation was determined by allocation to a group selected from a box with equal 
amounts of paper stating either placebo or magnesium and selected at time of recruitment. The trial was single blind with only the lead 
investigator being aware of the content of the cream. One participant dropped out of study before completion. Participants were excluded if they 
were taking magnesium supplementation in any form within a month of recruitment onto the trial, were under the age of 18y or above 
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the age of 60y.There were no height or weight restrictions, Written informed consent was com-pleted and ethical approval was granted 
by the University of Hertfordshire Health and Human Science Ethics Committee on 14th April 2014. Blood collection and blood and 
urine analysis was undertaken at the University of Hertfordshire Human Physiology Laboratory. 
 
Dietary magnesium intake was below the RNI in one of the placebo participants and three of the magnesium participants. This was not 
considered a bar to inclusion into the study as any change in serum or urinary Mg2+ from the cream could still be shown. High levels of 
physical exercise have been shown to deplete human Mg2+ status ([18]. Four participants were considered ªathletesº as they engaged 
in at least 2hrs of physical exercise at least 5 days per week during the study, three who were assigned to the Mg2+ intervention group 
and one assigned to receive placebo. All other 20 participants who completed the study were considered ªnon-athletesº, i.e. engaging 
in less than 2 hrs physical exercise per day for no more than 3 days per week during the study. Participants were instructed not to 
exercise 24h before blood draws, but ªathletesº may have disregarded this instruction, so results were statistically ana-lysed in two 
ways: 1. ªall subjectsº, including both athletes and non-athletes (n = 24 who completed the study) and 2. ªnon-athletesº (n = 20) which 
excluded the 4 athletes. Baseline serum and urine Mg2+ concentrations as well as dietary Mg2+ recorded in the randomised interven-
tion and placebo groups did not differ significantly from each other (P<0.05) (Tables 1 & 2) in either the ªall subjectsº or ªnon-athletesº 
groupings. 
 
 
Baseline measurements 
 
Baseline data consisted of a 24 hour urinary collection to assess baseline magnesium excretion and venous bloods to assess serum 
magnesium levels. (Tables 1 and 2). Urine was collected from the second urinary passing of the day until and including the first urinary 
passing of the next day. Blood collection could take place at any time of the day to suit the participants but each participant had to return at 
that same timeslot for the second blood collection. No food was allowed for the 3 hours before blood collection although water was allowed. 
 
 
Dietary analysis 
 
Each participant recorded a 4-day food diary (3 midweek days and 1 weekend day) prior to the intervention plus a second 
4-day food diary at the end of the 12±14 day period, giving a total of 8 days dietary analysis over the period of the 
intervention for each participant. This was analysed for Mg2+ intake using Diet Plan 6 software (Forestfield Software Ltd., 
West Sussex, UK). (Tables 1 and 2).  
 
Intervention 
 
After baseline measurements were taken, participants were randomly assigned to either the Mg2+ Cream or a placebo control cream and 
were instructed to apply 2 x 5ml spoonfuls of cream per day for two weeks. The resulting daily Mg2+ dose received by subjects in the Mg2+ 
 
Table 1. Demographic and baseline serum, urine and dietary magnesium (mean +/- s.d. [range]) for all subjects, athletes plus non-athletes.   
 Magnesium group N = 14 Placebo group N = 10 
   
Age (years) 34.8±15.3 36.6±14.6 
Height (cm) 171.2±8.9 173.8±12.4 
Weight Kg) 77.5±15.9 75.6±11.5 
Serum (mmo/l) 0.82±0.18 [0.62±1.24] 0.773±0.16 [0.56±1.16] 
Urine (mmol/24h) 4.07±1.62 [1.30±7.00] 4.6±2.1 [2.7±9.0] 
Dietary 9Mg) 294.9±93.8 [176±496] 329.1±91.9 [196±482] 
 
https://doi.org/10.1371/journal.pone.0174817.t001  
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Table 2. Demographic and baseline serum, urine and dietary magnesium (mean +/- s.d. [range]) for non-athletes only.   
 Magnesium group N = 11 Placebo group N = 9 
   
Age (years) 34.6±13.7 38.5±14.6 
Height (cm) 169.7±9.4 175.0±12.5 
Weight (Kg) 75.6±17.1 75.8±12.1 
Serum (mmol/l) 0.75±0.13 [0.62±1.07] 0.73±0.09 [0.56±0.85] 
Urine (mnol/24h) 4.08±1.34 [2.02±6.11] 4.80±2.1 [2.9±9.0] 
Dietary (mg) 285.8±82.2 [177±469] 331.0±97.3 [196±482] 
 
https://doi.org/10.1371/journal.pone.0174817.t002 
 
group consisted of 56mg of Mg
2+
. This was manufactured, in the course of research and devel-opment, for the Center for 
Magnesium Education & Research by Urist Cosmetics of Vancou-ver, B.C. Canada. For full ingredients see S1 Text Ingredients 
list. 
 
The placebo was a commercially available aqueous cream containing no magnesium (by analysis) and creams were packaged identically. 
Instructions to participants suggested that Mg2+ or placebo cream be applied to the stomach and torso in the first instance and then spread 
down to the legs. Time of day was not important, but no showering or washing could take place for a minimum of 3 hours after application. After 
12±14 days, final urine and blood samples were collected. The cream was applied up to and including the day of the final urine and blood 
collection. Participants were instructed to stop use of the cream if there was any adverse reaction, of which there were none. At the end of the 
trial compliance was ensured from verbal communication as well of collection of the trans-dermal cream container to ensure full usage. 
 
Sample collection 
 
Serum blood samples were collected by venepuncture from the median cubital, basillic or cephalic vein. Serum separator 
vacutainers were inverted 10 times before being left to rest for 30 minutes. Subsequently, samples were centrifuged at 
3000 rpm for 10 minutes. Serum was checked to be free from haemolysis and was immediately pipetted and frozen at -
80ÊC for sub-sequent analysis 
 
Urine was collected into 3 litre collection vessels over 24 hours. Urine was then decanted into a measuring vessel and volume of urine was 
recorded. The measuring vessel was then placed on a magnetic stirrer at 100rpm. To re-suspend the Mg2+, the pH was lowered to 3±3.25 by 
adding 5 M hydrochloric acid. Duplicate 1mL aliquots were frozen at -80ÊC for batch analysis. 
 
Analyses 
 
Urine and serum samples were analysed by colorimetric assay for magnesium (RX MONZA, Randox Laboratories Limited, County 
Antrim, United Kingdom). The machine was calibrated according to the manufacturer's instructions and results were calculated from the 
standard concentration curve generated using the manufacturer's calibration standard. Low urinary and serum Mg2+ were determined 
to be below 3.0mmol/24h and 0.65mmol/l respectively [19]. 
All urine and serum samples were frozen and stored at -80ÊC for between 4±12 weeks. 
 
Data analysis 
 
Serum and urinary Mg2+ data for both pre and post intervention were analysed for skewness and normality prior to 
statistical analysis. All data passed the normality test so a standard two tailed, paired t-test was used to compare baseline 
to post-intervention values (serum and urinary Mg) for within group analysis.  
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Fig 1. CONSORT flow diagram, showing inclusion and exclusion of participants in the study.   
https://doi.org/10.1371/journal.pone.0174817.g001 
 
Statistical analysis was conducted using SPSS V22 (IBM, New York, USA), with P value value of 0.05 accepted as 
statistically significant. 
 
 
 
Results 
 
Of the 29 subjects recruited, 1 was excluded for not meeting the criteria and 3 declined to par-ticipate after baseline data was 
collected. Fourteen participants were allocated to the magne-sium intervention group and completed the trial. Eleven were allocated to 
the placebo intervention from which one dropped out due to adverse reaction to the venepuncture at the 
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baseline blood collection before cream had been administered. Fig 1 depicts the inclusion and exclusion of the 
participants in the study. 
 
Urinary and serum response to trans-dermal magnesium application 
 
Mean serum and 24-hour urinary Mg2+ concentrations were obtained for all participants before and after a 2-week application 
period of the magnesium or placebo trans-dermal cream. Baseline (Tables 1 & 2) serum Mg2+ values were below normal 
reference values  
(0.65mmol/l) in one magnesium intervention participant and one placebo participant (both non-athletes), whilst the baseline 24-hr 
urinary Mg2+ excretion was below normal (3.0mmol/ 24h) in two placebo participants (one non-athlete, one athlete) and three 
magnesium participants (two non-athletes, one athlete); these were different participants for both the serum and urine. Of the five 
participants with low urinary excretion, three had below the RNI for dietary Mg2+ intake however this was not the case for the low 
serum Mg2+ subjects. 
 
All participants, Table 3 
 
There was no statistically significant effect of Mg2+ cream on either serum or urinary Mg2+ status. However, after the Mg2+ cream intervention 
there was a clinically relevant increase [11, 19] in serum magnesium (0.82 to 0.89 mmol/l) that was not seen in the placebo group (0.77 to 0.79 
mmol/L), but this was not statistically significant (p = 0.29). Similarly, there was a slight increase in magnesium urinary excretion in the Mg2+ 
group but again no statistical significance  
(p = 0.48). A percentage increase of 8.54% for serum Mg2+ and 9.1% in urinary Mg2+ was seen in the Mg2+ group while for the placebo group 
these figures were smaller, i.e. +2.6% for serum Mg2+ and -32% for urinary Mg2+. In the placebo group both serum and urine concentrations 
showed no statistically significant change after the application of the placebo cream. 
 
Non-athletes, Table 4 
 
For non-athlete participants (n = 11 in Mg group plus n = 9 in placebo group), there was a statistically significant rise (P = 
0.02) in serum Mg2+ in the intervention group which was not seen in the placebo group. Serum Mg2+ in the intervention 
showed a % change of +22.7% while that in the placebo group showed a +4.11% rise. Urinary Mg2+ did not show any 
significant change in either Mg2+ or placebo group although a large non-significant negative change could be seen in the 
placebo group (-32.50%) when compared with the 11.3% increase in the intervention group. 
 
Discussion 
 
Transdermal Mg2+ effect on serum Mg2+ 
 
Previous study of humans have shown that serial determinations of serum Mg2+ can prove useful as an indicator of changes in whole body 
Mg2+ status[17]. From this study, 56 mg/day 
 
Table 3. Influence of Trans-dermal Magnesium vs placebo cream application on Serum and Urinary Magnesium Concentrations (mean +/- 
S.D.) for all subjects, athletes plus non-athletes.   
 Serum Concentrations, (mmol/L)  Urinary Excretion (mmol/24h) 
      
Intervention Magnesium (n = 14) Placebo (n = 10)  Magnesium (n = 14) Placebo (n = 10) 
      
Pre 0.82±0.18 0.77±0.16  4.07±1.62 4.6±2.1 
Post 0.89±0.18 0.79±0.18  4.44±1.56 3.12±1.27 
%Change +8.54% +2.6% +9.1% -32% 
       
https://doi.org/10.1371/journal.pone.0174817.t003  
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Table 4. Influence of Trans-dermal Magnesium vs placebo cream application on Serum and Urinary Magnesium Concentrations (mean +/- 
S.D.) for non-athlete subjects.   
 Serum Concentrations,  (mmol/L) Urinary Excretion  (mmol/24h) 
       
Intervention Magnesium (n = 11)  Placebo (n = 9) Magnesium (n = 11)  Placebo (n = 9) 
       
Pre 0.75±0.13  0.73±0.09 4.08±1.34  4.80±2.10 
Post 0.92±0.18*  0.76±0.17 4.54±1.75  3.24±1.28 
%Change +22.7% +4.11% +11.27% -32.50% 
       
 
21. P<0.02 compared with ªpre-serum Mg2+ value  
 
https://doi.org/10.1371/journal.pone.0174817.t004 
 
Mg2+ applied as transdermal cream for 12±14 days had no statistically significant effect on serum concentration in this small (n = 25) 
human study when both athletes and non-athletes were included in the statistical analyses. However, a trend towards a rise in serum 
Mg2+ in the Mg2+ group could be seen with an increase of 0.07mmol/l, a clinically relevant rise in a mea-surement that is greater than 
many previous studies and a rise that would take months to show change with oral Mg2+ therapy [11, 19]. Zhang et al., [11] reported 
that in 41 trials, 941 partici-pants receiving a mean oral Mg supplement of 365 mg/day for a median of 12 weeks showed a mean rise of 
0.05 mmol/L circulating Mg (0.78 to 0.83 mmol/L). A meta-analysis of 27 trials by Zhang et al [8] investigating oral Mg2+ 
supplementation, showed a significant (p<0.001) rise in serum Mg with 200 mg/day oral Mg supplement or one month supplement 
duration but that higher doses ( 300 mg/day) or durations of supplementation ( 2 months) were required to achieve a mean rise of 0.05 
mmol/l in serum Mg2+. Additionally, studies included in the Zhang et al [8] meta-analysis show a baseline mean C.V. for the 27 serum 
Mg2+ studies of 9.3% for Mg groups and 10.8% for placebo groups, i.e. as little as half of the variance for baseline serum Mg2+ 
measurements in this study (C.V. = 21.9% and 17.3% for Mg2+ groups, all subjects and non-athletes respectively; C.V. = 20.7% and 
12.3% for placebo groups, all subjects and non-athletes respectively). This pilot study of all subjects, both athletes and non-athletes, 
shows that transdermal Mg2+ may possibly influence serum Mg2+ in a relatively short time frame (12±14 days), but a higher 
concentration of Mg2+ cream, a larger number of subjects given the serum Mg2+ variance, and perhaps a longer study is required to 
make any real conclusion.   
Although participants were told to refrain from exercise for 24 hours before blood and uri-nary collection, 4 participants were 
undertaking regular high intensity training, the effects of which may affect Mg2+ parameters that can last longer than 24 hours [18]. 
When the data from these four subjects were removed from the statistical analysis a significant effect of the Mg2+ cream on serum 
Mg2+ concentrations could be seen.(p = 0.02). Additionally, the %rise in serum Mg2+ in the non-athletes (+22.7%) was much larger 
than that shown in all subjects, i.e. both athletes and non-athletes (+8.54%). This is too small a sample size to reach a firm conclu-sion 
but this increase in percentage change in the non-athlete intervention group may be due to an additional uptake of Mg2+.from the cream 
which may have been utilised during exercise or for replenishment of Mg2+ stores rather than being transferred to serum in the athletic 
participants. This is an area of interest for further study. 
 
Further, this analysis of the serum Mg data for the non-athletes in the intervention group showed a mean increase from 0.75 to 0.92 mmol/l 
which may have clinical relevance in particular with relation to cardiovascular disease. In a meta-analysis by Del Gobbo et al (2013)[20], it was 
found that a rise of 0.2 mmol/L circulating Mg was associated with a 30% lower risk of cardiovascular disease and fatal ischemic heart disease. 
In addition, Lutsey et al.(2014) [21] found that after 20+ yrs follow up serum Mg showed a linear inverse association with the risk 
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of incident heart failure. Relative to those in the highest category of serum Mg, those in the lowest category were at 2.58 t imes greater risk of 
incident heart failure after demographic adjustments. In these quintiles, the lowest serum Mg quintile was 0.7 mmol/L, the second was 0.75, 
the third was 0.8, the 4th was 0.85 and the highest was 0.9 mmol/L, i.e. each quintile was 
 
0.05 mmol/l higher than the next lowest quintile (these results were converted from mEq/L by dividing by 2 to attain mmol/L). Our 
results show a mean rise of 0.05 mmol/L serum Mg2+ with daily application of transdermal Mg2+ for only two weeks, and when 
considering this Lut-sey[21] study and the Del Gobbo[20] results, our finding suggests a possibly significant favour-able impact of 
transdermal Mg on risk of heart failure that needs full study. 
 
Transdermal Mg effect on urinary Mg2+ 
 
Previous study of humans has suggested that 24-hr urinary Mg2+ excretion cannot be used as a measure of changes in 
whole body Mg2+ status [17].  
Upon analysis for all subjects, as well as for only non-athletes, use of the transdermal Mg2+ cream showed no significant rise in urinary Mg2+, a 
measurement that reflects short term intestinal absorption of Mg2+. However, subjects in the Mg2+ group showed slight rises in uri-nary Mg2+ 
(+9 to 11%) while those in placebo group showed a substantial decrease in urinary Mg2+ (-32%). Possibly the decreased urinary Mg2+ 
excretion in the placebo cream group repre-sents more active physiological Mg2+ retention processes that are not apparent in the Mg cream 
group ([15,16]. It has been suggested that 24-hour urine excretion of Mg2+ may be a bet-ter indicator of tissue status than the serum Mg2+ 
concentration, but it is highly variable and it is questionable whether it can be used to reliably assess a given individual's Mg2+ status.  
The trans-dermal cream contained 56 mg of Mg2+ administered daily. This is at the lower end of creams sold 
commercially. The recommended dose of the few commercially available creams range between 70mg/d to 400mg/d per 
day, therefore results of this study may repre-sent an ªunderdoseº of transdermal Mg2+. 
 
Conclusion 
 
No previous studies have looked at effects of transdermal Mg2+ in human subjects. In this two-week pilot study, transdermal delivery of 56 mg 
Mg/day (a low dose compared with commer-cial transdermal Mg2+ products available) showed a larger percentage change in both serum and 
urinary markers from pre to post intervention compared with subjects using the placebo cream. In addition, the rise in mean serum Mg2+ seen 
in the Mg2+ group was clinically relevant although only statistically significant (p<0.05) when non-athletes were analysed separately.  
Given the high variance in serum Mg2+ of these subjects, we suggest that future research focus on a larger number of 
human subjects given higher concentrations of Mg2+ cream appli-cation administered for longer durations to investigate 
whether transdermal application may show a significant contribution to improvement in magnesium status. It would also 
be of interest to look at the effect of transdermal Mg2+ supplementation on athletes as compared to a sedentary 
population group. 
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